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Abstract 
 
Autoimmunity results from a breakdown in tolerance to self-antigens.   Interleukin-
17A (IL-17A) is a cytokine that has been implicated in the development of certain 
autoimmune disorders, notably multiple sclerosis and its mouse model experimental 
autoimmune encephalomyelitis (EAE).  In order to further understand mechanisms 
that lead to the development of autoimmunity, the objectives of this study were to 
investigate the sequence of immunological events that lead to the development of an 
autoimmune response and to generate and characterise a reporter mouse for IL-17A. 
 
 EAE is a well-established model of an autoimmune response directed against self-
antigens  in  the  central  nervous  system  and  mimics  many  aspects  of  the  human 
disease multiple sclerosis.  EAE is a CD4 T cell-mediated disease, in that these cells 
can be used to transfer disease to naïve recipient mice.  Following EAE induction, 
IL-17A-expressing cells were increased in frequency within the CD4 and γδ T cell 
populations in the draining lymph nodes, with a simultaneous increase in the number 
of these cell populations in the blood. Disease development was associated with the 
appearance  of  IL-17A  and  IFN-γ-expressing  CD4  T  cells,  as  well  as  IL-17A-
expressing  γδ  T  cells  in  the  spinal  cord.    EAE  induction  requires  the  systemic 
administration  of  pertussis  toxin  for  disease  development.    It  was  found  that 
pertussis  toxin  enhanced  antigen-specific  IL-17A  and  IFN-γ  production  in  the 
periphery. 
 
An  IL-17A  reporter  mouse  was  generated  in  which  activation  of  the  IL-17A 
promoter  is  reported  by  expression  of  Enhanced  Yellow  Fluorescence  Protein 
(EYFP).  In order to generate the mouse, a strain was first generated in which Cre 
recombinase expression is driven by the IL-17A promoter. This mouse was then 
crossed  with  a  ROSA-26_EYFP  strain  in  which  expression  of  EYFP  in  the 
ubiquitously expressed ROSA-26 locus is usually inhibited by the presence of a 
LoxP-flanked-transcriptional stop sequence.  Expression of Cre recombinase would     Abstract 
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remove the transcriptional stop sequence, leading to irreversible expression of EYFP 
in all cells that had activated IL-17A and their progeny. 
 
The results from this study suggest that pertussis toxin can amplify antigen-specific 
cytokine responses in EAE, an effect which could be attributed to enhancing disease 
pathogenesis.  The IL-17A reporter mouse will be an invaluable tool to investigate 
the generation, lifespan and function of IL-17A-expressing cells in the development 
of immune responses. 
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Chapter 1: Introduction 
 
1.1 Overview of the immune system 
 
The immune system is comprised of an integrated network of cells and molecules 
that functions to protect organisms from infection.   
 
Contact  with  potentially  disease-causing  agents  can  occur  through  internal  or 
external  epithelial  surfaces,  including  the  respiratory  tract,  gastrointestinal  tract, 
urogenital tract and the skin.  Pathogen entry can be prevented at these sites by a 
number  of  constitutive  defense  mechanisms.    These  include  the  presence  of 
epithelial cell tight junctions which physically restrict pathogen entry, the secretion 
of  anti-microbial  agents  and  mucus  by  epithelial  cells  which  can  prevent 
microorganisms from adhering to the epithelium, and the presence of commensal 
microflora which out-compete pathogens for essential nutrients and attachment sites.  
Despite  these  defences,  pathogenic  microorganisms  such  as  bacteria,  viruses, 
parasites and fungi have developed ways to invade and establish infection in host 
tissue.  
 
Invading pathogens trigger the activation of a wide range of host receptors, referred 
to as Pathogen Recognition Receptors (PRRs).  PRRs encompass secreted receptors, 
produced by the liver, such as mannan-binding lectin, C-reactive protein and serum 
amyloid protein; cell-surface receptors such as macrophage mannose receptor and 
toll-like receptors (TLRs); and intra-cellular receptors such  as the protein kinase 
receptor  (PKR)  and  nucleotide-binding  oligomerization  domain  (NOD)  proteins.  
The  molecules  that  are  responsible  for  binding  and  activating  these  PRRs  are 
conserved  products  of  microbial  pathogens  known  as  Pathogen-Associated 
Molecular Patterns (PAMPs) and include lipopolysaccharide (LPS), which is a cell 
wall component of gram negative bacteria; unmethylated CpG DNA motifs found at 
a high frequency in microbial DNA sequences; bacterial flagellin; double stranded     Chapter 1: Introduction 
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RNA produced during viral infection; and zymosan, a component of yeast cell walls 
(Janeway  1989;  Janeway  and  Medzhitov  2002).      The  recognition  of  exogenous 
pathogenic agents by host receptors initiates a cascade of events, culminating in the 
recruitment and activation of a number of short-lived effector cells to the site of 
infection,  with  the  primary  goal  of  eliminating  the  pathogen.  This  process  is 
described as inflammation and can result in clearance of the pathogen and repair of 
damaged host tissues.  However, in the event that the pathogenic agent persists, 
clonal expansion of lymphocytes with receptors that specifically recognize antigens 
within the invading pathogenic organism is initiated.   The expansion and activation 
of these clones of cells and the effector mechanisms associated with them generates 
a highly specific immune response directed at the pathogenic insult.  The long-term 
survival  of  small  numbers  of  these  antigen-specific  clones  allows  for  the 
development of immunological memory, which provides immediate immunity upon 
re-infection with the same pathogen.  
 
The  immune  system  is  broadly  categorized  into  innate  and  adaptive  immunity.  
Innate immunity is the non-specific response induced by any invading pathogen and 
generally consists of all the cells and molecules involved in inflammation.  Adaptive 
immunity is the clonal expansion of pathogen-specific lymphocytes.  Despite this 
characterization, the two systems are closely interlinked and cells of the innate and 
adaptive immune systems can interact via the secretion of soluble molecules such as 
interleukins (ILs), chemokines and immunoglobulins. 
 
1.2 The main cellular components of the immune system 
 
1.2.1 Granulocytes and mast cells 
 
Granulocytes  or  polymorphonuclear  leukocytes  (PMNLs)  include  neutrophils, 
basophils and eosinophils.  These cells are short-lived, circulating in the blood of 
healthy individuals.  During an immune response, they are released in increased     Chapter 1: Introduction 
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numbers from their progenitors in the bone marrow and extravasate into infected 
tissue,  where  they  contribute  to  pathogen  eradication.  Neutrophils  represent  the 
major component of blood granulocytes, and are involved in the immune response 
against  a  wide  range  of  bacterial  infections.  They  are  one  of  the  first  types  of 
haematopoietic cell an invading pathogen will encounter and their primary function 
is to phagocytose and kill invading pathogens through their ability de-granulate, a 
process which releases anti-microbial molecules into the infected site (Nathan 2006). 
Eosinophils  and  basophils  are  smaller  populations  of  blood  leukocytes  and  are 
involved in the immune response against parasites and some viruses. Degranulation 
of  these  cells  results  in  the  release  of  pro-inflammatory  molecules  including 
histamine  from  basophils  and  neurotoxin,  eosinophil  cationic  proteins  and  major 
basic protein from eosinophils  (Stone, Prussin et al. 2010). 
 
Mast cells are tissue resident cells, which are predominantly associated with the 
immune  response  in  parasitic  infections.    They  reside  mainly  near  small  blood 
vessels and release substances such as histamine, prostaglandins and leukotrienes 
upon degranulation which affect vascular permeability and recruit other cells such as 
eosinophils and basophils to the site of infection (Stone, Prussin et al. 2010). 
 
1.2.2 Mononuclear phagocytes 
 
Mononuclear phagocytes are a broad characterisation of immune cells, which reside 
in  the  blood  and  in  tissues  during  steady  state  and  inflammatory  conditions  and 
encompass monocytes, macrophages and dendritic cells (DCs).     
 
Monocytes are a heterogenous population of cells that circulate in the blood, bone 
marrow  and  spleen  and  can  produce  cytokines  such  as  tumour  necrosis  factor 
(TNF)α, IL-1 and IL-10 in inflammatory conditions (Auffray, Sieweke et al. 2009).  
In an inflammatory environment they also have the capacity to migrate from the     Chapter 1: Introduction 
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blood  into  tissues  and  to  differentiate  into  inflammatory  DCs  and  macrophages 
(Serbina, Jia et al. 2008).   
 
Macrophages are tissue resident phagocytic cells, are present in lymphoid and non-
lymphoid tissues and play a role in steady-state tissue homeostasis via the clearance 
of apoptotic cells and the production of growth factors (Geissmann, Manz  et al. 
2010).    Macrophages  have  surface  PRRs,  which  allow  them  to  become  directly 
activated upon interaction with an infectious pathogen.  This induces the production 
of  a  wide  range  of  inflammatory  cytokines,  induces  their  killing  mechanisms, 
increases antigen presentation and allows them to directly activate antigen-specific T 
lymphocytes  (Gordon  2002).    They  are  a  heterogenous  population  of  cells  and 
encompass microglia in the central nervous system (CNS), dermal macrophages in 
the skin, and splenic and metallophilic macrophages in the spleen, all with different 
phenotypes  and  functions  (Geissmann,  Manz  et  al.  2010).  Although  many 
macrophage subsets are renewed solely from blood progenitors, there are exceptions, 
such  as  the  microglia,  which  have  self-  renewal  capacity  (Ajami,  Bennett  et  al. 
2007).   
 
Dendritic  cells  can  be  broadly  divided  into  classical  and  plasmacytoid  DCs.  
Classical DCs are specialised antigen processing and presenting cells.  They are the 
primary cell type able to activate naïve T lymphocytes and therefore trigger clonal 
expansion  of  antigen-specific  clones  (Banchereau  and  Steinman  1998).    As 
immature cells, the classical dendritic cells are highly migratory, in that they can 
move in and out of lymphoid and non-lymphoid tissues.  Like the macrophages, they 
possess PRRs on their surface, which allow them to be activated by an invading 
pathogen.  Upon activation, the classical DCs can be induced to express a range of 
cytokines and to migrate to lymphoid tissue where they can activate naïve T cell 
clones (Geissmann, Manz et al. 2010). Classical DCs are derived from blood-borne 
precursors, distinct from the monocytic cell precursors of macrophages (Merad and 
Manz 2009).  One exception to this is are the Langerhans cells in the skin which are 
thought to be derived from a blood-borne monocytic precursor (Ginhoux, Tacke et     Chapter 1: Introduction 
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al. 2006) and which also display self-renewal properties (Merad, Manz et al. 2002).   
Plasmacytoid DCs are longer lived cells than classical DCs and are present in the 
bone marrow and peripheral organs.  They respond to viral infection by producing 
Type I Interferons and can also act as antigen presenting cells to activate T cell 
responses (Colonna, Trinchieri et al. 2004). 
 
1.2.3 Natural killer (NK) cells 
 
NK cells are large granular lymphocytes which are present in lymphoid and non-
lymphoid tissue (Gregoire, Chasson et al. 2007).  They have the capability to kill 
virus-infected cells as well as tumour cells via the release of perforin and granzyme 
from their cytoplasmic granules, which initiates death of target cells by apoptosis. 
They are also a source of pro-inflammatory cytokines such as TNF-α and interferon 
(IFN)-γ (Vivier, Tomasello et al. 2008).  Their activation is controlled by activatory 
and inhibitory receptors.  In the mouse, inhibitory receptors are the Ly49 receptors 
and in humans the analogous set of receptors are the Killer Inhibitory Receptors 
(KIRs).  These receptors are involved in the recognition of Major Histocompatibility 
Complex (MHC) class I molecules which are expressed on the surface of most host 
cells.    Many  viruses  and  intracellular  bacteria  have  developed  ways  of  down-
regulating or completely shutting off MHC class I expression by host cells, however 
this down regulation of  MHC class I is a trigger for the activation of NK cells 
(Raulet and Vance 2006). NK cells can also be triggered to divide and up-regulate 
killing activity through Toll-like receptor (TLR) ligands (Sivori, Falco et al. 2004), 
through  detection  of  stress  induced  self-ligands  (Lanier  2005)  and  through  the 
actions of cytokines like Type I interferons produced by virus-infected cells, IL-12, 
IL-18 and IL-15 (Walzer, Dalod et al. 2005).  
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1.2.4 Lymphocytes 
 
The T and B lymphocytes of the adaptive immune system are derived from the 
common lymphoid progenitor in the bone marrow (Kondo, Weissman et al. 1997) 
and subsequently develop in the primary lymphoid organs: the bone marrow and 
thymus.  The lymphocytes that develop in the bone marrow are the B lymphocytes 
and the lymphocytes that develop in the thymus are the T lymphocytes. 
 
The B and T cell populations have an extraordinarily diverse set of receptors on their 
cell surface, with each cell having a unique specificity of receptor. These B and T 
cell  populations  are  collectively  capable  of  recognizing  virtually  any  molecular 
structure  and  each  cell  has  the  capacity  to  clonally  expand  upon  an  appropriate 
activation  stimulus.    The  B  cell  receptor  (BCR)  is  a  membrane-bound 
immunoglobulin  (Ig)  protein  composed  of  two  heavy  and  two  light  polypeptide 
chains (Schroeder and Cavacini 2010). The T cell receptor (TCR) is composed of an 
α polypeptide chain and a β polypeptide chain which have structural similarities to 
the heavy and light polypeptide chains of the immunoglobulin receptor (Bentley and 
Mariuzza 1996). Each receptor has a variable region, which is the external part of 
the  receptor  and  is  capable  of  interacting  and  binding  to  pathogen  molecules. 
Although the B and T cells have structurally similar antigen recognition receptors, 
their ability to recognise antigen is different. B cells recognise intact antigen directly 
through their BCR and T cells recognise fragments, which have been processed and 
presented on MHC and MHC-like molecules on the surface of antigen presenting 
cells (APCs).  The diverse repertoire of receptors on the B and T lymphocytes is 
generated  from  a  relatively  limited  set  of  genes  through  the  process  of 
recombination, which leads to the development of a unique antigen receptor on each 
individual  lymphocyte.    This  process  is  dependent  upon  the  recombination-
activating genes RAG1 and RAG2 (Schatz, Oettinger et al. 1989) and occurs in the 
bone marrow for the development of B cells and in the thymus for the development 
of T cells.   
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In the thymus the majority of developing T lymphocytes (thymocytes) differentiate 
into to the αβ T cell lineage.  αβ T lymphocytes can be further divided into cells 
expressing the CD4 receptor: the CD4 T cells, and T lymphocytes expressing the 
CD8 receptor: the CD8 T cells.  CD4 T cells are termed T helper cells as they were 
first defined on their ability to activate B cells to produce antibody.  The CD8 T cells 
are activated in response to intracellular infections and are termed cytotoxic cells as 
they  are  involved  in  the  direct  killing  of  infected  cells  via  the  release  of  toxic 
substances.  CD4  T  helper  cells  recognise  peptide  expressed  by  MHC  class  II 
molecules on the surface of APCs such as dendritic cells, macrophages and B cells.  
CD8 cytotoxic T cells recognise peptide expressed by MHC class I presented on the 
surface of most host cells. 
 
A small proportion of αβ T cells also express the cell-surface NK1.1 marker and are 
classified as NK T cells.  These cells express a very limited diversity of T cell 
receptors in comparison to the conventional T and B cells and recognise lipids and 
glycolipids presented by CD1 molecules rather than peptides presented by MHC 
(Godfrey, Pellicci et al. 2010).  A small population of developing thymocytes also 
rearrange the γ and δ chains of the TCR rather than the α and β chains.  These γδ T 
cells differ from the αβ T cells in the more restricted range of antigen specificities 
they  recognise  and  in  their  anatomical  distribution  in  the  periphery  (Chien  and 
Hampl 2000).   
 
B cells recognise intact antigen directly, which does not have to be presented by a 
specialised cell or molecule.  They internalise the antigen through their BCR and can 
process and present peptides from the antigen on MHC class II molecules, which are 
recognised by previously primed CD4 T helper cells.  This interaction between the B 
cell and the CD4 T helper cell is important for the activation and clonal proliferation 
of the B cell, by providing signalling through the CD40 receptor (Noelle, Roy et al. 
1992) but also via the action of cytokines such as IL-4 (Valle, Zuber et al. 1989) 
which can drive the proliferation and differentiation of the B cell into an antibody-
secreting plasma cell.  Antibodies secreted by activated B cells circulate in the blood     Chapter 1: Introduction 
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and extra-cellular fluid and have various effector functions (Schroeder and Cavacini 
2010).  The variable, antigen-binding region of the antibody molecule determines 
the specificity of the antibody and the constant region determines the isotype of the 
antibody.  Antibodies can bind directly to pathogens or toxic products, which can 
inhibit the actions of the pathogen or toxic product, therefore having a neutralising 
effect.  The binding of antibodies to pathogens can also enhance the recognition of 
pathogens  by  phagocytes  such  as  macrophages  and  neutrophils,  which  have 
receptors on their surface (Fc receptors) for the recognition of constant regions of 
antibody,  in  a  process  called  opsonisation.    The  formation  of  antibody-antigen 
complexes  can  also  activate  plasma  proteins  called  complement  proteins.    The 
activation  of  complement  results  in  an  inflammatory  cascade  involving  the 
recruitment and activation of many of the effector cells described above.  
 
1.3 Tolerance and autoimmunity 
 
Generation of the diverse range of lymphocyte receptors in the primary lymphoid 
organs has the potential to generate a large number of clones that are capable of 
binding to self-antigens with high affinity.  It is therefore important that self-reactive 
clones are regulated in order to prevent induction of an immune response directed 
against self-antigens in the periphery (an autoimmune response). 
 
Mechanisms by which tolerance against self-reactivity is achieved are classically 
divided into central and peripheral tolerance mechanisms. Central tolerance consists 
of  the  deletion  of  potentially  self-reactive  lymphocytes,  as  well  as  the  positive 
selection of regulatory lymphocyte populations in the primary lymphoid organs and 
peripheral tolerance consists of the mechanisms by which self-reactive lymphocytes, 
which have escaped central tolerance can be inhibited from causing pathology in the 
periphery.   
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1.3.1 Central tolerance 
 
TCR-expressing thymocytes are positively selected in the thymus for their ability to 
recognize self-MHC in context with self-antigen, thereby allowing mature T cells 
the capability to respond to foreign peptide presented by a self-MHC molecule in the 
periphery.  This  concept  was  originally  proposed  after  experiments  in  which  the 
MHC genotype of thymic grafts determined the MHC genotype to which T cells 
would  respond  in  the  periphery  (Fink  and  Bevan  1978).    The  use  of  transgenic 
models has subsequently shown that the inability to recognize self-MHC in context 
with self-antigen expressed by the thymic epithelium results in the death of T cells 
by apoptosis, also called death by neglect (Huesmann, Scott et al. 1991).  However, 
not all thymocytes that recognize self-peptide/self-MHC complexes enter into the 
periphery as this would lead to the generation of a peripheral T cell repertoire that 
was highly auto-reactive.  Indeed, there is also a process by which potentially auto-
reactive  T  cells  are  negatively  selected  in  the  thymus  before  release  into  the 
periphery.    This  theory  was  originally  proposed  by  Burnet  (Burnet  1976)  and  a 
classical  example  of  this  concept  of  negative  selection  is  in  mice  expressing  a 
transgenic  TCR  specific  for  the  male  H-Y  antigen.  These  transgenic  cells  are 
positively selected in female mice but negatively selected in male mice. (Kisielow, 
Bluthmann  et  al.  1988).    Negative  selection  of  thymocytes  can  be  mediated  by 
several  different  cell  types,  including  bone  marrow-derived  dendritic  cells  and 
macrophages, as well as thymic epithelial cells, in particular medullary epithelial 
cells (Gao, Lo et al. 1990; Webb and Sprent 1990; Sprent, Kosaka et al. 1992) The 
extent of negative selection is specified by the diversity of self-antigens that are 
presented within the thymus (Kyewski and Klein 2006).  Furthermore, mice resistant 
to myelin basic protein (MBP)-induced experimental autoimmune encephalomyelitis 
(EAE), an animal model for multiple sclerosis, have increased thymic expression of 
MBP (Liu, MacKenzie-Graham et al. 2001), suggesting that in these mice negative 
selection to this auto-antigen has been more thorough, leading to enhanced tolerance 
to disease development.  In addition, the thymic expression of occular auto-antigens 
also correlates with resistance to experimental autoimmune uveoretinitis (EAU), an     Chapter 1: Introduction 
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animal model for human uevitis (Egwuagu, Charukamnoetkanok et al. 1997), and 
levels of insulin expression in the thymus of mice modulated peripheral reactivity to 
insulin (Chentoufi and Polychronakos 2002). The mechanisms by which peripheral 
self antigens are expressed in the thymus for negative selection can include access 
via  the  blood  circulation.    For  example,  complement  protein  C5  can  access  the 
thymus via the blood circulation and can induce clonal deletion of C5-specific T 
cells (Volkmann, Zal et al. 1997). In addition, migratory DCs from the periphery 
have been shown to induce clonal deletion in the thymus (Bonasio, Scimone et al. 
2006). However, for the majority of peripheral antigens that are not blood-borne or 
are not presented by migratory DCs, negative selection is mediated by expression of 
these  tissue-restricted  antigens  (TRAs)  in  the  thymus  (Jolicoeur,  Hanahan  et  al. 
1994).  Regulation of the expression of ectopic TRAs in the thymus is controlled in 
part by the transcription factor AIRE (autoimmune regulator protein).  Indeed, AIRE 
is expressed in mouse and human medullary epithelial cells and mutations in the 
AIRE  gene  are  responsible  for  the  human  autoimmune  syndrome,  autoimmune 
polyendocrinopathy-candidiasis-ectodermal  dystrophy  (Pitkanen  and  Peterson 
2003).  Mice  lacking  AIRE  also  develop  organ-specific  autoimmune  disease 
(Anderson, Venanzi et al. 2002). 
 
The thymus is also an important location for the generation of regulatory CD4 T 
cells (T-regs), capable of inhibiting potentially auto-reactive immune responses in 
the periphery.  Early experiments showed that  mice thymectomized early in life 
developed organ-specific autoimmunity and that transfer of adult peripheral cells 
could prevent this development of disease (Nishizuka and Sakakura 1969).  It was 
subsequently shown that CD25
+ cells in the adult peripheral T cells were responsible 
for this suppression (Sakaguchi, Sakaguchi et al. 1995; Asano, Toda et al. 1996) and 
that these CD25
+ T cells could mediate suppression of CD4 T cell responses in vitro 
(Itoh,  Takahashi  et  al.  1999).      Development  of  T-regs  has  been  implicated  to 
involve interactions with self-peptide and MHC class II in the thymus.  This has 
been suggested after observations in transgenic mice where development of T-regs is 
dependent upon expression of endogenously re-arranged TCRs. Furthermore, when     Chapter 1: Introduction 
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the transgenic mice were crossed onto a RAG-deficient background and therefore 
solely  expressed  the  transgenic  TCR,  T-reg  development  was  abrogated  (Itoh, 
Takahashi et al. 1999).  The implications of this have directly been shown in mice 
expressing a transgenic TCR specific for MBP.  These mice developed autoimmune 
disease against the specific antigen but only when the transgenic strain was crossed 
onto a RAG-deficient background (Hori, Haury et al. 2002). In addition, retroviral 
expression of T-reg TCRs into CD25
- CD4
+ cells showed that the T-reg TCRs had 
more  efficient  interactions  with  MHC  class  II-bound  self  peptides  from  the 
periphery than CD25
- cells (Hsieh, Liang et al. 2004) The importance of T-regs in 
the tolerance against self has been implicated in mice that either lack these cells or 
that have mutations in genes involved in their development. One such example is 
mutations within the Forkhead box p3 (Foxp3) gene which is a transcription factor 
found to be expressed at a high levels in CD25
+ T regs (Fontenot, Gavin et al. 2003).  
Foxp3  mutations  result  in  immune  dysregulation  in  both  humans  (called  IPEX 
syndrome) and in mice, characterized by excessive lymphoproliferation, multi-organ 
infiltrates and wasting disease (Bennett, Christie et al. 2001; Brunkow, Jeffery et al. 
2001). 
 
Immature  B  cells  in  the  bone  marrow  expressing  an  auto-reactive  receptor  also 
undergo a selection process, which has been studied using transgenic mouse models. 
Upon encountering self-antigen in the bone marrow, self- reactive B cells have been 
shown to be deleted if the antigen is in high abundance and is multivalent such as 
multiple copies of MHC molecules on a cell surface (Nemazee and Burki 1989).  B 
cells  have  also  been  shown  to  enter  a  state  of  unresponsiveness,  called  anergy, 
induced by interaction with soluble antigen in the bone marrow.  These B cells leave 
the bone marrow but have a defect in signal transduction so they cannot be activated 
by antigen in the periphery (Cornall, Goodnow et al. 1995).  Self-reactive B cells 
also have the option to generate another BCR by process of rearranging genes of the 
light chain of the receptor (Tiegs, Russell et al. 1993). 
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1.3.2 Peripheral tolerance 
 
Self-reactive  lymphocytes  can  escape  the  process  of  negative  selection  in  the 
primary lymphoid organs and are present in the circulation of healthy individuals.  
For  example,  in  mice  with  a  transgenic  TCR  specific  for  MBP,  CD4
  T  cells 
expressing the receptor are positively selected and enter the periphery, however a 
spontaneous autoimmune reaction against MBP does not occur (Liu, Fairchild et al. 
1995).  This study went on to show that the transgenic CD4 MBP-specific T cells 
found in the periphery were of low affinity for peptide and infusion of the mice with 
an  MBP  with  high  affinity  for  the  transgenic  TCR  led  to  negative  selection  of 
thymocytes in the thymus whereas MBP with a low affinity for the transgenic TCR 
did not.  Thus, the authors concluded that potentially auto-reactive T cells with a low 
affinity for self-peptide/MHC must rely on peripheral tolerance mechanisms in order 
to remain non-pathogenic.  A similar study using double-transgenic mice engineered 
to express a TCR specific for chicken ovalbumin (OVA) as well as OVA peptide in 
the  thymus  medullary  epithelial  cells  and  pancreas  showed  that  these  mice 
developed low affinity OVA-specific T cells in the periphery, that did not induce an 
auto-reactive response against OVA in the pancreas under normal conditions (Zehn 
and Bevan 2006), which again showed that low affinity cells could escape central 
tolerance and enter the periphery. 
 
Studies in CD8 T cells have shown that peripheral tolerance of auto-reactive clones 
in  the  periphery  to  their  self-antigen  can  depend  on  the  level  of  self-antigen 
expressed. Moreover, even if an auto-reactive T cell is quite capable of making an 
antigen-specific response, the level of self-antigen expressed in the periphery might 
be so low that the T cell is ignorant to the presence of the auto-antigen (Kurts, 
Sutherland et al. 1999). Anatomical location can also make a contribution to the 
ignorance of auto-reactive T cells to the presence of auto-antigen.  Furthermore, 
mature  naïve  T  cells  normally  circulate  from  blood  to  the  secondary  lymphoid 
organs, to efferent lymph and then back to blood (Lammermann and Sixt 2008) and     Chapter 1: Introduction 
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are usually excluded from peripheral tissues where the likelihood of coming into 
contact with an APCs expressing high levels of self antigen is high.  
 
However, ignorance or deletion is not the only means by which peripheral tolerance 
in achieved.  In order for a T cell to become activated into an effector cell capable of 
contributing towards an antigen-specific response it must receive specific signals 
from  the  environment.  These  signals  include  triggering  of  the  TCR  via  peptide 
presented on MHC molecules, as well as co-stimulation through CD28 on the T cell 
surface and triggering of cytokine receptors (Lenschow and Bluestone 1993).  It has 
been shown that in the absence of co-stimulatory signals, T cells can enter a state of 
tolerance  known  as  anergy  characterised  by  inhibition  of  proliferation  and 
differentiation (Schwartz, Mueller et al. 1989).  The cells usually responsible for 
delivering these activation signals to CD4
 T cells are activated DCs and it has been 
shown that DCs can also adopt a tolerogenic phenotype whereby presentation of 
antigen to the T cell results in anergy.  This tolerogenic phenotype has been shown 
to be induced by apoptotoic cells  and it has been postulated that this process is 
important for the maintenance of self-tolerance against self-reactive T cells in the 
periphery (Hawiger, Inaba et al. 2001).  
 
Self-reactive B cells are also kept in check in the periphery by the absence of CD4 T 
cell help, which is required in most cases for the maturation of mature B cells into 
plasma  cells  (Fulcher  and  Basten  1997).      Self-reactive  B  cells  can  also  be 
eliminated  in  the  periphery,  in  germinal  centres  during  immune  responses. 
Moreover, B cells undergo a process called somatic hypermutation during clonal 
expansion and differentiation which allows them to modify their antigen receptor.  
If, in this process a strongly self-reactive receptor is generated, these cells can be 
deleted (Shokat and Goodnow 1995). 
 
In addition to the generation of T-regs in the thymus, de novo induction of Foxp3-
expressing  T-regs  in  the  periphery  can  also  be  induced  upon  immunisation 
(Apostolou and von Boehmer 2004). DCs can induce the generation of peripheral T-    Chapter 1: Introduction 
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regs (Mahnke and Enk 2005) in vivo and transforming growth factor (TGF) β has 
been shown to induce T-regs in vitro, that are capable of suppressing autoimmunity 
in vivo  (Luo, Tarbell et al. 2007).  The mechanisms by which T-regs can suppress 
effector T cell responses has been investigated mostly in in vitro studies and include 
providing competition for the T cell growth factor, IL-2 with effector cells, direct 
killing of effector cells via cytotoxic activity and expression of surface molecules 
such as galectin-1 which can induce cell cycle arrest in effector cells upon ligation 
(Shevach 2009). 
   
1.3.3 Autoimmunity 
 
Autoimmune  diseases  occur  as  a  result  of  specific  adaptive  immune  responses 
directed against self-antigens.   In the case of an adaptive immune response against a 
foreign pathogen, the antigen can be cleared resulting in a resolution of the immune 
response.  In autoimmunity, the persistence of the self-antigen induces a chronic, 
sustained reaction resulting in clinical disease. Autoimmunity can be distinguished 
from generalized immune pathology by the identification of a specific self-antigen 
against  which  the  response  is  directed.      Immune  pathology  is  the  result  of 
dysregulated immunity where the antigen against which the response is directed is 
either exogenous or, as yet, unidentified. 
 
Autoimmune diseases are classified as either organ-specific or systemic, depending 
on the nature of the auto-antigen to which the response is elicited.  Examples of 
organ-specific autoimmune diseases in which immune pathology is associated with a 
restricted organ include Hashimoto’s thyroiditis, Grave’s disease, Type 1 insulin-
dependent diabetes mellitus (IDDM), multiple sclerosis (MS), Myasthenia Gravis 
and  Goodpasture’s  syndrome.  Examples  of  systemic  autoimmune  disease  are 
systemic lupus erythematosus (SLE), Sjogren’s syndrome and rheumatoid arthritis 
(RA).   Most studies into the immunological aspects of these clinical diseases are 
investigated using mouse models in which antigen-specific autoimmune responses     Chapter 1: Introduction 
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are  actively  induced  against  an  endogenous  antigen,  such  as  in  EAE  (Tafreshi, 
Mostafavi et al. 2005), collagen-induced-arthritis (CIA) (Courtenay, Dallman et al. 
1980),  autoimmune  gastritis  (Scarff,  Pettitt  et  al.  1997)  or  autoimmune  ovarian 
disease (Rhim, Millar et al. 1992). Some mouse strains are highly susceptible to 
spontaneous induction of autoimmune diseases such as the C3H/He, MRL/lpr and 
NOD  mice  which  are  particularly  susceptible  to  autoimmune  gastritis,  SLE  and 
diabetes, respectively (Alderuccio and Toh 1998; Anderson and Bluestone 2005; 
Blank and Shoenfeld 2005). Autoimmunity is associated with the combination of 
both susceptibility alleles at multiple gene loci and environmental factors.  These 
factors lead to failure in self tolerance, resulting in an autoimmune reaction directed 
against  self.    Susceptibility  to  autoimmune  disease  has  most  consistently  been 
associated  with  MHC  genotype  (Fugger  2000).    However  other  genes  in  which 
polymorphisms  have  been  shown  to  be  associated  with  autoimmunity  include 
cytotoxic T lymphocyte antigen (CTLA)-4 (Donner, Rau et al. 1997) IL-2 (Encinas, 
Wicker et al. 1999) and Fas (Fischer, Rieux-Laucat et al. 2000) as well as a number 
of genes with no known immunological function (Wandstrat and Wakeland 2001).  
Genome-wide association studies (GWAS) have also recently highlighted particular 
DNA polymorphisms associated with autoimmune diseases such as Crohn’s disease, 
MS, RA, SLE, IDDM.  These include genes encoding IL-23-receptor (IL-23R), IL-
2RA, IL-17RA, chemokine receptor 6 (CCR6) and the transcription factor, STAT-3 
(Burton, Clayton et al 2007). 
 
Development of autoimmunity is not entirely attributable to the genetic sequence in 
that identical twins, which share the same genetic sequence, are often discordant for 
major autoimmune diseases (Bach 2005). This suggests that environmental factors 
also  play  a  role  in  autoimmune  disease  development.    A  number  of  infectious 
organisms carry epitopes that mimic self proteins, and activation of autoreactive T 
cells as a result of cross reactivity during infection can induce autoimmunity that 
persists after pathogen clearance (Horwitz, Bradley et al. 1998; Zhao, Granucci et al. 
1998;  Croxford,  Olson  et  al.  2005).    Other  infectious  organisms  may  target  the 
immune system, inducing a transient state of lymphopenia that may result in the     Chapter 1: Introduction 
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expansion of auto-reactive cells (Forrest, Menser et al. 1971; Kopelman and Zolla-
Pazner 1988; Morse, Sakaguchi et al. 1999).  In addition, some microbes can act as 
mitogenic  stimuli,  or  superantigens,  therefore resulting  in  the  activation  of  auto-
reactive  T  cells  (Brocke,  Gaur  et  al.  1993;  Cole  and  Griffiths  1993).    Another 
mechanism  by  which  infections  may  induce  autoimmune  disease  is  through 
bystander  activation  of  autoantigen  specific  T  cells  or  epitope  spreading  via 
generation of infection-associated inflammation.  For example in Theiler’s disease, 
infection  initially  induces  viral  specific  encephalomyelitis  in  mice,  which  is 
associated  with  T  cell  reactivity  to  viral  proteins,  however,  the  viral-specific 
response is replaced by an autoimmune response directed against the CNS proteins, 
MBP  and  proteolipid  protein  (PLP)  (Miller,  Vanderlugt  et  al.  1997)  Similarly, 
infection of mice with Coxackie B3 virus induced cardiomyositis first against viral 
proteins and then against auto-antigens (Wolfgram, Beisel et al. 1985) and Coxackie 
B4 virus could induce diabetes in non-autoimmune-prone mouse strains and could 
accelerate  diabetes  onset  in  diabetes-prone  NOD  mice  (Horwitz,  Bradley  et  al. 
1998). 
 
1.4 Development of T cell responses 
 
T cells circulate through the blood, lymphatics and lymphoid organs and constantly 
interact with both professional APCs such as DCs and macrophages as well as host 
cells  expressing  peptide  on  self-MHC  molecules.    In  a  normal,  steady  state 
environment, these interactions do not induce activation and proliferation of T cell 
clones  but  they  do  act  as  a  survival  signal,  reinforcing  the  process  of  positive 
selection that occurs in the thymus.  Induction of an inflammatory signal induced by 
injury or infection leads to the maturation of professional APCs, characterized by the 
up-regulation of surface MHC and of co-stimulatory molecules such as CD80 and 
CD86.  Mature APCs directly interact with and activate naïve T cells in the local 
lymphoid tissue, and also produce a range of pro-inflammatory cytokines, which can     Chapter 1: Introduction 
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regulate the differentiation of the responder cells (Banchereau and Steinman 1998; 
Joffre, Nolte et al. 2009). 
 
1.4.1 CD4 T helper subsets: Th1/Th2 cells 
 
In the 1980s, activated CD4 T cells were distinguished into two types of T cells 
based on their ability to activate B cell clones and induce the secretion of different 
types of immunoglobulin (Ig) from B cells.  They were described as Th1 cells and 
Th2 cells. (Mosmann, Cherwinski et al. 1986; Mosmann and Coffman 1989). Th1 
cells were described on the basis of IFN-γ and IL-2 secretion.  These cells could 
induce the production of certain types of IgG from B cells, in particular IgG2a, and 
were primarily involved in driving cell-mediated immune responses responsible for 
fighting infection against intracellular parasites.  Th2 cells were described based on 
their ability to secrete IL-4 and IL-5 and were able to induce the production of IgE 
from activated B cells, an immunoglobulin associated with the immune response 
against  helminth  infections  and  eosinophilic  inflammation  (Coffman  and  Carty 
1986).  The Th1/Th2 paradigm has now been well described and it is clear that the 
Th1 and Th2 CD4 T cells have distinct developmental pathways dependent upon the 
inflammatory environment in which they are activated.  IL-12, a cytokine expressed 
by cells of the innate immune system such as DCs and macrophages is crucial for 
Th1 differentiation and this occurs through the activation of Signal Transducer and 
Activator of Transcription (STAT)-4 and T box expressed in T cells (T-bet).  This 
activation pathway upregulates the expression of IFN-γ and downregulates IL-4 and 
IL-5 expression.  IL-4 has been shown to induce Th2 cell differentiation through the 
activation  of  the  transcription  factor  GATA-3,  which  upregulates  IL-4  and  IL-5 
expression but downregulates IFN-γ expression. Th1 responses are associated with 
the recruitment of phagocytic cells and in eradicating intracellular pathogens. Th2 
responses are involved in providing B cell help and in shaping the antibody response 
to  extracellular  pathogens  such  as  helminth  infections  (Rengarajan,  Szabo  et  al. 
2000; Szabo, Kim et al. 2000; Afkarian, Sedy et al. 2002).     Chapter 1: Introduction 
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1.4.2 CD4 T helper subsets: Th17 cells 
 
In 2005, Th17 cells were described as a third lineage of activated effector CD4 T 
cell that was distinct from the Th1 and Th2 lineages (Harrington, Hatton et al. 2005; 
Park, Li et al. 2005).  It was demonstrated in these papers that Th17 cells do not 
share any of the transcription factors involved in Th1 or Th2 development such as T-
bet, STAT-4, STAT-1, STAT-6 c-MAF or GATA-3, and that addition of blocking 
antibodies to cytokines associated with the Th1 and Th2 lineages including anti-IL-4 
and anti-IFNγ resulted in increased IL-17 expression.   
 
IL-17-producing CD4 T cells were originally described by Aggarwal et al in 2003 
(Aggarwal, Ghilardi et al. 2003).  The authors showed that activation of CD4 T cells 
in the presence of IL-23 led to enhanced IL-17 production.  This was followed by 
Cua et al who described the generation of a subset of CD4 T cells characterised by 
the production of IL-17A, IL-17F and TNFα (Cua, Sherlock et al. 2003; Langrish, 
Chen et al. 2005) which were generated in the presence of IL-23 whereas, in the 
presence of IL-12, CD4 T cells were polarised to an IFN-γ-producing cell subset. 
Despite this observation, it was known that naïve T cells do not express the IL-23 
receptor (IL-23-R) (Aggarwal, Ghilardi et al. 2003) and so IL-23 was unlikely to be 
the cytokine responsible for driving naïve T cells to become Th17 cells.  Studies 
showed that the combination of TGFβ and IL-6 were the factors required for the 
differentiation of Th17 cells from a population of naïve CD4 T cells and that IL-23 
was not required for the initial differentiation of these cells (Bettelli, Carrier et al. 
2006; Mangan, Harrington et al. 2006; Veldhoen, Hocking et al. 2006).  Although 
IL-23 was not involved in the initial steps driving the development of Th17 cells 
from naïve T cells it was found to play an important role in the stability of Th17 
cells in vivo and for Th17 cells to fully differentiate and exhibit effector function 
(McGeachy, Bak-Jensen et al. 2007).  TGFβ was also known to be involved in the 
generation  of  Foxp3-expressing  T-regs  and  culture  with  this  cytokine  alone  was 
involved in the generation of these cells.  Addition of IL-6 to the cultures suppressed 
the production of T-regs and supported the growth of Th17 cells suggesting that     Chapter 1: Introduction 
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these  two  T  cell  subtypes  could  arise  in  a  mutually  exclusive  manner  (Bettelli, 
Carrier et al. 2006).  
 
Expression of the transcription factor ROR-γt (RA-related orphan receptor gamma t) 
was found to be necessary and sufficient to drive the differentiation of Th17 cells 
(Ivanov,  McKenzie  et  al.  2006).    This  was  shown  in  experiments  with  mice 
expressing  green  fluorescent  protein  (GFP)  in  ROR-γt-expressing  cells,  which 
established  a  clear  association  between  ROR-γt  and  IL-17  expression.    In  these 
experiments, forced expression of ROR-γt in naïve T cells was sufficient to induce 
IL-17 expression.  STAT-3 has also been associated with development of Th17 cells 
(Yang, Panopoulos et al. 2007), as well as the transcription factor aryl hydrocarbon 
receptor (AHR) which is a ligand-dependent transcription factor (Quintana, Basso et 
al. 2008; Veldhoen, Hirota et al. 2008). 
 
1.5 Primary role for Th17 cells in the host defence against pathogens 
 
Th17 cells have been described as pathogenic cells in many autoimmune diseases. 
However,  Th17  cells  are  part  of  the  adaptive  immune  response  against  many 
exogenous pathogens.  It has been reported that infectious stimuli such as Borrelia 
burgdorferi and mycobacterial lysates can induce the secretion of IL-17 from T cells 
(Infante-Duarte, Horton et al. 2000).   In another study it was shown that Th17 cells 
were generated in response to conditioned medium from DCs pulsed with Klebsiella 
pneumoniae  and  that  IL-17R-deficient  animals  had  enhanced  sensitivity  to 
Klebsiella pneumoniae infection, suggesting a role for IL-17 in the host defense 
against Klebsiella pneumoniae (Happel, Dubin et al. 2005).  IL-17R-deficient mice 
infected with Klebsiella pneumoniae had an increased mortality rate compared to 
control mice and this was associated with a delay in neutrophil recruitment to the 
alveolar space and a more disseminated infection (Ye, Rodriguez et al. 2001).  IL-
17-producing T cells were also shown to be induced upon infection with Bacteroides 
fragilis (Chung, Kasper et al. 2003), and were shown to accumulate in the lung after     Chapter 1: Introduction 
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infection  with  Mycobacterium  tuberculosis  (Khader,  Bell  et  al.  2007).    In  these 
experiments depletion of IL-17 resulted in reduced recruitment of protective IFN-γ-
producing CD4
 T cells to the lung.  IL-17A was induced in response to systemic 
challenge with Candida albicans and IL-17AR knockout mice had reduced survival 
which was associated with a dramatic increase in fungal burden in the kidneys and 
impaired mobilization of peripheral neutrophils (Huang, Na et al. 2004). 
 
1.6 Role of Th17 cells in autoimmunity 
 
The role of Th17 cells in autoimmune responses has been studied in a number of 
autoimmune mouse models but most extensively in EAE, a mouse model of multiple 
sclerosis and CIA, a mouse model of rheumatoid arthritis. 
 
EAE was initially described as an autoimmune disease initiated by Th1 cells.  This 
was based upon experiments using T-bet-deficient mice, which were resistant to 
EAE  development  (Bettelli,  Sullivan  et  al.  2004)  and  by  adoptively  transferring 
disease  with  myelin  antigen-specific  Th1  cells  to  naïve  recipient  animals  (Das, 
Nicholson  et  al.  1997;  Ramirez  and  Mason  2000).    Studies  using  neutralising 
antibodies to IL-12p40 also suggested a role for Th1 in EAE (Leonard, Waldburger 
et al. 1995; Segal, Dwyer et al. 1998), although this was subsequently shown to be 
due to deletion of IL-23, which uses the same p40 subunit (Cua, Sherlock et al. 
2003).  In contrast, mice lacking IFN-γ (Ferber, Brocke et al. 1996) or the IFN-γ 
receptor (Willenborg, Fordham et al. 1996) were  highly susceptible to the disease 
suggesting that the IFN-γ produced by Th1 cells was not required for the disease or 
even had a protective role.   
 
Further investigations into the effector cell lineage important for the development of 
EAE studied the roles of the cytokines IL-23 and IL-12 (Langrish, Chen et al. 2005).  
IL-12 is a heterodimeric molecule formed by the subunits p35 and p40 and IL-23 is 
also a heterodimeric molecule, composed of p40 and p19.  In this study the authors     Chapter 1: Introduction 
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showed that animals deficient in p19 and therefore IL-23, were protected from EAE, 
whereas  mice  deficient  in  p35  were  highly  susceptible  to  disease  induction 
suggesting that IL-23, not IL-12 was important for disease pathology.  It was also 
reported that in the p19-deficient mice, similar numbers of T cells were found in the 
spinal cord after immunisation but that in contrast to WT mice there was a lower 
proportion of IL-17 and TNFα- expressing CD4 T cells, and a higher proportion of 
IFN-γ-  expressing  CD4  T  cells.    This  suggested  that  IL-23  was  responsible  for 
driving an IL-17-expressing CD4 T cell population that could induce EAE, and that 
IL-12, and consequently the Th1 pathway was dispensable for disease induction.   
Similarly,  the  absence  of  IL-23  was  protective  against  CIA  induction,  which 
correlated with absence of Th17 cells, and a loss of IL-12 was found to exacerbate 
disease symptoms (Murphy, Langrish et al. 2003). 
 
Further support for the role of Th17 cells in the development of EAE came from 
experiments with mice expressing a dominant-negative mutant TGF-β receptor II in 
CD4 T cells.  These mice were deficient in Th17 cells and were resistant to EAE 
(Veldhoen, Hocking et al. 2006).  In addition, RORγt-deficient animals lacked Th17 
cells  and  were  resistant  to  EAE  induction  (Ivanov,  McKenzie  et  al.  2006)    and 
ligation of the AHR with 6-formylindolo [3,2-b] carbazole (FICZ) was shown to 
increase Th17 responses and induce stronger EAE in mice (Quintana, Basso et al. 
2008; Veldhoen, Hirota et al. 2008). 
 
EAE can be induced passively by adoptive transfer of central nervous system (CNS) 
antigen-specific CD4
 T cells, however experiments using adoptive transfer of Th1 
and Th17-polarised antigen-specific cells to investigate the phenotype of the effector 
cells required to induce disease have shown conflicting results. In one study transfer 
of  Th17-polarised  antigen-specific  cells  into  naïve  mice  resulted  in  disease 
induction, whereas Th1-polarised antigen-specific cells did not, despite the presence 
of both effector cell types in the spinal cord.  This suggested that Th17 cells, rather 
than  Th1  cells  were  pathogenic  in EAE  (Langrish,  Chen  et  al.  2005).  However, 
despite these observations, other adoptive transfer studies have shown that both Th1     Chapter 1: Introduction 
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and Th17-polarised cells were able to induce disease (Kroenke, Carlson et al. 2008; 
O'Connor, Prendergast et al. 2008).  It is difficult to interpret results from these 
adoptive  transfer  experiments  because  the  transferred  cells  are  inevitably  not  a 
homogenous population of cells and have been polarised under different conditions 
in each study. 
 
The role of IL-17 in autoimmunity has been investigated using IL-17A knockout 
mice (Nakae, Nambu et al. 2003; Komiyama, Nakae et al. 2006) where onset of 
EAE and CIA was delayed and the severity of the diseases was reduced.  The same 
effect was seen by blocking IL-17A action with an anti-IL-17A antibody (Lubberts, 
Koenders et al. 2004) or administrating a soluble IL-17A receptor (Bush, Farmer et 
al.  2002).    However,  in  these  experiments  the  source  of  IL-17A  required  for 
autoimmunity was not addressed.  IL-17A has been reported to be expressed from 
non-CD4 T cells such as γδ T cells (Roark, Simonian et al. 2008) , CD8 T cells 
(Yen,  Harris  et  al.  2009)    and  NK  cells    (Michel,  Keller  et  al.  2007).      IL-17 
secretion  from  any  of  these  cell  types  could  be  attributed  to  development  of 
autoimmunity.    Furthermore,  IL-17A-expressing  γδ  T  cells  have  recently  been 
implicated in EAE pathogenesis (Sutton, Lalor et al. 2009).   
 
Studies in humans have also shown the presence of IL-17 and IL-17-producing T 
cells in patients with autoimmune disease. For example IL-17A-producing T cells 
have been detected in the gut of Crohn’s disease patients (Annunziato, Cosmi et al. 
2007), IL-17 protein has been detected in the synovium of patients with rheumatoid 
arthritis (Chabaud, Durand et al. 1999) and the IL-17A transcript has found to be up-
regulated in the leisions of patients with MS (Lock, Hermans et al. 2002; Lock and 
Heller 2003). 
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1.7 Interleukin-17 
1.7.1 The IL-17 gene family 
 
The IL-17 family of genes has six members: IL-17A-F, which have been grouped 
together based on similarities in their nucleotide sequences.  IL-17A and IL-17F are 
the  most  closely  related  of  all  the  family  members.    They  are  located  on 
chromosome 1 in mice and are separated by 45kbp with IL-17F downstream and in 
the  opposite  orientation  to  IL-17A.  They  share  50%  nucleotide  and  amino  acid 
sequence homology and have a number of conserved non-coding sequences within 
their locus (Akimzhanov, Yang et al. 2007). IL-17B-E have between 10% and 30% 
sequence homology with IL-17A and have different chromosomal locations (Gaffen, 
Kramer et al. 2006). 
 
IL-17A  was  first  cloned  in  1993  from  an  activated  mouse  cytotoxic  T  cell/  rat 
lymphoma hybridoma.  The nucleotide and amino acid sequence is highly conserved 
over  many  mammalian  species  and  the  amino  acid  sequence  of  murine  IL-17A 
shows  57%  homology  to  the  amino  acid  sequence  encoded  by  ORF13,  an 
immediate-early gene of Herpesvirus Saimiri  (Rouvier, Luciani et al. 1993).  The 
gene encodes a 1.35kb transcript including a 16bp polyA tail and a region of AT-
rich repeats in the 3’untranslated region.  These AT-rich repeats are typical in a 
number of transiently expressed genes such as  oncogenes, cytokines and growth 
factors and signify instability of the mRNA transcript (Shaw and Kamen 1986). 
 
Over-expression of IL-17A in vitro has revealed that the protein can be expressed as 
a  38kDa  disulphide-linked  homodimeric  protein  in  both  glycosylated  and  non-
glycosylated forms (Yao, Fanslow et al. 1995; Yao, Painter et al. 1995). Findings 
have also shown that IL-17A and IL-17F can form heterodimers (Chang and Dong 
2007; Liang, Long et al. 2007). 
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1.7.2 IL-17 Receptors 
 
The first receptor for IL-17A was identified in 1995 (IL-17AR), which bound to 
viral and murine IL-17A recombinant proteins in vitro.  Engagement of IL-17R by 
these ligands induced the activity of NFκB and the production of IL-6 by fibroblast 
cells, demonstrated by the use of an IL-17R monoclonal antibody which blocked 
these effects (Yao, Fanslow et al. 1995).  Northern blot analysis indicated that IL-
17AR mRNA could be detected in most tissues including the spleen, kidney, lungs 
and liver with weaker signals in the brain, heart, skeletal muscle and testes (Yao, 
Fanslow et al. 1995).  The binding affinity of the cloned human IL-17RA for IL-17A 
was found to be relatively low and it was postulated that an additional subunit might 
cooperate  with  IL-17AR  to  create  a  receptor  complex  that  would  be  capable  of 
eliciting the biological responses seen using low concentrations of IL-17A (Yao, 
Spriggs et al. 1997).  
1.7.3 Actions of IL-17 
 
The events resulting from IL-17 ligation include up-regulation of a large range of 
inflammatory  and  haematopoietic  chemokines  and  cytokines,  bone  metabolism 
genes and transcription factors. IL-17 in the presence of TNFα has been shown to 
stabilize the mRNA of IL-6 (Shimada, Andoh et al. 2002) and IL-17 alone has been 
shown to stabilise the mRNA of G-CSF (Cai, Gommoll et al. 1998). IL-17 has also 
been  shown  to  activate  intracellular  transcription  factors  such  as  NFκB  (Yao, 
Fanslow et al. 1995), C/EBPβ and C/EBPδ (Ruddy, Wong et al. 2004). 
 
Human  and  viral  IL-17A  were  shown  to  induce  the  secretion  of  IL-6,  IL-8, 
Prostaglandin E2 and G-CSF from primary cultures of synovial fibroblasts (Fossiez, 
Djossou et al. 1996).  The effects of IL-17A on synovial fibroblasts could also be 
modulated by the use of other cytokines.  For example, TNF-α and IFN-γ had an 
additive effect on IL-17A-induced secretion of IL-6 and while neither IL-17A or 
TNF-α alone had any affect on the secretion of GM-CSF, the combination of these     Chapter 1: Introduction 
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two cytokines induced synovial fibroblasts to produce GM-CSF (Fossiez, Djossou et 
al. 1996).  IL-17 was also shown to up-regulate the release of a range of cytokines 
including IL-1β, TNF-α and IL-6 from non-stimulated adherent human monoctyes 
(Jovanovic, Di Battista et al. 1998) This IL-17-induced release of cytokines by cells 
of the innate immune system has been linked to the neutrophil recruitment seen in 
rat bronchoalveolar lavage after administration of recombinant IL-17A (Laan, Cui et 
al.  1999)  and  to  the  proliferation  and  differentiation  of  CD34
+  haematopoietic 
progenitors  into  neutrophils  when  cultured  in  the  presence  of  irradiated  human 
fibroblasts and IL-17 (Fossiez, Djossou et al. 1996). An association between IL-17A 
and  neutrophil  maturation  and  recruitment  was  also  shown  using  an  adenovirus 
over-expression  system  in  which  murine  IL-17A  cDNA  was  expressed  using 
adenovirus infection and resulted in a 10-fold rise in the absolute neutrophil count 
(Schwarzenberger,  La  Russa  et  al.  1998).      IL-17A  has  also  been  shown  to  be 
involved  in  the  induction  of  osteoclast  differentiation  from  osteoclast  progenitor 
cells, a pathway dependent upon receptor activator of NFκB (RANK) and RANK-
ligand (Kotake, Udagawa et al. 1999; Bar-Shavit 2007). 
1.8   Experimental Autoimmune Encephalomyelitis (EAE): a mouse model of 
autoimmunity 
1.8.1 History of EAE 
 
In the 1930s, experiments using Rhesus monkeys showed that injection with rabbit 
brain and brain extracts could induce a mild paralysis associated with perivascular 
infiltrates  and  demyelination  (Rivers,  Sprunt  et  al.  1933).    Experiments  that 
measured the antibody response induced after intra-peritoneal injections of rabbit 
brain  into  rabbits  showed  a  proportional  relationship  between  antibody  titre,  the 
amount  of  emulsion  injected  and  the  number  of  animals  affected  by  paralysis, 
suggesting that the demyelination may have been caused by an immune response 
(Schwentker  and  Rivers  1934).    Several  groups  then  began  to  try  to  boost  this 
antibody production by administering brain emulsions with killed Mycobacterium 
and paraffin oil, an adjuvant strategy described by Freund and McDermott (Freund,     Chapter 1: Introduction 
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McDermott  et  al.  1942).    The  model  was  termed  experimental  autoimmune 
encephalomyelitis  (EAE)  and  could  be  induced  in  recipient  animals  by  multiple 
injections  of  the  emulsion  (Kabat,  Wolf  et  al. 1947;  McGeachy,  Stephens  et  al. 
2005).    The  disease  was  subsequently  induced  in  a  number  of  different  species 
including guinea pigs, rabbits, goats, mice, rats, hamsters, dogs, sheep, marmosets 
and  chickens.    Clinical  features  of  the  disease  progression  in  each  species  are 
characterised by paralysis although the histopathology and the disease progression 
varies,  depending  on  the  species  used  (Baxter  2007).    The  histopathological 
characteristics  seen  in  EAE  have  similarities  with  some  human  demyelinating 
diseases such as multiple sclerosis and post-infectious encephalomyelitis.  Some of 
the major features in common include the destruction of the myelin sheaths, nerve 
cells and supporting structures in the CNS, the perivascular location of the lesions in 
the  CNS,  the  inflammation  associated  with  the  lesions  and  the  presence  of 
immunoglobulin in the CNS and in the cerebrospinal fluid (CSF) (Baxter 2007).  
EAE  is  therefore  used  as  an  animal  model  of  neuroinflammation  and  immune-
mediated tissue injury to study these diseases.  
 
1.8.2 Models of EAE 
 
Originally, whole spinal cord or brain extracts were used to elicit EAE, however 
specific  encephalitogenic  peptides  are  now  used  with  increased  potency. 
Experiments  attempting  to  isolate  the  encephalitogenic  agent  in  the  brain 
preparations focussed on myelin, a material which forms a layer around the axon of 
nerves in the CNS.  It was found that a specific protein of myelin, MBP could elicit 
EAE  more  effectively  than  whole  myelin  (Laatsch,  Kies  et  al.  1962).    Other 
commonly used peptides to elicit EAE include peptides of myelin oligodendrocyte 
glycoprotein (MOG) (Mendel, Kerlero de Rosbo et al. 1995) and of PLP (Tuohy, Lu 
et al. 1989), two other proteins found in CNS myelin,  The combination of peptide 
and strain of animal is important in the outcome of disease.  For example, Lewis 
Rats are responsive to a MBP peptide but not a MOG peptide, and C57BL/6 mice     Chapter 1: Introduction 
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are responsive to a MOG peptide but not a MBP peptide.  Furthermore, the strain of 
animal  used  also  affects  the  clinical  progression  and  pathology  of  disease.    For 
example, using SJL/J or Biozzi ABH mice induces a relapsing/ remitting disease 
whereas  using  C57BL/6  mice,  induces  a  self-limited  or  chronic  EAE 
(Krishnamoorthy and Wekerle 2009). 
 
EAE  was  initially  induced  by  active  immunisation,  however  experiments  to 
investigate the pathogenic components of disease required the use of passive transfer 
experiments where disease could be transferred by auto-antigen specific T cell lines 
(Ben-Nun, Wekerle et al. 1981).  The Lewis rat was the animal of choice for a long 
time due to its high susceptibility to disease by active immunisation with MBP in 
complete Freunds adjuvant (CFA) (Lipton and Freund 1952).  More recently, mice 
have been more popular due to the use of this species to generate genetic knockouts 
and  mutants  (Krishnamoorthy  and  Wekerle  2009)    Spontaneous  models  of  EAE 
have  also  been  developed  which  have  transgenic  T  cell  or  B  cell  receptors 
expressing  CNS-antigen  specificity  (Goverman,  Woods  et  al.  1993;  Lafaille, 
Nagashima et al. 1994; Waldner, Whitters et al. 2000; Bettelli, Pagany et al. 2003; 
Krishnamoorthy, Lassmann et al. 2006; Pollinger, Krishnamoorthy et al. 2009). 
 
1.8.3 Cell types involved in the pathogenesis of EAE 
 
In the 1970s a number of experiments showed that EAE was T cell mediated by 
depletion of thymus derived cells and transfer of T cells into depleted recipients 
which restored disease. (Gonatas and Howard 1974; Bernard, Leydon et al. 1976; 
Ortiz-Ortiz, Nakamura et al. 1976; Stohl and Gonatas 1980).  Then in the 1980s, 
anti-CD4  antibodies  efficiently  reduced  EAE  in  rats  (Brostoff  and  Mason  1984; 
Brinkman, Ter Laak et al. 1985). This suggested that CD4 T cells were responsible 
for EAE pathogenesis. 
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Although many studies have concentrated on CD4 T cells in EAE there have been 
reports that auto-antigen specific CD8 T cells can also transfer disease into wild type 
recipients and CD8 T cells have been found in MS lesions (Babbe, Roers et al. 2000; 
Huseby, Liggitt et al. 2001; Ford and Evavold 2005). γδ T cells have also been 
reported in the inflammatory infiltrate in EAE (Rajan, Asensio et al. 2000; Gao, 
Rajan et al. 2001).  One study showed that depletion of these cells immediately prior 
to disease onset, reduced EAE severity (Rajan, Gao et al. 1996). γδ T cells have also 
been shown to be a source of pro-inflammatory cytokines and chemokines in EAE 
(Rajan,  Klein  et  al.  1998;  Rajan,  Asensio  et  al.  2000).      Another  recent  report 
showed that adoptive transfer of γδ T cells along with CD4 T cells was required for 
EAE pathogenesis (Sutton, Lalor et al. 2009). 
 
Injection of monoclonal antibodies against MOG protein enhanced demyelination in 
a  transfer  model  of  EAE  suggesting  a  role  for antibody  in  disease  pathogenesis 
(Schluesener, Sobel et al. 1987).   In addition, depletion of B cells using a depletion 
antibody  suggested  that  B  cells  were  necessary  for  EAE  in Lewis  rats  (Gausas, 
Paterson et al. 1982) and mice (Myers, Sprent et al. 1992).  In a MOG peptide-
specific transgenic model of EAE, T cells were shown to selectively expand myelin-
specific B lymphocytes (Pollinger, Krishnamoorthy et al. 2009) and in a model using 
TCR and BCR transgenic mice, in which the majority of both the B cells and the T 
cells were specific for MOG, B cells were shown to present auto-antigen to T cells 
(Bettelli,  Baeten  et  al.  2006;  Krishnamoorthy,  Lassmann  et  al.  2006).  However, 
immunisation  of  IgM  heavy  chain-deficient  mice  with  MBP  resulted  in  EAE 
induction which was clinically similar to the wild type (Wolf, Dittel et al. 1996).  
Also, a study by Hjelmstrom et al, showed that MOG peptide-induced EAE could be 
induced in B cell-deficient (muMT) mice suggesting that B cells and antibodies were 
dispensable  for  primary  demyelination  in  this  model  (Hjelmstrom,  Juedes  et  al. 
1998).  Another study repeated these findings but also showed that if mice were 
immunised with whole MOG protein, rather than the 35-55 peptide used normally in 
the induction protocols then mice were resistant to EAE (Lyons, San et al. 1999). 
Depletion  of  B  cells  using  an  anti-CD20  antibody  before  MOG  35-55  peptide     Chapter 1: Introduction 
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immunisation  exacerbated  EAE  symptoms  and  depletion  after  disease  onset 
suppressed  clinical  disease,  suggesting  reciprocal  roles  for  B  cells  in  EAE 
(Matsushita, Yanaba et al. 2008). 
 
Inflammatory infiltrates in EAE have been described as containing monocytic cells 
(Raine 1984; Traugott 1989; Owens and Sriram 1995). Perivascular macrophages 
are  resident  APCs  of  the  CNS  that  are  continuously  renewed  by  bone  marrow-
derived precursors (Hickey and Kimura 1988).  Microglia are also a subpopulation 
of resident monocytic cells in the CNS which up-regulate MHC class II expression 
and can present antigen in an inflammatory environment (Kreutzberg 1996; Carson, 
Reilly et al. 1998).  Macrophages and microglia have also been shown to up-regulate 
B7 molecules suggesting that these cells can stimulate T cell responses (De Simone, 
Giampaolo  et  al.  1995;  Gerritse,  Laman  et  al.  1996;  Li,  Cuzner  et  al.  1996; 
Issazadeh, Navikas et al. 1998).  Activated macrophages and microglia in EAE are 
sources of inflammatory and toxic mediators such as TNFα (Renno, Krakowski et al. 
1995) IL-1 (Bauer, Berkenbosch et al. 1993), reactive oxygen species (Huitinga, 
Ruuls et al. 1995) and nitric oxide (Okuda, Nakatsuji et al. 1995) and are thought to 
be major players involved in the process of demyelination (Raine 1984). However, 
Sedgwick et al passively transferred activated CD4 T cells into recipient Lewis rats 
that had been irradiated and were therefore leukopenic.  These rats developed severe 
EAE despite the few infiltrating non-T cells into the CNS suggesting these non-T 
cells  were  superfluous  to  disease  induction  (Sedgwick,  Brostoff  et  al.  1987).  
Despite  this  finding,  other  studies  have  shown  a  positive  correlation  between 
activated macrophages in the CNS and disease severity (Berger, Weerth et al. 1997) 
and that depletion of macrophages prevented disease onset (Tran, Hoekstra et al. 
1998). 
 
Studies  have  also  reported  the  presence  of  neutrophils  or  PMNLs  in  the  CNS 
infiltrate  of  animals  with  EAE  using  both  flow  cytometry  and 
immunohistochemistry  methods.    These  include  in  rats  with  hyperacute  EAE 
(Lampert 1967; Levine 1974), in the Biozzi AB/H mouse model (Allen, Baker et al.     Chapter 1: Introduction 
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1993), in Balb/C mice (Maatta, Sjoholm et al. 1998), and also in C57BL/6 mice 
using immunisation with MOG peptide (Bettelli, Sullivan et al. 2004; Wu, Cao et al. 
2010).  During infections, PMNLs release a variety of agents at the site of infection 
including  degradative  enzymes  and  products  of  the  oxidative  burst  (Campoccia, 
Hunt et al. 1993).  They can also produce cytokines and chemokines capable of 
signalling to other cells (Bazzoni, Cassatella et al. 1991).  In one study using SJL/J 
mice immunised with MBP peptide, depletion of polymorphonuclear cells beginning 
at day 8 after immunisation significantly delayed, and in some cases prevented the 
onset of clinical EAE, however depletion of these cells from day 1 until day 7 had 
no effect on disease.  These experiments suggested that PMNLs were acting in the 
effector  phase  of  EAE  in  this  model  although  the  authors  did  not  address  the 
mechanism by which this occurred (McColl, Staykova et al. 1998). 
 
1.8.4 Migration of cells into the central nervous system 
 
The CNS has previously been described as an immunologically privileged site due to 
the reported absence of resident classical APCs, and the lack of a lymphatic drainage 
system (Ransohoff, Kivisakk et al. 2003).  It was also shown that the brain does not 
reject  foreign  tissue  grafts  (Medawar  1948)  highlighting  that  the  CNS  is 
immunologically distinct from other peripheral organs.   Immune reactions however 
do  occur  in  the  CNS  such  as  in  viral  infections,  ischemia,  or  in  inflammatory 
diseases such as MS (Ransohoff, Kivisakk et al. 2003) and leukocytes are found in 
distinct regions of the CNS in healthy individuals (Svenningsson, Andersen et al. 
1995).  There is also evidence to suggest that CSF drains into the cervical lymph 
nodes (Widner, Moller et al. 1988; Cserr and Knopf 1992). 
 
The movement of plasma components, red blood cells and leukocytes into the CNS 
is  controlled  by  the  blood-brain  barrier (BBB)  and  the  blood-cerebrospinal  fluid 
barrier  (BCSFB)  (Zlokovic  2008).    These  are  highly  specialised  endothelial  cell 
barriers possessing intercellular tight junctions which line the walls of the cerebral     Chapter 1: Introduction 
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blood  vesssels  (Huber,  Egleton  et  al.  2001).    During  a  variety  of  inflammatory 
conditions leukocytes cross the BBB or BCSFB and can enter the CNS (Zlokovic 
2008). 
 
The process of leukocyte movement from the bloodstream into tissues is mediated 
by interactions between leukocytes and endothelial cells lining the blood vessel wall.  
Leukocytes make transient contact with the vascular endothelium, which is mediated 
by  adhesion  molecules  such  as  α4-integrins  and  leukocyte  function-associated 
antigen 1 (LFA-1) on the surface of the leukocyte and their respective ligands, such 
as intra-cellular adhesion molecule 1 (ICAM-1) and P-selectin on the endothelial 
lumen.   After this initial tether, leukocytes roll along the vascular wall and bind 
chemotactic factors, such as chemokines immobilised on the endothelial surface. 
Chemokines bind G-protein coupled receptors on the leukocyte surface, a process 
which enhances the avidity and affinity of the interaction between integrins and their 
ligands and facilitates subsequent diapedesis of the leukocyte (Ransohoff, Kivisakk 
et al. 2003). 
 
Chemokines  are  secreted  chemoattractant  proteins  that  bind  to  cell  surface  G 
protein-coupled  receptors  (Olson  and  Ley  2002).    The  interactions  between 
chemokines  and  chemokine  receptors  are  important  for  leukocyte  trafficking  in 
steady state and inflammatory environments.   For example, the chemokine receptor, 
CCR7 is expressed on naïve T cells which is important for the migration of naïve T 
cells across high endothelial venules into the lymph nodes and then further into the T 
cell  areas  of  the  lymph  nodes,  via  interaction  with  the  chemokines  CCL19  and 
CCL21  produced  by  endothelial  and  stromal  cells  of  lymphoid  organs  (Forster, 
Schubel et al. 1999; Gunn, Kyuwa et al. 1999).  Upon activation in the lymph nodes 
T cells lose their expression of CCR7 facilitating movement of activated cells out of 
the lymph nodes.  Th1 cells express high levels of CCR5 and CXCR3, Th2 cells 
express high levels of CCR4 and CCR8 (Bonecchi, Bianchi et al. 1998; Loetscher, 
Uguccioni  et  al.  1998)  and  Th17  cells  have  been  shown  to  express  CCR6 
(Yamazaki, Yang et al. 2008) which can influence the migration of these cells into     Chapter 1: Introduction 
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inflammatory sites where the respective ligands are expressed.  For example, CCR5 
binds  the  chemokines  CCL3,  CCL4  and  CCL5  with  high  affinity  which  are 
expressed in the lung, CNS, skin and liver, CCR4 binds CCL17 and CCL22 which 
are expressed in Th2 inflammatory sites including the lung and skin and CCR6 binds 
CCL20  which  is  expressed  in  the  intestine  and  the  skin  (Olson  and  Ley  2002).  
Chemokine expression in tissues can also be induced by inflammatory stimuli.  For 
example, CCL20 expression is induced in the CNS during EAE (Liston, Kohler et al. 
2009). 
 
In  EAE,  antibodies  specific  for  α4-integrin  reduced  the  severity  of  disease 
(Yednock, Cannon et al. 1992) and have been used in the treatment of MS with 
some success (Tubridy, Behan et al. 1999; Miller, Khan et al. 2003) suggesting a 
central role for α4-integrin in disease pathogenesis.   A role for P-selectin has also 
been described in trafficking of leukocytes to the CNS in EAE (Kerfoot and Kubes 
2002; Piccio, Rossi et al. 2002).  C-C Chemokine Receptor 2 (CCR) 2-deficient 
mice (Fife, Huffnagle et al. 2000) are resistant to EAE, which has been attributed to 
a lack of monocytes in the CNS.  Two reports have also shown that CCR6-deficient 
mice  had  greatly  reduced  disease  severity  (Liston,  Kohler  et  al.  2009;  Reboldi, 
Coisne et al. 2009; Villares, Cadenas et al. 2009) which was attributed in one study 
(Reboldi, Coisne et al. 2009) to the inability of Th17 cells, which express high levels 
of CCR6 to access the CNS and in the other to the reduced priming of auto-reactive 
CD4 T cells in the draining lymph nodes (Liston, Kohler et al. 2009).  However, in 
contrast to these findings, two other reports demonstrated that CCR6-deficient mice 
were susceptible to disease with enhanced disease severity over wild-type mice due 
to reduced T-regs infiltrating the spinal cord (Villares, Cadenas et al. 2009) and 
enhanced  IL-17A  and  IFN-γ  responses  in  the  periphery  (Elhofy,  Depaolo  et  al. 
2009). 
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1.8.5 The role of pertussis toxin in the induction of EAE 
 
Lee and Olitsky were the first to report that pertussis vaccine administered into the 
peritoneum  would  enhance  the  development  of  encephalomyelitis  in  mice  after 
administration of mouse brain antigens in CFA  (Lee and Olitsky 1955).  It was 
further noted that fractions of Bordetella pertussis cells (vaccine) rich in histamine-
sensitizing factor were involved in increasing encephalitogenic activity of the spinal 
cord emulsions (Levine and Wenk 1965; Levine, Wenk et al. 1966).  The histamine-
sensitizing factor was also called pertussigen and is now known as pertussis toxin.   
 
Inclusion of pertussis toxin in the immunisation protocol for EAE can enhance EAE 
severity in mice that are susceptible to the disease induced by CNS antigens and 
CFA alone, and to allow EAE development in mice that are not susceptible in this 
way (Munoz and Mackay 1984).  Although not required in some models such as in 
the  development  of  spontaneous  EAE  in  the  MBP  transgenic  mice  (Goverman, 
Woods et al. 1993),  administration of pertussis toxin has been shown to enhance 
onset and incidence of disease. In the Lewis rat, administration of pertussis toxin 
was  not  required  for  EAE  onset  but  could  change  the  clinical  progression  and 
pathology of disease (Levine and Wenk 1965; Levine, Wenk et al. 1966). MOG-
induced  EAE  in  C57BL/6  mice  requires  the  administration  of  pertussis  toxin 
(Tafreshi,  Mostafavi  et  al.  2005).  The  mechanisms  by  which  pertussis  toxin 
influences the development of EAE are not clearly defined, however administration 
of  pertussis  toxin  was  shown  to  override  genetic  checkpoints  important  for  the 
development of EAE (Linthicum and Frelinger 1982; Blankenhorn, Butterfield et al. 
2000).   
 
Pertussis toxin is an AB exotoxin which is secreted from the bacterium Bordetella 
pertussis,  the  agent  that  causes  whooping  cough  (Mooi  1988).   The  exotoxin  is 
composed of six subunits which are arranged in an A-B structure. The B oligomer, 
composed  of  the  subunits  S2-S5  (with  two  copies  of  S4),  attaches  to  surface 
glycoproteins expressed on a variety of mammalian cells and allows the A oligomer,     Chapter 1: Introduction 
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composed  of  subunit  S1,  to  enter  the  cell.    The  A  oligomer  is  the  enzymatic 
component of the toxin and is responsible for ADP-ribosylating G proteins inside the 
cell.  This ADP-ribosylation, inactivates G-protein coupled receptors and therefore 
inhibits signalling events downstream of this receptor (Reisine 1990).   
 
In  Bordetella  pertussis  infection,  pertussis  toxin  is  released  and  has  modulatory 
effects on the host immune system, presumably to allow an infection to become 
established. For example, the toxin has been shown to delay neutrophil recruitment 
to  the  airways  in  B  pertussis  infection  (Carbonetti,  Artamonova  et  al.  2003; 
Kirimanjeswara, Agosto et al. 2005) and depletion of airway macrophages enhanced 
B pertussis infection with a pertussis toxin-deficient strain up to wild type levels 
suggesting that resident airway macrophages may be the primary target for pertussis 
toxin in B pertussis infection (Carbonetti, Artamonova et al. 2007).  Pertussis toxin 
has also been shown to suppress serum antibody responses to B pertussis antigens 
after infection (Carbonetti, Artamonova et al. 2004)to reduce MHC II molecules on 
the  surface  of  human  monocytes  (Shumilla,  Lacaille  et  al.  2004),  to  modulate 
surface  markers  on  dendritic  cells  (Martino,  Volpe  et  al.  2006)  and  to  induce 
generalised  lymphocytosis  due  to  the  failure  of  cells  to  migrate  back  to  the 
peripheral lymphoid tissue  (Spangrude, Braaten et al. 1984).    
 
Pertussis toxin has been hypothesised to facilitate immune cell entry into the CNS 
by increasing permeability across the BBB.  In the 1970s it was reported that use of 
pertussis toxin in Lewis rats increased vascular permeability in the central nervous 
system and this increase in permeability was associated with the development of 
paralysis when mice were induced for EAE (Bergman and Munoz 1975; Bergman, 
Munoz et al. 1978).  Moreover, use of pertussis toxin alone has been shown to allow 
influx of plasma components into the central nervous system (Amiel 1976; Clifford, 
Zarrabi  et  al.  2007).  Experiments  using  intravital  microscopy  of  the  murine 
microvasculature showed that injection of pertussis toxin increased the rolling and 
adhesion of activated lymphocytes which  could  be inhibited with antibodies that 
blocked P-selectin (Kerfoot, Long et al. 2004).  In addition to an effect on vascular     Chapter 1: Introduction 
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permeability, pertussis toxin may facilitate EAE by acting as an adjuvant to drive T 
cell responses to auto-antigens. Indeed, pertussis toxin has been shown to enhance 
antigen specific cytokines to hen egg white lysozyme (HEL) (Shive, Hofstetter et al. 
2000), to enhance Th1 and Th2 responses (Hofstetter, Shive et al. 2002; Denkinger, 
Denkinger  et  al.  2007)  and  also  Th17  responses  (Chen,  Howard  et  al.  2007; 
Hofstetter, Grau et al. 2007).  
 
1.9 Thesis aims 
 
IL-17A is an evolutionary conserved molecule whose expression is involved in the 
development  of  immune  responses.    Mice  lacking  IL-17A  expression  have  less 
efficient  immune  responses  to  pathogens  such  as  Klebsiella  pneumoniae  and 
Candida  Albicans,  resulting  in  a  reduced  ability  to  clear  the  pathogens  and  an 
increase in severity of disease.  In addition, reduced IL-17A expression leads to a 
reduction  in  the  severity  of  autoimmune  mouse  models  such  as  Experimental 
Autoimmune  Encephalomyelitis  (EAE)  and  Collagen  Induced  Arthritis  (CIA). 
However, the understanding of how induction of IL-17A expression relates to either 
resolution of an infection or development of immune pathology is still incomplete.  
 
In order to further understand the IL-17A response in infection and autoimmunity, to 
investigate  the  conditions  in  which  an  IL-17A-associated  immune  response  can 
manifest  in  immune  pathology,  to  determine  which  cells  are  responsible  for 
expressing IL-17A and which signals are responsible for inducing its expression, the 
aims of this PhD were: 
 
1)  To investigate the sequence of immunological events in the lymph nodes, 
blood  and  spinal  cord  in  the  development  of  the  IL-17A-associated 
autoimmune response, EAE. 
 
2)  To investigate how pertussis toxin (an agent required to be administered for 
disease pathology in EAE) modulates the sequence of immunological events     Chapter 1: Introduction 
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in  EAE  and  to  investigate  whether  pertussis  toxin  modulates  IL-17A 
expression in EAE. 
 
3)  To generate and characterise a reporter mouse to irreversibly label all cells 
that  have  activated  the  IL-17A  promoter  and  their  progeny    Chapter 2: Materials and methods 
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Chapter 2: Materials and Methods 
2.1 Mice 
 
C57BL/6 female mice aged 6-8 weeks were used for all experiments.  Mice were 
bred and housed at the NIMR facility under Specific Pathogen Free (SPF) conditions 
and all experiments were carried out in accordance with Home Office guidelines. 
 
2.2 Immunisations 
 
Buffers/solutions/media:  
 
•  Dulbecco’s Phosphate Buffered Saline containing 1g/L D-Glucose, 36mg/ml 
Pyruvate, CaCl2, MgCl2 (D-PBS) (Invitrogen) 
 
2.2.1 Preparation and injection of MOG/CFA emulsion 
 
Desiccated,  heat-killed  Mycobacterium  tuberculosis  H37Ra  (Difico  laboratories) 
was prepared at 5mg/ml in incomplete Freund’s adjuvant (IFA) to form complete 
Freund’s adjuvant (CFA).  MOG peptide35-55 (MEVGWYRSPFSRVVHLYRNGK) 
from PepLogic was prepared at 5mg/ml in D-PBS.  CFA and MOG peptide35-55 
preparations were combined in equal volumes which resulted in H37Ra and MOG 
peptide35-55 at a final concentration of 2.5mg/ml.  This mixture was then emulsified 
using an homogeniser, which was carried out on ice, homogenising approximately 3 
times for 30 seconds, with a gap of approximately 30 seconds in between to prevent 
the  emulsion  from  warming.    100µl  of  the  emulsion  was  injected  in  total 
subcutaneously into the base of the tail using a 19 gauge needle so each mouse 
received 250µg of H37Ra and 250µg of MOG peptide35-55.   50µl of the emulsion 
was injected either side of the tail.      Chapter 2: Materials and methods 
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2.2.2 Preparation and injection of pertussis toxin  
 
Pertussis  toxin  (Calbiochem)  was  prepared  at  2µg/ml  in  D-PBS  and  100µl  was 
injected  into  the  peritoneal  cavity  using  a  27  gauge  needle  so  that  each  mouse 
received 200ng of pertussis toxin.  As indicated in the results, pertussis toxin was 
either injected alone or at the same time as the MOG CFA injection, with a booster 
given 2 days later, or on days 1 and 3, days 3 and 5, or days 5 and 7 following the 
MOG CFA injection.   In the experiment in which pertussis toxin was injected alone, 
without MOG CFA injection, 100µl of D-PBS was injected at the same time points 
into control mice. 
 
2.2.3 Scoring of mice 
 
Mice were scored for signs of clinical EAE from day 8 following the base of tail 
injection.  Scoring was as follows: score 0- no symptoms, score 1- flaccid tail, score 
2 –impaired righting reflex and/or gait, score 3 – partial hind limb paralysis, score 4- 
complete  hind  limb  paralysis,  score  5-  complete  hind  limb  paralysis  and  partial 
forelimb paralysis. 
 
2.3 Isolation of cell populations 
 
Buffers/solutions/media: (all reagents Sigma unless otherwise stated) 
 
•  Ammonium chloride potassium carbonate lysis buffer (ACK) (distilled-H2O 
containing 150mM NH4Cl, 10mM KHCO3 and 0.1mM Na2EDTA) 
•  D-PBS  containing  1g/L  D-Glucose,  36mg/ml  Pyruvate,  9.01mM  CaCl2, 
4.93mM  MgCl2  (Invitrogen),  supplemented  with  0.5%  Bovine  Serum 
Albumin (BSA). 
•  Phosphate buffered saline (PBS)      Chapter 2: Materials and methods 
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•  Air  buffered  Iscove’s  modified  Dulbecco’s  medium  (AB-IMDM) 
supplemented with 0.5% BSA. 
 
2.3.1 Blood 
 
Mice were sacrificed by Schedule 1 Killing using a rising concentration of CO2 and 
approximately  500µl  of  blood  was  collected  immediately  afterwards  by  cardiac 
puncture using a 27 gauge needle. The blood was added to 200µl of heparin sodium 
salt (reconstituted in 5ml distilled-H2O), mixed thoroughly and stored on ice.  Red 
blood cells were lysed by adding 4ml of ACK lysis buffer, mixing and leaving for 7 
minutes at room temperature.  At least 4ml of D-PBS was then added to stop the 
lysis  reaction  and  the  cells  were  collected  by  centrifugation  (1200rpm  for  4 
minutes). ACK lysis was repeated, and the cells were subsequently re-suspended in 
D-PBS. 
 
2.3.3 Spinal cord 
 
A cardiac perfusion was carried out by injecting 10ml of PBS into the left ventricle 
of the heart.  The spinal column was dissected out from the base of the tail up to the 
base of the brain and placed immediately into cold PBS.  It was then cut into small 
sections and the spinal cord was carefully removed using forceps.  The spinal cord 
was placed into AB-IMDM and the tissue was mechanically disrupted by mashing 
through a 70µm cell strainer.  Cells were collected by centrifugation (1200rpm for 4 
minutes) and were re-suspended in 10ml of 30% Percoll (GE Healthcare, prepared in 
D-PBS).    This  mixture  was  centrifuged  for  20  minutes  at  2000rpm  and 
approximately 9.5ml of supernatant was removed from the leukocyte pellet using a 
Pasteur pipette.  The pellet was washed and re-suspended in D-PBS. 
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2.3.4 Draining lymph nodes 
 
The para-aortic and inguinal lymph nodes were removed and placed in AB-IMDM.  
A single cell suspension was prepared in AB-IMDM by mechanical disruption of the 
tissue and filtering through a 70µm cell strainer. 
 
2.3.5 Cell counting 
 
Leukocyte preparations for flow cytometry analysis from the lymph nodes, blood 
and spinal cord were counted using the Casy-1 cell counter (Sharfe system) which 
counts all cells between 4.8-15µM. 
 
2.4 Flow cytometry analysis 
 
Buffers/solutions/media: (all reagents Sigma unless otherwise stated) 
 
•  FACS buffer (PBS containing 0.5% sodium azide and 0.5% BSA) 
•  D-PBS  containing  1g/L  D-Glucose,  36mg/ml  Pyruvate,  CaCl2,  MgCl2 
(Invitrogen), supplemented with 0.5% BSA. 
•  Iscove’s  modified  Dulbecco’s  medium  (IMDM)  supplemented  with  10% 
FCS  (Biosera),  0.1mM  β-Mercaptoethanol  and  Penicillin-streptomycin-
glutamine (200units/ml 200µg/ml and 4mM, respectively) (Invitrogen). 
 
2.4.1 Staining for cell-surface antigens  
 
Cells were re-suspended at 0.5-5x10
6 cells per 200µl of FACS buffer containing a 
1:10  dilution  of  anti-Fc  receptor  antibody  (concentrated  supernatant  prepared  in-
house from a 2.4G2 hybridoma) for at least 15 minutes on ice.  The cells were then 
collected by centrifugation (4 minutes at 1200rpm) and resuspended in 200µl of     Chapter 2: Materials and methods 
  59 
antibody  cocktail  (Table  2.1)  prepared  in  FACS  buffer.    7-aminoactinomycin  D 
(7AAD) was included in the stain at 2.5µg/ml, if required and staining was carried 
out for at least 30 minutes on ice in the dark.  Cells were washed with FACS buffer 
(by  centrifuging  the  cells  at  1200rpm  for  4  minutes,  discarding  the  supernatant, 
resuspending  the  pellet  in  wash  fluid  and  then  collecting  the  cells  again  by 
centrifugation) and were fixed by resuspending in 200µl of paraformaldehyde-based 
intra-cellular (IC) fixation buffer (eBioscience) for 20 minutes at room temperature 
in the dark.  The cells were then washed in FACS buffer and stored at 4°C before 
analysis by flow cytometry. 
 
2.4.2 Intra-cellular IL-17A and IFN-γ staining  
 
For  staining  of  intra-cellular  cytokines,  a  4hour  stimulation  with  Phorbol  12,13, 
Dibutyrate (PdBu), ionomycin and brefeldin A was required.  In order to capture 
cell-surface  molecules  that  could  potentially  be down-regulated  upon  stimulation 
with these mitogenic stimuli, cell-surface staining was carried out first.  For this, 
cells  were  re-suspended  at  0.5-5x10
6  cells  per  200µl  of  D-PBS  (containing  no 
sodium azide as the cells must be kept viable for further stimulation) containing a 
1:10  dilution  of  anti-Fc  receptor  antibody  (concentrated  supernatant  prepared  in-
house from 2.4G2 hybridoma) for at least 15 minutes on ice. The cells were then 
collected by centrifugation (1200rpm, 4 minutes), resuspended in 200µl of D-PBS 
containing a cocktail of antibodies to extra-cellular markers  (Table 2.1), and were 
left for at least 30 minutes on ice in the dark.  7AAD was not included in the cocktail 
at this stage.   Following extra-cellular staining, the cells were washed with D-PBS, 
re-suspended at approximately 2x10
6 cells/ml in IMDM medium containing PdBu at 
0.05µg/ml, ionomycin at 0.5µg/ml and brefeldin A at 2µg/ml and incubated at 37°C 
for  4  hours.  Cells  were  then  harvested  by  centrifugation  (1200rpm,  4  minutes), 
washed  in  FACS  buffer  and  re-suspended  in  FACS  buffer  containing  7AAD  at 
2.5µg/ml for 15 minutes on ice in the dark.  Excess 7AAD was washed from the 
cells by two washes in FACS buffer and the cells were fixed by re-suspending in     Chapter 2: Materials and methods 
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200µl  of  para-formaldehyde-based  IC  fixation  buffer  for  20  minutes  at  room 
temperature  in  the  dark.    The  cells  were  collected  by  centrifugation  and  were 
permeabilised in 100µl of the detergent, IGEPAL CA-630 (diluted 1:100 in distilled 
H2O and prepared 1:10 in FACS buffer) for 4 minutes at room temperature.  200µl 
of FACS buffer was added to inhibit the permeabilisation, and the cells were re-
suspended in 200µl of intra-cellular staining antibodies (Table 2.2) for at least 30 
minutes  at  room  temperature  in  the  dark.  Fluorochrome-conjugated  streptavidin 
(Pacific Orange-conjugated streptavidin from Invitrogen) was included in the intra-
cellular staining cocktail as required.  The cells were then collected by centrifugation 
at 1200rpm for 4 minutes and were washed and resuspended in FACS buffer before 
flow cytometry analysis. 
 
2.4.3 Intra-cellular Foxp3 staining 
 
A  Foxp3  staining  buffer  set  from  eBioscience  was  used  according  to  the 
manufacturer’s instructions.  0.5ml of Foxp3 Fix-Perm buffer (diluted 1:3 in Fix-
Perm diluent) was added to the cells instead of IC fixative described in the intra-
cellular cytokine staining protocol above, followed by 40 minutes incubation in the 
fridge.    The  cells  were  then  collected  by  centrifugation  (1200rpm.  4  minutes), 
washed with 2ml of permeabilisation buffer (diluted 1:10 in distilled H20) and re-
suspended  in  100µl  of  permeabilisation  buffer  containing  a  cocktail  of  staining 
antibodies including anti-Foxp3 APC (Table 2.1) Staining was carried out at room 
temperature  for  40  minutes  and  the  cells  were  washed  twice  in  2ml  of 
permeabilisation buffer before re-suspending in  FACS buffer for flow cytometry 
analysis.  
 
The cells were analysed by flow cytomery, collecting at least 500,000 events per 
sample.  Flow cytometric analysis was performed using four-colour analysis on the 
FACSCalibur (BD) and seven-colour analysis on the FACSCanto II (BD). The data     Chapter 2: Materials and methods 
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were analysed using Flowjo software (Tree Star) as shown in Chapter 3 for lymph 
nodes, blood and spinal cord (Figure 3.1, 3.5 and 3.12, respectively). 
 
2.5 Bleeding of mice and Vetscan analysis 
 
Mice were bled by cutting the end of the tail and collecting approximately 80µl of 
blood  into  a  heparin-coated  capillary  tube.    The  blood  was  expelled  from  the 
capillary tube using a Gilson pipette and mixed in an eppendorf tube.  5µl of this 
was mixed with 45µl of PBS for measurement of the number and percentage of 
blood granulocytes, monocytes and lymphocytes on a Vetscan HM II (Abaxis). 
 
2.6 Assessment of MOG-specific cytokine production  
 
Buffers/solutions/media: (all reagents Sigma unless otherwise stated) 
 
•  Iscove’s  modified  Dulbecco’s  medium  (IMDM)    supplemented  with  10% 
FCS  (Biosera),  0.1mM  β-mercaptoethanol  and  Penicillin-streptomycin-
glutamine (200units/ml 200ug/ml and 4mM, respectively) (Invitrogen). 
 
2.6.1 Stimulation of lymph node cells 
 
Lymph node cells were counted as described in section 2.3.5 and cultured in U-
shaped 96-well plates at 1x10
6 cells per 200µl of IMDM medium supplemented with 
either MOG35-55 peptide (MEVGWYRSPFSRVVHLYRNGK) at a concentration of 
20µg/ml  or  PdbU  and  ionomycin  at  concentrations  of  0.05µg/ml  and  0.5µg/ml, 
respectively. Supernatants were recovered after incubation for 24 hours at 37°C and 
were stored at -20°C for future analysis.   
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2.6.2 Flow cytometry staining 
 
For flow cytometry analysis of the MOG35-55 peptide-stimulated cells (described in 
section 2.6.1), brefeldin A was added to the medium at a concentration of 2µg/ml 
after 18 hours of culture and the cells were cultured for a further 6 hours. Cells were 
harvested and stained with 7AAD at 2µg/ml in FACS buffer for 15 minutes on ice in 
the  dark.  They  were  then  washed  twice  with  FACS  buffer,  followed  by 
permeabilisation,  fixation  and  staining  with  antibodies  specific  for  intra-cellular 
cytokines  (Table  2.2)  as  described  in  section  2.4.2.  Antibodies  to  cell-surface 
markers (Table 2.1) were this time also included in the same antibody cocktail. 
 
2.6.3 Detection of IL-17A and IFN-γ protein in culture supernatnants 
 
IL-17A  and  IFN-γ  protein  in  supernatant  samples  was  determined  using 
Flowcytomix mouse Th1/Th2 10plex kit (Bender MedSystems) as directed by the 
manufacturer’s  instructions.    Briefly,  anti-IL-17  and  anti-IFN-γ  antibody-coated 
beads were incubated with 10µl of supernatant sample or kit standard plus biotin-
conjugated detection antibodies, specific for different epitopes of IL-17 and IFN-γ.  
Standards were prepared by three-fold dilution using recombinant cytokines from 
the Flowcytomix kit with a top concentration of 20ng/ml.  The bead mixture was 
then incubated with PE-conjugated streptavidin before analysis of the samples using 
FACSCalibur.    The  FACS  data  were  analysed  using  Flowcytomix
Tm  Pro  2.3 
Software which determined IL-17 and IFN-γ protein concentrations for each sample 
in pg/ml. 
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2.7 Assessment of cell migration 
 
Buffers/solutions/media: (all reagents Sigma unless otherwise stated) 
 
•  Roswell  Park  Memorial  Institute-1640  (RPMI)  medium  (Invitrogen), 
supplemented with 0.5% fatty acid free BSA 0.1mM β-mercaptoethanol  and 
Penicillin-streptomycin-glutamine  (200units/ml  200ug/ml  and  4mM, 
respectively) from Invitrogen (Assay medium) 
•  FACS buffer (PBS containing 0.5% sodium azide and 0.5% BSA) 
•  D-PBS containing 1g/L D-Glucose, 36mg/ml Pyruvate, CaCl2, MgCl2 (D-
PBS) from Invitrogen 
 
Transwell  inserts  from  polycarbonate  membrane  24  well  transwell  permeable 
supports (Corning CoStar) were coated with 100µl of D-PBS containing 2µg/ml 
fibronectin and left overnight.  The following day, the fibronectin was removed and 
replaced with 1% fatty acid free BSA  in D-PBS (blocking solution) and left for at 
least one hour.  Peripheral lymph nodes were harvested and placed in assay medium.  
A single cell suspension was then prepared by mechanical disruption of the tissue 
and filtering through a 70µm cell strainer.  For cells treated with pertussis toxin in 
vitro, cells were then  adjusted to a concentration of 5x10
6 cells/ ml using assay 
buffer  and  pertussis  toxin  was  added  to  half  of  the  cells  at  a  concentration  of 
10ng/ml.  The cells were then incubated at 37°C for 2 hours followed by a wash and 
re-suspension in assay medium at 1x10
7 cells/ ml.  For assessment of migration of 
cells after in vivo treatment with pertussis toxin, peripheral lymph node cells were 
removed from the mouse and re-suspended directly in assay buffer at 1x10
7 cells/ml 
without any in vitro incubation period.  CCL21 ligand (R&D Systems) was prepared 
in assay buffer with a top dilution of 200ng/ml and subsequent 2-fold dilutions.  The 
blocking solution in the transwell inserts was removed and 100µl of cell suspension 
was added to each insert, followed by addition of 600µl of CCL21 at the appropriate 
concentration underneath each transwell.  Input controls were included in the plate 
which  contained  600µl  of  assay  medium  plus  100µl  of  cell  suspension  in  the     Chapter 2: Materials and methods 
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absence of the transwell insert.  The plates were incubated at 37°C for 4 hours and 
then  the  cell  suspensions  underneath  the  transwell  inserts,  as  well  as  the  input 
control suspensions were transferred into FACS tubes, rinsing each well thoroughly 
with  FACS  buffer.    The  cells  were  centrifuged  (1200rpm,  4  minutes)  and  re-
suspended  in  FACS  buffer  containing  7AAD  (2.5µg/ml),  anti-CD4  PE  and  anti-
TCRβ FITC (Table 2.1) and left for at least 30 minutes on ice in the dark.  Cells 
were then collected by  centrifugation (1200rpm, 4 minutes) and re-suspended in 
300µl of FACS buffer.  A solution of unlabelled, calibrite beads (BD) was prepared 
by adding 2-3 drops to 5ml of FACS buffer.  100µl of this was then added to each 
sample  before  analysis  using  a  FACSCalibur.  Approximately  2000  beads  were 
acquired for each sample and the percentage of migration was calculated as follows: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Number of cells per bead  
in sample 
=  Number of CD4 T cells acquired / Number of 
beads acquired 
 
   
% migration of input 
 
= 
 
Number of cells per bead in sample /  
Number of cells per bead in input control 
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Table 2.1 Cell-surface antibodies used for flow cytometry 
 
Marker  Clone  Conjugate  Supplier 
TCRβ  H57-597  Biotin  eBioscience 
TCRβ  H57-597  PE  eBioscience 
TCRβ  H57-597  FITC  BD Pharmingen 
CD4  RM4-5  eFluor 450  eBioscience 
CD4  RM4-5  PE  BD Pharmingen 
CD19  MB19-1   FITC  eBioscience 
CD19  RM7705  APC  Invitrogen 
CD8α  53-6.7  APC  eBioscience 
CD8α  5H10  Pacific Orange  Caltag  
Ly6G  1A8  PE  BD Pharmingen 
Neutrophil (Allotypic marker)  7/4  Alexa Fluor 700  AbD Serotec 
γδ TCR  eBioGL3  APC  eBioscience 
 
Table 2.2 Intra-cellular antibodies used for flow cytometry 
 
Marker  Clone  Conjugate  Supplier 
IL-17A  TC11-18H10.1  FITC  Biolegend 
IL-17A   TC11-18H10.1  PE  BD Pharmingen 
IFN-γ  XMG1.2  PE  eBioscience 
Foxp3  FJK-16s  APC  eBioscience 
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2.8 Cloning 
 
Buffers/solutions/media: (all reagents from Sigma unless otherwise stated) 
 
•  TAE  buffer (made  by  the  NIMR  media  lab):  40mM  Tris  Acetate  (pH8), 
1mM EDTA  
•  TFB1:  30mM  Potassium  Acetate,  10mM  CaCl2,  50mM  MnCl2,  100mM 
RbCl, 15% Glycerol (adjusted to pH5.8) 
•  TFB 2: 10mM MOPS, 75mM CaCl2, 10mM RbCl2, 15% Glycerol (adjusted 
to pH6.5)  
•  STET buffer: 0.1M NaCl, 10mM Tris.Cl (pH8), 1mM EDTA, 5% Triton X-
100 
•  LB medium (made by the NIMR media lab) 
 
2.8.1 Phenol:Chloroform DNA extraction 
 
An equal volume of Phenol:Chloroform:Isoamyl alcohol saturated with 10mM Tris 
(pH 8), 1mM EDTA was added to the bacterial or ES cell DNA solution.  After 
briefly vortexing, the mixture was centrifuged for 30 seconds at 3000 rpm at room 
temperature to separate the aqueous and organic phases.  The top aqueous phase was 
removed and transferred to a new tube containing 1 ml of 96% ethanol and 0.1M 
sodium acetate (pH 5.2).  The tube was mixed by inversion and stored at -70ºC for at 
least 1 hour.  The DNA pellet was collected by centrifugation for 30 minutes at 3000 
rpm, washed once in 70% ethanol and dissolved in molecular biology grade water 
(5Prime) or TE buffer (Qiagen). 
 
2.8.2 DNA Restriction Enzyme Digests 
 
Restriction enzymes and buffers (which differ in salt and magnesium concentration 
and pH) were obtained from New England Biolabs and Roche.  Digestions were     Chapter 2: Materials and methods 
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carried out using the restriction enzyme buffer diluted 1:10 in the final reaction mix 
and using restriction enzyme at no more than 5% of the final volume.  For digestions 
with  two  different  restriction  enzymes,  which  required  different  buffers,  two 
separate reactions were carried out.  The DNA was purified after the first reaction 
with either phenol:chloroform extraction and ethanol precipitation or using a Qiagen 
PCR purification column as described in the manufacturers’ instructions. 
 
2.8.3 Agarose Gel Electophoresis 
 
0.5-2%  agarose  gels  were  prepared  using  agarose  dissolved  in  1  x  TAE  buffer 
(prepared  in  distilled-H20).    Ethidium  bromide  was  added  at  a  concentration  of 
0.2mg/ml.  1kb and 100bp DNA ladders were used from New England Biolabs.  
DNA was supplemented with Orange G loading buffer at a concentration of 1:5 
before loading into the gel. The gels were run for approximately 1 hour at 80-100V. 
DNA was visualized and photographed under short wave UV light. 
 
2.8.4 Extracting DNA fragments from agarose gels 
 
After running the DNA digest the appropriate DNA fragment was cut out from the 
agarose gel under short wave UV light using a scalpel blade. DNA was extracted 
from the agarose slice using a Qiagen Gel Extraction kit or GeneClean kit from 
Anachem according to the manufacturer’s instructions. 
 
2.8.5 De-phosphorylation of DNA fragments 
 
Linear  DNA  fragments  with  complementary  sticky  ends  were  de-phosphorylated 
using  Shrimp  Alkaline  Phosphatase  (SAP,  Roche  Biomolecular)  to  remove  5’ 
phosphate groups.  This was done by adding 2 units of SAP per 1µg of DNA in the 
restriction enzyme digest.  Buffer was used at a dilution of 1:10 in the final reaction     Chapter 2: Materials and methods 
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mix.  This was incubated for 30 minutes at 37ºC, followed by 30 minutes at 56ºC 
and then 10 minutes at 70ºC. 
 
2.8.6 Filling in 5’ overhangs 
 
This  was  carried  out  on  restriction  enzyme  digested  DNA  by  adding  dNTPs 
(Invitrogen) at a final concentration of 200µM each and 8 units of Klenow fragment 
(Promega)  per  1µg  of  DNA  used  in  the  restriction  digest.  Klenow  is  the  larger 
fragment of DNA polymerase I which retains 5’-3’ polymerase activity but has lost 
5’-3’  exonuclease  activity,  making  it  useful  for  filling  in  overhangs.    This  was 
incubated  at  room  temperature  for  30  minutes.    The  DNA  was  subsequently 
phenol:chloroform extracted and ethanol precipitated as described in section 2.8.1. 
 
2.8.7 Ligation reactions 
 
Ligation of DNA insert fragments (I) into vectors (V) were carried out using T4 
DNA ligase supplied from Roche. Ligations were carried out at ratios of 3:1 and 5:1 
(I:V).    Amounts  of  DNA  for  the  ligation  reactions  were  determined  using  the 
following formula: 
 
Amount of V (ng) X Length of I (Kbp)      X       I:V    = Amount of I (ng) 
Length of V (Kbp) 
 
 1 unit of the enzyme was used per ligation reaction, with ligase buffer diluted 1:10 
in a final volume of 10µl. The ligation reactions were carried out at 16ºC overnight. 
2.8.8 Transformation of plasmid DNA and preparation of competent bacteria 
 
One Shot INVαF’ competent cells from Invitrogen were used for transformation of 
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DH10B  E  coli  were  used  for  other  transformations.    Transformations  using 
commercial bacteria were carried out according to the manufacturer’s instructions.  
Transfomations  using  DH10B  E  coli  was  carried  out  as  follows:    Cells  were 
defrosted on ice, removed from the freezing vial and transferred to a round-bottomed 
tube.  4µl of ligation reaction was added to the cells and carefully mixed.  After a 30 
minute incubation on ice the cells were heat-shocked at 42ºC for 40 seconds and 
then incubated on ice for 2 minutes.  2.5 ml of LB medium without addition of 
antibiotics was added  and the  cells  were incubated for 45 minutes at 37ºC with 
shaking.    Aliquots  were  plated  out  onto  LB  agar  plates  supplemented  with  an 
appropriate antibiotic (Ampicillin or Carbenicillin at 100µg/ml) at 37ºC overnight. 
To prepare the competent DH10B E Coli cells a single colony of DH10B E Coli 
from an LB agar plate was inoculated in 2.5 ml LB medium and incubated overnight 
at 37ºC with shaking.  This whole culture was then added to 250ml of LB medium 
containing 20mM MgSO4 and the culture was grown in a 1L conical flask at 37ºC 
and 300rpm until the optical density absorbance at 600nm reached between 0.4 and 
0.6.  The cells were then pelleted by centrifugation at 3000rpm for 30 minutes at 4ºC 
and the pellet was re-suspended in 100 ml of ice cold TFB1.  The re-suspended cells 
were incubated on ice for 5 minutes at 4ºC and the cells were collected as before.  
All subsequent steps were performed on ice, in the cold room with chilled pipettes, 
tubes and flasks.  The cells were gently re-suspended in 10ml of ice cold TFB 2 and 
incubated on ice for 15-60 minutes before aliquoting 200µl of the suspension in 
freezing vials.  The vials were snap-frozen in dry ice before storage at -70ºC. 
 
2.8.9 Small-scale plasmid DNA preparation 
 
A single colony was picked from an LB-agar plate and inoculated into 5ml of LB 
medium  supplemented  with  the  appropriate  selection  antibiotic  (Ampicillin  or 
Carbenicillin at 100µg/ml ) for growth overnight at 37ºC, shaking at 5000 rpm.  The 
bacterial cultures were transferred to 1.5ml eppendorfs and centrifuged at 3000 rpm 
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in 350µl of STET buffer supplemented with 50mg/ml lysosyme. The tubes were 
incubated for 40 seconds at 100ºC before centrifuging at 3000 rpm for 15 minutes at 
room  temperature.    Cell lysate  with  genomic  DNA  was  removed  using  a  sterile 
toothpick and the plasmid DNA and RNA was precipitated by adding 420µl of room 
temperature isopropanol and 40µl of 3M sodium acetate (pH 5.2).  This was mixed 
and stored at room temperature for 10 minutes before centrifuging for 3000 rpm for 
15 minutes at 4ºC.  The nucleic acid pellet was washed with 70% ethanol, air-dried 
and dissolved in 30µl molecular grade water (5 Prime). 
 
2.8.10 Large-scale plasmid DNA preparation 
 
A  single  colony  was  picked  from  an  LB  agar  plate,  inoculated  into  250µl  LB 
medium supplemented with the appropriate selection antibiotic (Chloramphenicol at 
12.5µg/ml or Ampicillin or Carbenicillin at 100µg/ml) and incubated overnight for 
13  hours.    The  bacterial  culture  was  pelleted  by  centrifugation  at  4000  rpm  for 
20minutes.  Preparation of plasmid DNA was carried out using a plasmid MAXI 
prep  kit  from  Qiagen  and  Bacterial  Artificial  Chromosome  (BAC)  DNA  was 
prepared  using  a  Nucleobond  BAC  100  kit  from  Clontech,  according  to  the 
manufacturer’s instructions. 
 
2.8.11 Polymerase chain reactions and site-directed mutagenesis 
 
2.5-6.25 Units of Thermoprime Plus DNA polymerase (Thermo Scientific) was used 
for PCR reactions.  Reactions were supplemented with 1.25µM of each primer, 3mM 
MgCl2  and  0.5mM  of  each  dNTP  with  enzyme  buffer  diluted  1:10  in  the  final 
reaction mix volume. 
 
Site-directed mutagenesis of exon 2 of the IL-17A gene in the targeting plasmid was 
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approximately  500ng  of  plasmid  DNA  as  the  starting  template.    The  upstream 
primer was designed incorporating the mutation in exon 2 (AT →CA). 
 
Primers (supplied from MWG-Biotech AG) and PCR protocols: 
 
Amplification of the 5’ long arm of homology for the IL-17A_Cre construct (Chapter 
4, Figure 4.2): 
 
Sense primer (red arrow Figure 2.1): 
 5’ cga gtc gac tta att acc agt ttc tca gtc tca 3’ 
Anti-sense primer (red arrow Figure 2.1): 
 3’ tcg act agt cct gcg cgt ttg tac cgt tcg aac agg tgg tac 5’ 
 
Initial denaturation - 95°C, 1 minute 
Denaturation - 95°C, 30 seconds 
Annealing - 56°C, 30 seconds 
Elongation - 72°C, 4 minutes 
38 cycles 
 
Amplification  of  the  5’  external  probe  for  the  IL-17A  Southern  blot  (Chapter  4, 
Figure 4.4): 
 
Sense primer (black arrow Figure 2.1): 
5’ ctc gta ctc agg atc cag gta tta ttc tca ggg c 3’ 
Anti-sense primer (black arrow Figure 2.1): 
 3’ gat tgg ttg gcc agg gag ctc 5’ 
 
Initial denaturation - 95°C, 2 minutes 
Denaturation– 95°C, 2 minutes 
Annealing- 65°C, 30 seconds 
Elongation– 72°C, 25 seconds     Chapter 2: Materials and methods 
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30 cycles 
 
Site-directed mutagenesis of IL-17A exon 2 for the IL-17A_Cre construct (Chapter 
4, Figure 4.2): 
 
Sense primer (blue arrow Figure 2.1): 
 5’ ccc ttc tag tct ctg cag ctg ttg ctg ctg ctg agc 3’ 
Anti-sense primer (blue arrow Figure 2.1): 
3’ gct cag cag cag caa cag ctg cag aga cta gaa ggg 5’ 
 
Initial denaturation - 95°C, 30 seconds 
Denaturation– 95°C, 30 seconds 
Annealing- 55°C, 1 minute 
Elongation– 68°C, 6 minutes 
16 cycles 
 
2.9 Blotting and hybridisation 
 
Buffers/solutions/media: (all reagents from Sigma unless otherwise stated) 
 
•  20x SSC : 3M NaCl, 0.3M sodium citrate. 
•  Hybridisation solution: 3 x SSC, 0.1% Sodium Dodecyl Sulfate (SDS), 10 x 
Dehardt’s solution, 10% Dextran sulphate 
•  Denaturation solution: 0.5M NaOH, 1.5M NaCl 
•  Neutralising solution: 0.5M Tris pH 7.4, 1.5M NaCl 
•  20% SDS (Bio Rad) 
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2.9.1 Southern Blot 
 
10µg of genomic DNA, or half of the DNA generated from Embryonic Stem (ES) 
cell clones, was digested with the appropriate restriction enzyme in a final volume of 
50µl in the presence of BSA (final concentration 100µg/ml, New England Biolabs) 
overnight at 37ºC. The genomic DNA digest was electrophoresed on a 0.8% agarose 
gel at 30V overnight.  The following day the gel was photographed under short wave 
UV light and was washed for 40 minutes in denaturation solution followed by 40 
minutes in neutralisation solution.  The DNA was blotted onto a positively charged 
nylon transfer membrane (GE Healthcare) via upward capillary transfer using 20x 
SSC.    This  was  done  overnight  followed  by  immobilisation  of  DNA  onto  the 
membrane by baking at 80ºC for 2 hours. 
 
2.9.2 Radiolabelling of DNA probes 
 
DNA probes were labelled using Ready-To-Go DNA labelling beads (Amersham 
Biosciences).  Approximately 100ng of DNA probe was denatured at 100ºC for 5 
minutes followed by immediately cooling on ice for 5 minutes.  This was mixed 
with 1.1 MBq of [α
32P]-dCTP and added to the Ready-To-Go DNA labelling beads 
reaction  mix  containing  dATP,  dGTP,  dTTP,  Klenow  fragment  and  random 
oligodeoxyribonucleotides.  After 30 minutes at 37ºC the radiolabelled probes were 
extracted from the reaction mix using a NICK column (Amersham Biosciences) as 
per  the  manufacturer’s  instructions.    The  NICK  column  is  for  purification  of 
radiolabelled DNA from unincorporated radiolabelled nucleotides using gravity flow 
chromatography. 
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2.9.3 Hybridisation of Southern Blots 
 
Membranes were soaked in 2x SSC and pre-hybridised using 50ml hybridisation 
solution and 500µl denatured salmon sperm DNA (100µg/ml final concentration).  
This  was  carried  out  for  at  least  2  hours  in  Hybaid  bottles  placed  in  a  rotating 
Hybaid oven at 65ºC.  Radiolabelled DNA probe was mixed with 400µl of salmon 
sperm DNA (10mg/ml) and denatured at 100ºC for 5 minutes before adding to the 
pre-hybridisation  mix  and  incubating  at  65ºC  overnight.    The  next  day  the 
membranes were washed as follows: twice using 100ml 3x SSC, 0.1% SDS then 
twice using 100ml 0.3x SSC, 0.1% SDS at 65ºC for 30 minutes.  The intensity of 
signal to background was measured after each wash using a Geiger counter.  The 
membranes were wrapped in Saran Wrap and exposed to Kodak BioMax MS film at 
-70ºC.  The films were developed after 24 hours and re-exposed for a further 10 days 
if required. 
 
2.10 ES cell targeting 
 
Buffers/solutions/media: (all reagents from Sigma unless otherwise stated) 
 
•  EF medium: DMEM supplemented with 15% FCS (HyClone from Peribo), 
2mM  glutamine  (Invitrogen),  Penicillin/Streptomycin  (50  units/ml  / 
50µg/ml), 0.1mM MEM non-essential amino acids (Invitrogen) 
•  ES medium: DMEM supplemented with 15% FCS (HyClone from Peribo), 
2mM  glutamine  (Invitrogen),  Penicillin/Streptomycin  (50  units/ml  / 
50µg/ml), 0.1mM MEM non-essential amino acids (Invitrogen), 0.1mM B-
mercaptoethanol, LIF-ESGRO (1000units/ml) 
•  Trypsin:  0.25%  Trypsin,  1.3mM  EDTA,  119mM  NaCl,  837.6µM 
Na2HPO4.12H2O,  1.76mM  KH2PO4,  4.96mM  KCl,  5.5mM  D-glucose, 
24.76mM  Tris,  2.5x10
-4  %  Phenol  Red.  Adjusted  to  pH  7.6  and  sterile 
filtered.     Chapter 2: Materials and methods 
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•  Lysis Buffer (0.1% NaCl, 1%SDS, 0.5mg/ml Proteinase K) 
•  Hepes buffered saline (HBS): 137mM NaCl, 5mM KCl, 0.7mM Na2HPO4, 
6mM dextrose, 21mM Hepes (adjusted to pH7.1) 
•  D-PBS  containing  1g/L  D-Glucose,  36mg/ml  Pyruvate,  CaCl2,  MgCl2 
(Invitrogen), supplemented with 0.5% BSA. 
 
2.10.1 Preparation of G418-resistant embryonic fibroblasts 
 
To  make  G418  resistant  embryonic  fibroblasts  a  mouse  in  which  the  neomycin 
resistance  gene  is  expressed    (β-2m
-/-)  was  mated  with  a  wild  type  female.  The 
pregnant female was sacrificed at day 13 or 14 of gestation and the embryos were 
dissected out free of extra-embryonic membranes in sterile conditions.  The embryos 
were killed by placing on ice for a few minutes.  Each embryo was then washed in 
70% ethanol followed by D-PBS and the soft organs including the liver, gut and 
brain  were  dissected  out.    The  remaining  carcass  was  cut  into  small  pieces  and 
incubated for 2-18 hours at 4ºC followed by 37ºC for 10 minutes in a 15ml falcon 
tube with 2ml/embryo of trypsin.  The embryonic tissue was pipetted and an equal 
volume of EF medium was added.  The debris was allowed  to settle for 2 minutes 
and then the supernatant was removed and plated out into one 200ml tissue culture 
flask in 50ml EF medium.  The flask was incubated at 37ºC for 3 days until the cells 
reached extreme confluency, changing the medium after the first 24 hours.  The 
fibroblasts  were  then  split  1:5  and  passed  into  5  new  200ml  flasks,  which  was 
repeated  3  days  later.    After  a  further  3  days  the  cells  from  all  25  flasks  were 
collected, γ-irradiated (3500 rads) and were frozen in EF medium containing 12% 
Dimethyl Sulfoxide (DMSO) at 4 million or 20 million cells/vial. 
 
2.10.2 ES cell culture 
 
Embryonic stem cells from 129/Sv mice were expanded by growth on a feeder layer 
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state by incorporation of leukaemia inhibitory factor (LIF) in the growth medium.  6 
cm culture dishes were coated in 3 ml 0.1% gelatine for 30 minutes and then 2 
million embryonic fibroblasts were added in 5ml of ES culture medium.  Feeders 
were left overnight to attach and form a monolayer before addition of the embryonic 
stem cells.  The cells were allowed to grow to confluency at 37ºC over a few days, 
changing the medium every day, before trypsinising and splitting onto fresh 6 cm 
plates. Trypsinising was carried out by washing cells first in D-PBS and then adding 
0.5ml trypsin for 3 minutes at 37°C. 1 ml of ES medium was added to inhibit the 
reaction and the cells were pipetted vigorously to generate a single cell suspension.  
They were then washed by centrifugation in 10 ml of ES medium at 1200 rpm for 5 
minutes at room temperature and plated onto fresh plates. 
 
2.10.3 Electroporation of 129Sv ES cells 
 
The  targeting  construct  plasmid  was  digested  with  SalI  restriction  enzyme, 
phenol:chloroform  extracted,  ethanol  precipitated  and  dissolved  in  sterile  TE 
(Qiagen) at a concentration of 2mg/ml.  Embryonic stem cells were grown to 50-
100% confluency, trypsinised and re-suspended in Hepes buffered saline (HBS) with 
7x10
-4%  2-mercaptoethanol  at  a  concentration  of  1x10
7  cells/ml.  40µg  of  the 
linearised targeting construct was added to 0.8ml of the cell suspension in a 0.4cm 
microcuvette  (Bio  Rad)  and  electroporated  using  a  gene  pulser  at  400  volts  and 
25µF.  The cell suspension was then added to 3.4 ml of ES cell medium and plated 
onto 4 x 10cm plates containing monolayers of 4 million feeder cells so that each 10 
cm plate received 2 million electroporated embryonic stem cells.  Selection of the 
neomycin resistance gene-containing clones was initiated after 24 hours by changing 
the medium to ES medium containing 300µg/ml G418.  Clones were selected over a 
period  of  10  days,  changing  the  medium  on  the  plates  every  two  days.  G418-
resistant clones were picked in PBS, trypsinised using trypsin diluted 1:3 with D-
PBS and added to 96-well plates prepared the previous day with 2 x 10
4 feeders/ 
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24-well plates containing 1.3 x 10
5 feeders/ well. Cells were grown for another 5 
days before trypsinising and freezing half of each well in ES medium containing 
12% DMSO.  The other half of the cells were incubated overnight at 37ºC with 
400µl of lysis buffer.  DNA from the ES cell clones was then phenol:chloroform 
extracted and ethanol precipitated. 
 
2.11 Statistical analysis 
 
Statistical analysis was performed using GraphPad Prism 5.0 for Mac (GraphPad, 
USA).    A  non-parametric  test  was  used  to  determine  statistical  significance.  
Comparision of two groups was performed using the Mann-Whitney U-Test, and 
comparison of three or more groups was performed using the Kruskal-Wallis test 
with Dunn’s post test.  In both tests, P>0.05 was considered not significant. 
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Figure 2.1 Representation of IL-17A genomic DNA and primer locations 
 
The IL-17A locus is comprised of three exons, indicated as E1, E2 and E3. Sense 
and anti-sense primers are indicated by arrows pointing to the right and to the left, 
respectively.  Black arrows represent primers to generate the 5’ external probe, red 
arrows represent primers to generate the 5’ long arm of homology and blue arrows 
represent primers to generate the double point mutation in exon 2.      Chapter 2: Materials and methods 
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Chapter 3: Characterisation of the immunological events leading to 
the development of an IL-17-associated autoimmune response 
 
3.1 Introduction 
 
EAE is a mouse model of autoimmunity in which the myelin sheath of the CNS is 
subject to attack by the immune system.  The clinical outcome of this is progressive 
paralysis of the limbs.   Immunisation with a myelin peptide in the presence of 
adjuvant, results in the activation of CD4 T cells in the peripheral lymphoid organs 
which  when  adoptively  transferred  into  naïve  recipients  are  capable  of  inducing 
disease  (Mendel,  Kerlero  de  Rosbo  et  al.  1995).  The  phenotype  of  these 
encephalitogenic CD4 T cells and the signals required to generate them are therefore 
areas of intense research. 
 
Activation, expansion and differentiation of naïve CD4 T cells into effector T helper 
cells in an immune response is dependent upon activation of the TCR, delivery of a 
co-stimulatory signal as well as by signalling through cytokine receptors. It was for a 
long time believed that myelin peptide-specific Th1 effector cells, expressing IFN-γ 
are required for disease pathology in EAE.  However, the more recent description of 
IL-17A-expressing Th17 effector cells has challenged this opinion and there is much 
evidence now suggesting that Th17 cells, not Th1 cells are important for disease 
pathology (Langrish, Chen et al. 2005; Veldhoen, Hocking et al. 2006). 
 
In  C57BL/6  mice,  the  combination  of  sub-cutaneous  immunisation  with  MOG 
peptide emulsified in CFA and systemic administration of pertussis toxin provide the 
appropriate  conditions  for  induction  of  encephalitogenic  cells  and  subsequent 
disease development.  The Mycobacterium tuberculosis (Mtb) component of CFA 
contains PAMPs which are thought to activate TLRs such as TLR1 and TLR2 on 
dendritic cells and macrophages (Brightbill, Libraty et al. 1999; Underhill, Ozinsky     Chapter 3 
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et al. 1999; Akira, Uematsu et al. 2006), and it is this process which is believed, in 
part, necessary to initiate proliferation and activation of MOG-specific CD4 T cell 
clones.  Although the specific consequences of this activation have not yet been 
identified, it was shown that Mtb can stimulate the production of TGFβ and IL-6 
from bone marrow-derived dendritic cells in vitro, which are responsible for driving 
the  generation  of  IL-17-producing  CD4  T  cells  in  mice  from  naïve  precursors 
(Veldhoen, Hocking et al. 2006). Pertussis toxin is usually given systemically in the 
form  of  either  an  intraperitoneal  or  intravenous  injection  and  has  been  used  to 
facilitate EAE development since the 1970s, with the prevailing explanation that it 
opens up the blood brain barrier, allowing activated auto-antigen specific T cells to 
enter the central nervous system (CNS). Immunisation with CNS peptides in CFA 
was sufficient to induce EAE in early experiments with mice (Olitsky and Yager 
1949) and Lewis rats (Lipton and Freund 1952) and pertussis toxin is not required in 
some transgenic mouse models of EAE (Goverman, Woods et al. 1993; Waldner, 
Whitters  et  al.  2000),  suggesting  that  myelin  peptide  and  CFA  are  sufficient  to 
generate  encephalitogenic  T  cells  in  the  absence  of  pertussis  toxin.    Indeed, 
experiments in the 1970s, when it was first discovered that pertussis toxin could 
enhance disease severity, showed that pertussis toxin does in fact influence vascular 
permeability and that this could explain its role in EAE (Bergman and Munoz 1975; 
Bergman, Munoz et al. 1978).  Moreover, pertussis toxin injected alone into mice 
has been shown to allow the influx of normally excluded serum proteins into the 
brain (Clifford, Zarrabi et al. 2007). However, in adoptive transfer models of EAE, 
cells are normally removed from actively immunised mice (with myelin peptide, 
CFA  and  pertussis  toxin)  and  adoptively  transferred  into  recipient  mice  without 
injection  of  pertussis  toxin  (Langrish,  Chen  et al.  2005;  Kroenke,  Carlson  et  al. 
2008;  O'Connor,  Prendergast  et  al.  2008;  Stromnes,  Cerretti  et  al.  2008; Sutton, 
Lalor et al. 2009), suggesting that the direct effects of pertussis toxin on the blood 
brain  barrier  (Kerfoot,  Long  et  al.  2004;  Clifford,  Zarrabi  et  al.  2007)  may  be 
dispensable for CD4 T cells to enter the spinal cord and initiate disease.  In addition, 
it is intriguing that pertussis toxin is routinely administered at day 0 and 2, in the 
priming stage of disease, rather than later when cells are ready to enter the CNS.      Chapter 3 
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The aims of this chapter were therefore to define the sequence of immunological 
events that result from immunisation with MOG CFA and pertussis toxin and result 
in clinical EAE, and to investigate specifically the contribution of pertussis toxin to 
this immune response. 
 
3.2 Effect of pertussis toxin on the sequence of immunological events in EAE 
 
In order to do address the role of pertussis toxin in the development of EAE we first 
wanted  to  detail  the  sequence  of  immunological  events  induced  by  MOG  CFA 
immunisation alone, in order to establish the contribution of this component of the 
EAE  induction  protocol,  an  immunisation  which  in  most  cases  does  not  lead  to 
clinical  disease.    It  would  then  be  possible  to  investigate  how  administration  of 
pertussis toxin modulates this response in order to highlight particular characteristics 
that are associated with EAE development.  We chose to track the appearance of IL-
17A  and  IFN-γ-expressing  effector  CD4  T  cells  (namely  Th17  and  Th1  cells, 
respectively) in the draining lymph nodes (as this is the predominant site for primary 
lymphocyte activation), the blood and the spinal cord where they contribute to a 
myelin-specific immune response.  
 
Other  cell  types  that  may  influence  the  ability of  these  effector  CD4  T  cells  to 
initiate disease progression were also assessed.  These included the Foxp3 regulatory 
CD4 T cells which have been shown to be induced to proliferate in EAE in response 
to MOG peptide and to have suppressive activity on peripheral MOG-specific CD4 
T cell responses (Korn, Reddy et al. 2007).  The importance of regulatory T cells in 
EAE  has  been  shown  in  experiments  where  depletion  of  CD25+  cells  prior  to 
disease induction can overcome the requirement for pertussis toxin in the induction 
protocol (Montero, Nussbaum et al. 2004).  Interestingly, pertussis toxin was also 
shown  to  reduce  the  number  and  function  of  Foxp3  regulatory  T  cells  in  vivo 
(Cassan,  Piaggio  et  al.  2006).    TCRδ-deficient mice  develop  EAE  with  reduced     Chapter 3 
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severity and recently a role for γδ T cells in EAE has been implicated (Sutton, Lalor 
et al. 2009).  In this paper the authors described that IL-17A-expressing γδ T cells 
were detected at high frequency in the spinal cords of mice with EAE and were 
required for MOG-specific IL-17A production.  Neutrophils have been shown to 
infiltrate the spinal cord in mice with EAE (Wu, Cao et al. 2010), and are thought to 
contribute to the demyelination observed in the CNS.  Indeed, a polymorphonuclear 
cell depletion antibody administered from day 8 after immunisation reduced disease 
severity and in some cases prevented the onset of disease (McColl, Staykova et al. 
1998). Neutrophil accumulation in peripheral tissues has also been associated with 
IL-17 expression (Forlow, Schurr et al. 2001; Ye, Rodriguez et al. 2001).  
 
3.2.1 Analysis of cell populations in the draining lymph nodes after MOG CFA 
immunisation  
 
A cohort of 20 C57BL/6 female mice were immunised with MOG CFA into the base 
of the tail.  The draining lymph nodes (inguinal and para-aortic) and blood were 
analysed on day 3 and day 7 following immunisation.  Non-immunised, C57BL/6 
female mice were analysed as controls. 
 
The flow cytometry gating strategy used for analysis of the draining lymph nodes 
(dLNS)  is  shown  in  Figure  3.1.    A  gate  was  first  drawn  around  cells  of  an 
approximately equivalent size to those counted by the Casy 1 cell counter (counted 
cells).  This was followed by gating  ‘singlets’ using FSC-W /FSC-H discrimination.  
Finally, live, 7AAD-negative cells were gated. (Figure 3.1A) 7AAD is a DNA-
binding dye that can only access the nucleus following loss of membrane integrity 
during onset of death (Philpott, Turner et al. 1996). 
 
In the mouse, lymph nodes are composed predominantly of T and B lymphocytes.   
Assessment of these lymphocyte populations showed that CD4 and CD8 T cells 
represented approximately 40% and 25% of lymph node cells respectively, B cells     Chapter 3 
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represented approximately 15% and γδ T cells represented less than 1%. An example 
of these populations in a non-immunised C57BL/6 mouse is shown in Figure 3.1B.  
 
As well as extra-cellular markers, T cells were also assessed for expression of intra-
cellular  IL-17A,  IFN-γ  and  Foxp3  protein.    This  was  done  following  a  4  hour 
stimulation with Phorbol 12,13 dibutyrate (PdBu), ionomycin and brefeldin A. PdBu 
activates  Protein  Kinase  C,  ionomycin  upregulates  intra-cellular  calcium  and 
brefeldin A prevents extra-cellular secretion of proteins and therefore retains protein 
inside the cell for detection by fluorescent antibodies.  The combined effects of this 
stimulation resulted in the detection of a distinct population of IL-17A and IFN-γ-
expressing cells.  Assessment of IL-17A and IFN-γ-expressing populations in the 
lymph nodes of a non-immunised mouse showed that approximately 1% of CD4 T 
cells and 7% of CD8 T cells stained positively for IFN-γ and less than 1% of both 
CD4 and CD8 T cells stained positively for IL-17A (Figure 3.1C). 10% of γδ T 
cells  also  expressed  IL-17A  when  measured  by  intra-cellular  cytokine  staining. 
(Figure 3.1D).  Foxp3-expressing cells represented about 4% of the CD4 T cell 
population (Figure 3.1E). 
 
Following immunisation with MOG CFA, lymphocyte populations in the dLNs of 
individual mice were assessed 3 days and 7 days later (Figure 3.2).   There was an 
overall  increase  in  the  number  of  all  the  cell  populations  measured  after 
immunisation  when  compared  to  non-immunised  control  mice  and  statistical 
analysis using the Kruskal Wallis test and a Dunn’s post test showed that this was 
significant  in  all  cell  types  by  day  7  and  in  CD4  and  CD8  T  cells  by  day  3. 
Expansion of any cell population in the lymph nodes could be a result of increased 
migration into the lymph nodes, reduced egress out of the lymph nodes, increased 
proliferation, increased survival, or de novo generation of those cells.  However, the 
results of previous studies suggest that this non-selective expansion of lymphocyte 
populations in the draining lymph nodes in response to immunisation is likely to be 
associated  with  reduced  egress  of  cell  populations  following  antigen  challenge     Chapter 3 
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(Mackay,  Marston  et  al.  1992)  involving  down  regulation  of  the  Sphingosine-1-
Phosphate (S1P) receptor (Matloubian, Lo et al. 2004). 
 
Activation of T cells into an effector phenotype is characterised by modification of 
the expression of a number of genes including the up-regulation of a number of 
cytokine  genes.      The  number  of  IL-17A-expressing,  IFN-γ-expressing  and  IL-
17A/IFN-γ-expressing CD4 T cells increased in number following immunisation by 
day 7 (Figure 3.3A). Within the CD4 T cell population, the percentage of IL-17A-
expressing  and  IL-17A/IFN-γ-expressing  cells  was  also  increased  significantly  at 
day  7,  whereas  the  percentage  of  IFN-γ-expressing  cells  within  the  CD4  T  cell 
population was significantly reduced by day 7 (Figure 3.3B). The number of IL-
17A-expressing  γδ  T  cells  was  also  increased  after  immunisation  which  was 
statistically significant by day 7 when compared to the non-immunised mice (Figure 
3.4A) and was accompanied by an increase in the percentage of IL-17A-expressing 
cells within the γδ T cell population. There was also an increase in the number of 
Foxp3-expressing  CD4  T  cells  by  day  7  following  immunisation  and  this  was 
accompanied by an increase in the percentage of Foxp3-expressing cells within the 
CD4 T cell population (Figure 3.4B).    
 
In conclusion, MOG CFA immunisation alone induces an increase in the number of 
all cell populations measured in the lymph nodes with a relative increase in the 
proportion of IL-17A and Foxp3-expressing cells within the CD4 population, and 
IL-17A-expressing cells within the γδ T cell population. 
 
3.2.2 Analysis of cell populations in the blood after MOG CFA immunisation 
 
We  then  wanted  to  investigate  whether  activated  effector  cells  that  had  been 
observed in the lymph nodes, characterised by their expression of IL-17A and IFN-γ 
could migrate to the blood in the mice immunised with MOG CFA alone. The blood 
of individual mice was analysed by flow cytometry for the presence of activated     Chapter 3 
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CD4 T cells expressing IL-17A and IFN-γ and γδ T cells expressing IL-17A, 3 days 
and 7 days following immunisation with MOG CFA.  A Vetsan was used to measure 
the number of lymphocytes in the blood, which identifies these cells based on size 
and granularity.  Therefore, by placing a flow cytometry gate on the lymphocyte 
population,  the  number  of  cytokine-expressing  T  cell  populations  could  be 
determined. An example of the flow cytometry analysis is shown in Figure 3.5. 
 
IL-17A-expressing CD4 and γδ T cells were significantly increased in number in the 
blood  by  day  7  after  immunisation,  whereas  the  IFN-γ-expressing  CD4  T  cells 
showed  no  increase  in  number.  (Figure  3.6A) This  reflected  the  increase  in  the 
percentage of IL-17A-expressing cells in the CD4 T cell and γδ T cell populations in 
the lymph nodes at this time point and suggested that these effector cells had left the 
lymph  node  immediately  and  migrated  to  the  blood.    There  was  also  a  clear 
population of CD4 T cells expressing both IL-17A and IFN-γ in the blood after 
immunisation as illustrated in the flow cytometry plots in Figure 3.5. The number of 
CD4  T  cells  expressing  both  IL-17A  and  IFN-γ  increased  at  day  7  following 
immunisation (Figure 3.6A).  
 
Under  steady  state  conditions,  neutrophils  mature  from  their  bone  marrow 
progenitors  and  are  released  into  the  peripheral  circulation,  a  process  which  is 
dependent upon the actions of a number of cytokines and chemokines such as G-
CSF and CXCL12 (von Vietinghoff and Ley 2008).  In response to inflammation or 
injury, neutrophil mobilisation is accelerated which is important for the increased 
turnover  of  cells  at  the  site  of  inflammation.    The  signals  required  for  this 
accelerated mobilisation are likely to involve inflammatory cytokines, such as IL-
17A, which has been shown to upregulate G-CSF production (Fossiez, Djossou et al. 
1996). In EAE, depletion of polymorphonuclear cells in the effector stage of disease 
reduced the severity of symptoms suggesting these cells play a role in disease.  We 
therefore  wanted  to  address  how  MOG  CFA  immunisation  influenced  the 
mobilisation  of  neutrophils  into  the  peripheral  circulation.  There  was  a  small 
increase in the number of granulocytes measured using a Vetscan on day 3 following     Chapter 3 
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MOG  CFA  immunisation  and  also  further  at  day  7  when  compared  to  non-
immunised mice.   The increase was not statistically significant when analysed using 
the  Kruskal  Wallis  test  and  Dunn’s  post  test,  however  the  data  is  bi-modally 
distributed and clearly some mice have developed neutrophilia in response to MOG 
CFA immunisation (Figure 3.6B). 
 
3.2.3 Effect of administration of pertussis toxin in combination with MOG CFA 
immunisation on clinical disease  
 
We had established that the signals induced by MOG CFA immunisation alone were 
sufficient  to  generate  IL-17A  and  IFN-γ-  expressing  effector  cells  in  the  lymph 
nodes which could travel to the blood.  MOG CFA immunisation was also sufficient 
to induce mild neutrophilia in some mice.  However, this immunisation protocol is 
not  sufficient  for  the  development  of  clinical  EAE.    Development  of  disease 
symptoms  is  dependent  on  the  administration  of  pertussis  toxin.    We  therefore 
wanted to address how pertussis toxin influenced the peripheral immune response 
following MOG CFA immunisation.  A cohort of mice were immunised with MOG 
CFA,  with  intra-peritoneal  administration  of  pertussis  toxin  and  the  sequence  of 
immune events was assessed and compared to immunisation with MOG CFA alone. 
 
Figure 3.7 shows the clinical analysis of two groups of mice injected with either 
MOG CFA alone, or with MOG CFA and pertussis toxin.  The pertussis toxin was 
administered by intraperitoneal injection on day 0 (on the same day as the MOG 
CFA injection) and on day 2.  Administering pertussis toxin in combination with 
MOG CFA increased the incidence of disease from 17.8% (5 out of 28 mice) to 
70.8%  (17  out  of  24  mice)  (Figure  3.7A).    Consequently,  the  mean  maximum 
clinical score was significantly higher (using Mann Whitney U test) in the pertussis 
toxin-treated group (Figure 3.7A) and the mean clinical score of the pertussis toxin-
treated mice over time was substantially higher than the mice given MOG CFA only 
(Figure  3.7B).  Clinical  scores  for  individual  mice  is  shown  at  day  18  and  the     Chapter 3 
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difference between the two groups was highly significant (Figure 3.7C). In those 
mice that did get disease in each group, the day of onset was also earlier in the 
pertussis toxin-treated group, although this difference was not significant (Figure 
3.7A). 
3.2.4 Effect of administration of pertussis toxin in combination with MOG CFA 
immunisation on cell populations in the draining lymph nodes 
 
The number of cell populations from the dLNs was determined for individual mice 3 
days and 7 days following immunisation with MOG CFA and pertussis toxin and 
this was compared to the number of these cell populations in the mice immunised 
with MOG CFA alone. 
 
The number of all the cell populations investigated was reduced at day 7 in the mice 
which  received  pertussis  toxin  compared  to  the  pertussis  toxin-untreated  group, 
however this was only determined as significant, using the Mann Whitney U- Test, 
for B cells (Figure 3.8).  Cell movement into and out of the lymph nodes is largely 
dependent  on  G-coupled  receptor  signalling,  a  signalling  pathway  which  can  be 
inhibited by pertussis toxin (Reisine 1990).  Furthermore, this observation is likely 
to be a result of the effect of pertussis toxin on cell migration.  It could be that 
pertussis toxin either reduced recruitment of lymphocytes to the lymph nodes or 
increased  egress  of  lymphocyte  populations  out  of  the  lymph  nodes  at  this  time 
point. 
 
Although inclusion of pertussis toxin in the immunisation protocol also resulted in a 
marginal,  non-significant  reduction  in  the  number  of  IL-17A-expressing,  IFN-γ-
expressing and IL-17A/IFN-γ-expressing CD4 T cells, at day 7 (Figure 3.9A), the 
proportion  of  IL-17A-expressing,  IFN-γ-expressing  and  IL-17A/IFN-γ-expressing 
cells within the CD4 T cell population did not change (Figure 3.9B).  Similarly, 
although after the administration of pertussis toxin there was a small reduction in the 
number of IL-17A-expressing γδ T cells and Foxp3-expressing CD4 T cells, the     Chapter 3 
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percentage  of  IL-17A-expressing  cells  within  the  γδ  T  cell  population  and  the 
percentage  of  Foxp3-expressing  cells  within  the  CD4  T  cell  population  did  not 
change (Figure 3.10A and B). This suggested that pertussis toxin was not enhancing 
the increase of IL-17A-expressing effector cells in the lymph nodes seen after MOG 
CFA immunisation, although the reduction in the total number of CD4 T cells could 
perhaps indicate that the egress of these cells into the blood was enhanced. 
 
3.2.5 Effect of administration of pertussis toxin in combination with MOG CFA 
immunisation on cell populations in the blood  
 
Comparison of the number of effector cells in the blood after administration with 
MOG  CFA  and  pertussis  toxin  and  with  MOG  CFA  alone  showed  that  even  if 
pertussis toxin was increasing the egress of lymphocytes out of the lymph nodes this 
was not having any significant affect on the accumulation of cytokine-expressing 
cells in the blood (Figure 311A). 
 
The number of granulocytes in the blood was increased in the pertussis toxin-treated 
group at day 3 (Figure 3.11B). There was also an increase in the pertussis toxin-
treated group at day 7, however this was not significant.  Similar to immunisation 
with MOG CFA alone, immunisation with MOG CFA and pertussis toxin lead to bi-
modal distribution of granulocyte numbers indicating that pertussis toxin enhanced 
the neutrophilia observed in response to MOG CFA immunisation. 
3.2.6 Effect of administration of pertussis toxin in combination with MOG CFA 
immunisation on cell populations in the spinal cord prior to the onset of disease 
 
It had so far been demonstrated that pertussis toxin was not having any striking 
effect on the immune response induced by MOG CFA with regard to the activation 
of IL-17A and IFN-γ-expressing cells in the lymph nodes and the appearance of 
these cells in the blood prior to the onset of disease.  In attempt to further investigate     Chapter 3 
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the  mechanism  by  which  pertussis  toxin  was  facilitating  disease,  we  wanted  to 
assess how pertussis toxin was influencing the sequential appearance of leukocytes 
in the spinal cord leading to clinical disease. 
 
Cells from the spinal cord of non-immunised mice, MOG CFA-immunised mice and 
MOG CFA-immunised mice with injection of pertussis toxin at day 0 and 2 were 
analysed sequentially at day 3, day 7 and day 10 after immunisation to determine 
how pertussis toxin alters the influx of cells into the spinal cord before the onset of 
disease. 
 
Leukocytes including lymphocytes, monocytes and granulocytes were isolated from 
the spinal cord by percoll separation, counted and analysed by flow cytometry.  Due 
to low cell recovery (<1x10
6 cells per mouse in mice that did not show signs of 
EAE), the spinal cords of 3 or 4 mice from each group were pooled and an average 
cell count per mouse was determined.  For flow cytometry analysis, a gate was first 
drawn  around  cells  of  an  approximately  equivalent  size  to  those  counted  by the 
leukocyte counter (counted cells). This was followed by gating on ‘singlets’ using 
FSC-W /FSC-H discrimination.  Dead cells were excluded by gating on the 7AAD-
negative  cells.    For  lymphocyte  staining,  an  additional  lymphocyte  gate  was 
included (Figure 3.12A).  Absolute numbers of cell populations were calculated by 
determining  the  percentage  of  the  cell  population  of  the  total,  counted  cells.  
Neutrophils were defined based on their extra-cellular expression of Ly6G and an 
epitope recognised by 7/4 antibody, and monocytes were defined based on their 
expression an epitope recognised by 7/4 antibody but the  absence of Ly6G.  B cells 
were defined based on the expression of CD19, CD4 T cells on the expression of the 
TCRβ receptor and the CD4 co-receptor and γδ T cells on the expression of the γδ 
TCR (Figure 3.12B). 
 
The number of Ly6G-expressing neutrophils in the spinal cord increased at day 7 
following immunisation with MOG CFA alone and these numbers were maintained 
at day 10.  Administering pertussis toxin did not substantially alter the influx of     Chapter 3 
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neutrophils into the spinal cord up to the onset of disease (Figure 3.13A).  The 
number of 7/4+ monocytes increased at day 3 following immunisation with MOG 
CFA alone and further at day 7 and day 10.  Pertussis toxin-treated mice had fewer 
7/4+ monocytes at day 10, prior to the onset of disease (Figure 3.13A).   The value 
shown  is  the  mean  of  three  results  from  separate  EAE  experiments  where  three 
spinal cords were pooled in each experiment.  To confirm this result, more mice 
would need to be analysed.   Nevertheless, a down regulation in the number of 7/4+ 
monocytes in the pertussis toxin-treated group could be the result of fewer cells 
being recruited to the spinal cord or it could be due to down regulation of the epitope 
recognised by 7/4 antibody as the monocytes differentiate into antigen-presenting 
cells (Henderson, Hobbs et al. 2003). 
 
The number of B cells, CD4 T cells and γδ T cells in the spinal cord is shown over 
time following immunisation in Figure 3.13B. The number of B cells in the spinal 
cord was reduced after immunisation both in the presence and absence of pertussis 
toxin when compared to non-immunised mice.  CD4 T and γδ T cells were increased 
only in the pertussis toxin-treated group at day 10 following immunisation when 
compared to non-immunised mice.   
 
In conclusion, the signals induced by MOG CFA immunisation alone were sufficient 
to recruit neutrophils and monocytes to the spinal cord prior to the onset of disease, 
but  CD4 and γδ T cells were only observed to increase in the spinal cord in the mice 
that had received pertussis toxin.   
 
Effector CD4 T cells have been shown to enter the spinal cord before the onset of 
clinical EAE, therefore day 10 was chosen as a time point immediately before the 
onset of EAE to analyse IL-17A, IFN-γ and Foxp3-expressing cells.  Figure 3.14 
shows examples of cytokine staining in CD4 (A) and γδ T cells (B) at day 10.  In the 
pertussis toxin-treated mice, clear populations of CD4 T cells expressing IL-17A, 
IFN-γ or both IL-17A and IFN-γ could be detected, as well as γδ T cells expressing 
IL-17A.  The percentage of CD4 and γδ T cells in the pertussis toxin-untreated     Chapter 3 
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group was lower but some cytokine-expressing cells within this population could 
still be detected. In the non-immunised group detection of cytokine-expressing cells 
was less convincing due to such a low percentage of CD4 T cells.  Nevertheless, 
non-immunised mice were still analysed in this way as a baseline control (Figure 
3.14). 
 
The  profile  of  effector  cells  detected  in  the  spinal  cord  at  day  10  following 
immunisation is shown in Figure 3.15.   The number of CD4 T cells expressing IL-
17A,  IFN-γ  and  both IL-17A  and IFN-γ  together  (Figure  3.15A)  as  well  as  the 
number of IL-17A-expressing γδ T cells (Figure 3.15B) increased slightly in the 
mice immunised with MOG CFA alone over that detected in non-immunised mice. 
This suggested that the cells activated to express IL-17A and IFN-γ following MOG 
CFA immunisation could, to some extent, access the spinal cord in the absence of 
pertussis toxin before the onset of disease.  The number of these effector cells in the 
pertussis toxin treated mice however was clearly higher still, indicating that these 
cells  either  had  an  enhanced  ability  to  enter  the  spinal  cord  or  that  they  were 
proliferating more in the target organ. 
 
The number of Foxp3 expressing CD4 T cells was also increased in the spinal cord 
10  days  following  immunisation  with  MOG  CFA  and  pertussis  toxin  when 
compared  to  non-immunised  mice  and  mice  immunised  with  MOG  CFA  alone  
(Figure 3.15C), suggesting again that these cells were not recruited or were not 
proliferating in mice without the administration of pertussis toxin.   
 
 
3.2.7 Effect of administration of pertussis toxin in combination with MOG CFA 
immunisation on cell populations in the spinal cord at the peak of disease 
 
Spinal cords were also analysed during disease symptoms at day 18 to investigate 
how the inflammatory reaction progresses in mice immunised with MOG CFA alone     Chapter 3 
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compared  to  mice  immunised  with  MOG  CFA  and  pertussis  toxin.  The 
inflammatory infiltrate of MOG CFA and pertussis toxin-immunised mice with EAE 
symptoms  (mice  with  disease  represented  the  vast  majority  of  this  group)  was 
compared to MOG CFA-immunised mice without EAE symptoms (mice without 
disease represented the vast majority of this group).  The inflammatory infiltrate of 
the spinal cords of mice within the MOG CFA-immunised group that did get disease 
was  also  included  for  comparison.    All  groups  were  also  compared  to  non-
immunised mice.  Mice with disease were analysed individually, however the mice 
without disease were pooled in groups of three and an average taken for calculation 
of absolute numbers. 
 
Ly6G-expressing neutrophils and 7/4+ monocytes were increased in number in the 
mice with disease irrespective of pertussis toxin treatment when compared to non-
immunised mice and mice lacking disease but immunised with MOG CFA in the 
absence of pertussis toxin (Figure 3.16A).  CD4 and γδ T cells followed a similar 
trend, in that they were increased in numbers in the mice with disease irrespective of 
pertussis  toxin  treatment  compared  to  the  two  groups  of  mice  lacking  disease.  
Numbers of B cells were lower in all immunised mice, compared to non-immunised 
mice  irrespective  of  disease  or  pertussis  toxin  treatment  (Figure  3.16B).    This 
indicated  that  the  presence  of  monocytes,  neutrophils,  CD4  and  γδ  T  cells  are 
associated  with  disease  development  rather  than  pertussis  toxin  treatment  and  it 
could be that the effects of pertussis toxin are exerted at an earlier time point in 
disease induction. 
 
IL-17A, IFN-γ and Foxp3-expressing CD4 T cells as well as IL-17A-expressing γδ T 
cells were all increased in number in the diseased mice irrespective of pertussis toxin 
treatment  when  compared  to  immunised  mice  without  EAE  or  non-immunised 
controls (Figure 3.17A-C).  This indicated that these cells were either proliferating 
more  readily  or  were  being  recruited  more  efficiently  in  the  mice  with  disease.  
Again, this result may be a consequence of disease development suggesting that the 
effect of pertussis toxin may be important at an earlier time point.      Chapter 3 
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3.2.8 Summary 
 
From these experiments it was established that the signals induced by MOG CFA 
immunisation alone were sufficient to induce IL-17A and IFNγ -expressing CD4 
cells  as  well  as  IL-17A-expressing  γδ  T  cells  in  the  lymph  nodes,  which  could 
migrate to the blood and could access the spinal cord but no more than the basal 
level  seen  in  non-immunised  mice.    These  signals  were  also  sufficient  to  allow 
neutrophil and monocyte infiltration into the spinal cord before the onset of disease, 
however  their  persistence  in  the  spinal  cord  was  associated  with  disease 
development.  The signals from pertussis toxin were additionally required to allow 
the accumulation of cytokine-expressing T cell populations in the spinal cord which 
could  be  the  result  of  enhanced  recruitment  or  enhanced  proliferation  of  these 
activated cells in the target organ.  
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Figure 3.1 Flow cytometry gating strategy used for analysis of cells in draining 
lymph nodes. 
 
Para-aortic and inguinal lymph nodes from a non-immunised mouse were harvested 
and the cells were analysed by flow cytometry. For analysis of flow cytometry data a 
gate was first drawn to exclude cell debris (counted cells), singlets were gated by 
FSC-H/FSC-W discrimination and live cells were gated based upon exclusion of 
7AAD (A). B cells were defined by expression of cell-surface CD19, T cells were 
defined based upon expression of the CD4 and CD8 co-receptors and γδ T cells were 
defined  based  upon  expression  of  the  γδ  TCR  (B).  Lymph  node  cells  were 
stimulated for four hours with PdBu, ionomycin and brefeldin A and stained for 
intra-cellular IL-17A, IFN-γ and Foxp3.  Intra-cellular IL-17A and IFN-γ expression 
is shown in CD4 and CD8 T cells (C), IL-17A expression is shown in γδ T cells (D) 
and intra-cellular Foxp-3 expression is shown in CD4 T cells (E). 
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Figure 3.2 Non-selective expansion of lymphocytes in the draining lymph nodes 
following immunisation with MOG CFA 
 
C57BL/6 mice were immunised at the base of the tail with MOG CFA emulsion and 
the numbers of lymphocytes in the para-aortic and inguinal lymph nodes (draining 
lymph nodes) were assessed three days and seven days later. Age and sex-matched, 
non-immunised C57BL/6 mice were analysed as controls (open circles). Cell counts 
were performed by a Casy-1 cell counter and assessment of different populations 
was carried out by flow cytometry as described in Figure 3.1.  The dots represent 
individual mice and the mean for each group is shown as a horizontal line.  Shown 
are the results of three independent experiments. Statistical analysis was performed 
by the Kruskal-Wallis test with a Dunn’s post test. (*) indicates P-value = 0.01-0.05, 
(**) indicates P-value = 0.001-0.01, (***) indicates P-value= <0.001. 
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Figure 3.3 IL-17A and IFN-γ expression within the CD4 T cell population in the 
draining lymph nodes following immunisation with MOG CFA  
 
C57BL/6 mice were immunised at the base of the tail with MOG CFA emulsion.  
The  draining  lymph  nodes  were  harvested  three  days  and  seven  days  later  and 
assessed for intra-cellular IL-17A and IFN-γ protein expression by flow cytometry 
following a four hour stimulation with PdBu, ionomycin and brefeldin A. Age and 
sex-matched,  non-immunised  C57BL/6  mice  were  analysed  as  controls  (open 
circles). Total numbers of CD4 T cells expressing intra-cellular IL-17A and IFN-γ 
were determined (A). The percentage of IL-17A and IFN-γ-expressing cells within 
the CD4 T cell population are shown in  (B). The dots represent individual mice and 
the mean is shown as a horizontal line. Shown are the results of three independent 
experiments.  Statistical analysis was performed by the Kruskal-Wallis test with a 
Dunn’s post test. (*) indicates P-value = 0.01-0.05, (**) indicates P-value = 0.001-
0.01, (***) indicates P-value= <0.001. 
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Figure  3.4  IL-17A  expression  within  the  γδ  T  cell  population  and  Foxp3 
expression  within  the  CD4  T  cell  population  in  the  draining  lymph  nodes 
following immunisation with MOG CFA  
 
C57BL/6 mice were immunised at the base of the tail with MOG CFA emulsion.  
The draining lymph nodes were harvested three days and seven days later and 
assessed for intra-cellular IL-17A and Foxp3 protein expression by flow cytometry 
following a four hour stimulation with PdBu, ionomycin and brefeldin A. Age and 
sex-matched, non-immunised C57BL/6 mice were analysed as controls (open 
circles). Total numbers of γδ T cells expressing intra-cellular IL-17A and the 
percentage of IL-17A expressing cells within the γδ T cell population are shown in  
(A). Total numbers of CD4 T cells expressing intra-cellular Foxp3 and the 
percentage of Foxp3-expressing cells within the CD4 T cell population are shown in  
(B). The dots represent individual mice and the mean is shown as a horizontal line.  
Shown are the results of three independent experiments.  Statistical analysis was 
performed by the Kruskal-Wallis test with a Dunn’s post test. (*) indicates P-value = 
0.01-0.05, (**) indicates P-value = 0.001-0.01, (***) indicates P-value= <0.001 
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Figure 3.5 Flow cytometry gating strategy used for the analysis of CD4 and γδ 
T cell populations in the blood. 
 
Blood was collected by cardiac puncture and red blood cells were lysed by ACK 
lysis.  The remaining cells were stimulated for four hours with PdBu, ionomycin and 
brefeldin A and analysed by flow cytometry.  For flow cytometry analysis, a gate 
was  drawn  around  lymphocytes,  ‘singlets’  were  gated  on  by  FSC-H/FSC-W 
discrimination and live cells were gated on based upon exclusion of 7AAD (A).  IL-
17A and IFN-γ-staining is shown in CD4 and γδ T cell populations from a mouse 
analysed on day 7 following base of tail immunisation with MOG CFA emulsion 
(B). 
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Figure 3.6 IL-17A-expressing CD4 T cells, IL-17A-expressing γδ T cells and 
granulocytes in the blood following immunisation with MOG CFA 
 
C57BL/6 mice were immunised at the base of the tail with MOG CFA emulsion. 
Blood was collected by cardiac puncture three days and seven days later and red 
blood cells were lysed by ACK lysis.  The remaining cells were stimulated for four 
hours with PdBu, ionomycin and brefeldin A and analysed by flow cytometry. A 
sample  of  blood  was  also  taken  from  the  tail  of  the  mice  before  sacrifice  and 
analysed using a Vetscan to determine the number of lymphocytes, monocytes and 
granulocytes  in  the  blood.  Age  and  sex-matched,  non-immunised  C57BL/6  mice 
were analysed as controls (open circles).  Using a combination of the number of 
lymphocytes determined from the Vetscan and percentages of cells from the flow 
cytometry analysis, the number of IL-17A
+  (top left), IFN-γ
+ (bottom left), and IL-
17A
+IFN-γ
+ (bottom right) CD4 T cells as well as IL-17A
+ γδ T cells (top right) in 
the blood were determined (A).  Granulocyte numbers from the Vetsan analysis are 
shown in (B). The dots represent individual mice and the mean for each group is 
shown  as  a  horizontal  line.  Shown  are  the  results  from  three  independent 
experiments.  Statistical analysis was performed by the Kruskal-Wallis test with a 
Dunn’s post test. (*) indicates P-value = 0.01-0.05, (**) indicates P-value = 0.001-
0.01, (***) indicates P-value= <0.001. 
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Figure 3.7 Following immunisation with MOG CFA, injection of pertussis toxin 
enhances the incidence of clinical disease. 
 
C57BL/6 mice were immunised at the base of the tail with MOG CFA emulsion in 
the presence or absence of pertussis toxin treatment.  Pertussis toxin, where given 
was  administered  by  intraperitoneal  injection  on  the  same  day  as  MOG  CFA 
immunisation, followed by a second dose two days later.  Mice were scored for 
symptoms of paralysis and the incidence, mean day of onset and mean maximum 
score were determined for each group of mice (A).  The progression of the disease in 
the two groups of mice is illustrated by expression of mean clinical score against 
time following immunisation (B).  The clinical scores of individual mice at day 
eighteen following immunisation is shown in (C) Red dots or lines indicate mice 
injected  with  pertussis  toxin  in  combination  with  MOG  CFA  immunisation  and 
black dots or lines indicate mice immunised with MOG CFA only. Shown are the 
results  of  three  independent  experiments.  Statistical  analysis  was  carried  out 
between the two groups for the day of onset, the maximum score and the score at 
day eighteen using the Mann-Whitney U-Test. (***) indicates P-value= <0.001. 
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Figure 3.8 Following immunisation with MOG CFA, injection of pertussis toxin 
results in a non-selective reduction in the number of T cells and B cells in the 
draining lymph nodes  
 
C57BL/6 mice were immunised at the base of the tail with MOG CFA emulsion in 
the presence or absence of pertussis toxin treatment.  Pertussis toxin, where given 
was  administered  by  intraperitoneal  injection  on  the  same  day  as  MOG  CFA 
immunisation, followed by a second dose two days later.  Numbers of lymphocytes 
in the para-aortic and inguinal lymph nodes (draining lymph nodes) were assessed 
three  days  and  seven  days  after  MOG  CFA  immunisation.    Cell  counts  were 
performed by a Casy-1 cell counter and assessment of different populations was 
carried out by flow cytometry.    Red dots indicate individual mice injected with 
pertussis  toxin  in  combination  with  MOG  CFA  immunisation  and  black  dots 
indicate individual mice immunised with MOG CFA only.   The mean for each 
group is shown as a horizontal line. Shown  are the results of three independent 
experiments.  Statistical analysis was carried out using the Mann-Whitney U-Test. 
(*) indicates P-value = 0.01-0.05.  
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Figure 3.9 Following immunisation with MOG CFA, injection of pertussis toxin 
does not significantly alter IL-17A and IFN-γ expression within the CD4 T cell 
population in the draining lymph nodes. 
 
C57BL/6 mice were immunised at the base of the tail with MOG CFA emulsion in 
the presence or absence of pertussis toxin treatment.  Pertussis toxin, where given 
was  administered  by  intraperitoneal  injection  on  the  same  day  as  MOG  CFA 
immunisation, followed by a second dose two days later. The draining lymph nodes 
were harvested three days and seven days after the MOG CFA immunisation and 
assessed for intra-cellular IL-17A and IFN-γ protein expression by flow cytometry 
analysis following a four hour stimulation with PdBu, ionomycin and brefeldin A. 
Total numbers of CD4 T cells expressing intra-cellular IL-17A and IFN-γ protein are 
shown in (A). The percentage of IL-17A and IFN-γ-expressing cells within the CD4 
T cell population are shown in (B). Red dots indicate individual mice given pertussis 
toxin  in  combination  with  MOG  CFA  immunisation  and  black  dots  indicate 
individual mice given MOG CFA immunisation only.  The mean for each group is 
shown  as  a  horizontal  line.  Shown  are  the  results  from  three  independent 
experiments.  
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Figure  3.10  Following  immunisation  with  MOG  CFA,  injection  of  pertussis 
toxin  does  not  significantly  alter  Foxp3  expression  within  the  CD4  T  cell 
population or IL-17A expression within the γδ T cell population in the draining 
lymph nodes. 
 
C57BL/6 mice were immunised at the base of the tail with MOG CFA emulsion in 
the presence or absence of pertussis toxin treatment.  Pertussis toxin, where given 
was  administered  by  intraperitoneal  injection  on  the  same  day  as  MOG  CFA 
immunisation, followed by a second dose two days later. The draining lymph nodes 
were harvested three days and seven days after the MOG CFA immunisation and 
assessed for intra-cellular IL-17A and Foxp3 protein expression by flow cytometry 
analysis following a four hour stimulation with PdBu, ionomycin and brefeldin A. 
Total  numbers  of  γδ  T  cells  expressing  intra-cellular  IL-17A  protein  and  the 
percentage of IL-17A-expressing cells within the γδ T cell population are shown in 
(A). Total numbers of CD4 T cells expressing intra-cellular Foxp3 protein and the 
percentage of Foxp3-expressing cells within the CD4 T cell population are shown in 
(B). Red dots indicate individual mice given pertussis toxin in combination with 
MOG CFA immunisation and black dots indicate individual mice given MOG CFA 
immunisation only.  The mean for each group is shown as a horizontal line. Shown 
are the results from three independent experiments.  
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Figure  3.11  Following  immunisation  with  MOG  CFA,  injection  of  pertussis 
toxin does not significantly alter the number of IL-17A- and IFN-γ-expressing 
CD4 and γδ T cell populations in the blood, but results in a marginal increase 
in the number of granulocytes 
 
C57BL/6 mice were immunised at the base of the tail with MOG CFA emulsion in 
the presence or absence of pertussis toxin treatment.  Pertussis toxin, where given 
was  administered  by  intraperitoneal  injection  on  the  same  day  as  MOG  CFA 
immunisation, followed by a second dose two days later. Blood was collected by 
cardiac puncture three days and seven days following MOG CFA immunisation and 
red blood cells were lysed by ACK lysis.  The remaining cells were stimulated for 
four hours with PdBu, ionomycin and brefeldin A and analysed by flow cytometry. 
A sample of blood was also taken from the tail of the mice before sacrifice and 
analysed using a Vetscan to determine the number of lymphocytes, monocytes and 
granulocytes  in  the  blood.    Using  a  combination  of  the  number  of  lymphocytes 
determined  from  the  Vetscan  and  percentages  of  cells  from  the  flow  cytometry 
analysis, the number of IL-17A
+ (top left), IFN-γ
+ (bottom right) and IL-17A
+IFN-γ
+ 
(bottom left) CD4 T cells, as well as IL-17A
+ γδ T cells (top right) in the blood were 
determined (A).  The number of granulocytes determined by the Vetscan is shown in 
(B). Red dots indicate individual mice injected with pertussis toxin in combination 
with MOG CFA immunisation and black dots indicate individual mice immunised 
with MOG CFA alone.  The mean for each group is shown as a horizontal line. 
Shown are the results of three independent experiments.  Statistical analysis was 
carried out using the Mann-Whitney U-Test. (**) indicates P-value = 0.001-0.01.  
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Figure  3.12  Flow  cytometry  gating  strategy  for  analysis  of  spinal  cord 
leukocytes 
 
Leukocytes were prepared from the spinal cord as described in section 2.3.3 and 
assessed by flow cytometry.  For analysis, a gate was first drawn to exclude cell 
debris (counted cells), singlets were gated by FSC-H/FSC-W discrimination, live 
cells were gated by 7AAD exclusion and for analysis of lymphocyte populations an 
additional lymphocyte gate was drawn (A).  Neutrophils were defined based upon 
expression  of  Ly6G  and  an  epitope  detected  by  7/4  antibody.  Monocytes  were 
defined  based  upon  expression  of  an  epitope  detected  by  7/4  antibody  and  the 
absence of Ly6G expression.  B cells were detected by expression of CD19, CD4 T 
cells by expression of TCRβ and CD4, and γδ T cells based upon expression of γδ 
TCR.  Ly6G, 7/4 and CD19 staining are shown in a mouse 7 days following MOG 
CFA  and  pertussis  toxin  immunisation  and  CD4,  TCRβ  and  TCR γδ  staining  is 
shown in a mouse of disease score 4 at day 18 following MOG CFA and pertussis 
toxin immunisation (B). 
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Figure 3.13 CD4 and γδ T cells accumulate in the spinal cord before the onset 
of clinical disease. 
 
C57BL/6 mice were immunised at the base of the tail with MOG CFA emulsion in 
the presence or absence of pertussis toxin treatment.  Pertussis toxin, where given 
was  administered  by  intraperitoneal  injection  on  the  same  day  as  MOG  CFA 
immunisation,  followed  by  a  second  dose  two  days  later.    Spinal  cords  were 
harvested  three  days,  seven  days  and  ten  days  following  the  MOG  CFA 
immunisation  (prior  to  disease  onset)  and  leukocytes  were  analysed  by  flow 
cytometry.  Age and sex-matched, non-immunised C57BL/6 mice were analysed as 
controls at the same time points as the immunised mice were analysed (blue bars). 
Mean and standard deviation of three independent experiments are shown, where, in 
each  experiment  three  spinal  cords  were  pooled.    Numbers  of  monocytes  and 
neutrophils are shown in (A). Numbers of lymphocytes are shown in (B). Red bars 
indicate groups of mice injected with pertussis toxin in combination with MOG CFA 
immunisation and black bars indicate groups of mice immunised with MOG CFA 
alone. ND = not determined. 
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Figure 3.14 Analysis of intra-cellular IL-17A and IFN-γ protein expression in 
CD4 and γδ T cells in the spinal cord before the onset of clinical disease. 
 
C57BL/6 mice were immunised at the base of the tail with MOG CFA emulsion in 
the presence or absence of pertussis toxin treatment.  Pertussis toxin, where given 
was  administered  by  intraperitoneal  injection  on  the  same  day  as  MOG  CFA 
immunisation, followed by a second dose two days later. Age and sex-matched, non-
immunised C57BL/6 mice were analysed as controls. Leukocytes were isolated from 
the spinal cords ten days following MOG CFA immunisation and assessed for IL-
17A and IFN-γ expression by flow cytometry following a 4 hour stimulation with 
PdBu, ionomycin and brefeldin A. Three spinal cords were pooled from each group 
of mice. Examples of the staining are shown from non-immunised mice, and MOG 
CFA immunised mice injected with and without pertussis toxin.  IL-17A and IFN-γ 
staining in CD4 T cells is shown in (A) and IL-17A staining in γδ T cells is shown in 
(B). 
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Figure 3.15 Accumulation of IL-17A-, IFN-γ- and Foxp3-expressing T cells in 
the spinal cord before the onset of clinical disease 
 
C57BL/6 mice were immunised at the base of the tail with MOG CFA emulsion in 
the presence or absence of pertussis toxin treatment.  Pertussis toxin, where given 
was  administered  by  intraperitoneal  injection  on  the  same  day  as  MOG  CFA 
immunisation, followed by a second dose two days later. Leukocytes were isolated 
from the spinal cords ten days following MOG CFA immunisation and assessed for 
IL-17A,  IFN-γ  and  Foxp3  expression  by  flow  cytometry  following  a  four  hour 
stimulation  with  PdBu,  ionomycin  and  brefeldin  A.  Age  and  sex-matched,  non-
immunised C57BL/6 mice were analysed as controls at the same time points as the 
immunised mice were analysed (blue bars).  For each time point, three spinal cords 
were pooled from each group of mice.  The mean and standard deviation from three 
independent experiments is illustrated in the bar charts. Numbers of IL-17A
+, IL-
17/IFN-γ
+ and IFN-γ
+ CD4 T cells are shown in (A), numbers of IL-17A
+ γδ T cells 
are shown in (B) and numbers of Foxp3
+ CD4 T cells are shown in (C).  Red bars 
indicate groups of mice injected with pertussis toxin in combination with MOG CFA 
immunisation and black bars indicate groups of mice immunised with MOG CFA 
alone. 
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Figure  3.16  Monocytes,  neutrophils,  CD4  and  γδ  T  cells  accumulate  in  the 
spinal  cords  of  mice  with  clinical  disease,  irrespective  of  pertussis  toxin 
treatment 
 
C57BL/6 mice were immunised at the base of the tail with MOG CFA emulsion in 
the presence or absence of pertussis toxin treatment.  Pertussis toxin, where given 
was  administered  by  intraperitoneal  injection  on  the  same  day  as  MOG  CFA 
immunisation, followed by a second dose two days later. Leukocytes were isolated 
from  the  spinal  cords  eighteen  days  following  MOG  CFA  immunisation  and 
assessed by flow cytometry.  Age and sex-matched, non-immunised C57BL/6 mice 
were  analysed  as  controls  at  the  same  time  points  as  the  immunised  mice  were 
analysed  (blue  bars).    For  the  non-immunised  group  (blue  bars)  and  the  group 
immunised with MOG CFA alone (black bars) that did not develop disease, three 
spinal cords were pooled in two independent experiments and the mean and standard 
deviation are shown.  For the mice immunised with MOG CFA alone that developed 
disease, four mice were analysed individually and the mean and standard deviation 
are shown (black patterned bars).  For the mice immunised with MOG CFA and 
pertussis toxin, fifteen mice were analysed individually and the mean and standard 
deviation are shown (red bars). Monocytes and neutrophils are shown in (A) and 
lymphocytes are shown in (B). 
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Figure  3.17  IL-17A,  IFN-γ  and  Foxp3-expressing  CD4  and  γδ  T  cells 
accumulate  in  the  spinal  cord  of  mice  with  clinical  disease,  irrespective  of 
pertussis toxin treatment 
 
C57BL/6 mice were immunised at the base of the tail with MOG CFA emulsion in 
the presence or absence of pertussis toxin treatment.  Pertussis toxin, where given 
was  administered  by  intraperitoneal  injection  on  the  same  day  as  MOG  CFA 
immunisation, followed by a second dose two days later. Leukocytes were isolated 
from  the  spinal  cords  eighteen  days  following  MOG  CFA  immunisation  and 
assessed for intra-cellular IL-17A, IFN-γ and Foxp3 expression by flow cytometry 
following a four hour stimulation with PdBu, ionomycin and brefeldin A. Age and 
sex-matched, non-immunised C57BL/6 mice were analysed as controls at the same 
time  points  as  the  immunised  mice  were  analysed  (blue  bars).    For  the  non-
immunised group (blue bars) and the group immunised with MOG CFA alone that 
did  not  develop  disease  (black  bars),  three  spinal  cords  were  pooled  in  two 
independent experiments and the mean and standard deviation are shown.  For the 
mice  immunised  with  MOG  CFA  alone  that  developed  disease,  four  mice  were 
analysed  individually  and  the  mean  and  standard  deviation  are  shown  (black 
patterned  bars).    For  the  mice  immunised  with  MOG  CFA  and  pertussis  toxin, 
fifteen mice were analysed individually and the mean and standard deviation are 
shown (red bars). IL-17A
+, IL-17A/IFN-γ
+ and IFN-γ
+ CD4 T cells are shown in (A), 
IL-17A
+ γδ T cells are shown in (B) and Foxp3
+ CD4 T cells are shown in (C). 
     Chapter 3 
  128 
     Chapter 3 
  129 
3.3  Investigating  the  effect  of  pertussis  toxin  in  the  priming  phase  of  EAE 
development. 
 
In the first part of this chapter, IL-17A and IFN-γ-expressing CD4 T cells could be 
detected  at  similar  frequencies  in  the  lymph  nodes  and  blood  of  mice  with  and 
without pertussis toxin injection, but effector cells entering the spinal cord were 
increased in numbers in the mice treated with pertussis toxin.  This immediately 
suggested that pertussis toxin was not having any striking affect on the ability of 
effector cells to be primed and enter the blood circulation.   However, it seemed 
intriguing that in the standard protocol for EAE, pertussis toxin is administered at 
days 0 and 2, at the initiation stage of disease, well before effector cells begin to 
enter the spinal cord.  The first aim of the next part was therefore to investigate the 
time frame in which pertussis toxin was exerting its effects in EAE.   In order to 
investigate this we wanted to determine how long after injection of pertussis toxin, 
it’s effects could be detected in vivo.   In addition, we wanted to specifically address 
how the timing of pertussis toxin administration affected disease outcome. 
 
The  development  of  EAE  is  dependent  upon  the  generation  of  MOG-specific 
effector cells, which are approximately 0.2% of the CD4 T cells in the lymph nodes 
according to MOG-tetramer staining in EAE (Korn, Reddy et al. 2007).  In the first 
part of this chapter, effector T cells were assessed based on production of IL-17A 
and IFN-γ in response to PdBu and ionomycin stimulation and any differences in the 
ability of the MOG-specific CD4 T cells to express these cytokines may have been 
undetectable.  We therefore wanted to assess the peripheral MOG-specific cytokine 
response  from  mice  immunised  with  MOG  CFA  with  or  without  pertussis  toxin 
injection. 
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3.3.1 Pertussis toxin affects the migration capacity of CD4 T at the initiation 
stage and up to the onset of disease in EAE 
  
The observation in Figure 3.8, that pertussis toxin-treated mice had fewer cells in 
the  draining  lymph  nodes  could  be  attributed  to  the  effect  of  pertussis  toxin  on 
immune cell migration (Spangrude, Braaten et al. 1984)   Indeed, pertussis toxin has 
ADP-ribosylase  activity  which  can  inhibit  G-protein  receptor  signalling  (Reisin 
1990) such as the signalling in chemokine receptors. Chemokine receptor signalling 
is critical for cell trafficking including movement of cells in and out of the lymph 
nodes  and  migration  of  cells  into  peripheral  tissues  in  steady  state  as  well  as 
inflammatory conditions.  We therefore wanted to assess how pertussis toxin was 
influencing the function of chemokine receptors on CD4 T cells in vivo and also to 
assess the time frame in which it was doing this.  This would give information about 
the timing in which pertussis toxin could potentially be acting in EAE. 
 
We chose to investigate the effect of pertussis toxin on the migration of CD4 T cells 
to CCL21, a chemokine that signals through CCR7. CCR7 is expressed on naïve 
CD4 T cells and is involved in the recruitment of cells to the lymph nodes under 
steady  state  conditions  (Forster,  Davalos-Misslitz  et  al.  2008),  however  its 
importance in EAE has been implicated in mice that are deficient in CCR7 which are 
resistant to disease development (Kuwabara, Ishikawa et al. 2009). 
 
An assay was first performed to demonstrate the effect of pertussis toxin on the 
migration of CD4 T cells to CCL21.  This is shown in Figure 3.18A.  Whole lymph 
node  cells  were  treated  with  and  without  pertussis  toxin  for  2  hours  prior  to 
performing the migration assay.   In the absence of pertussis toxin, CD4 T cells 
migrated to CCL21 in a dose-dependent manner.  The cells that had been treated 
with  pertussis  toxin  showed  no  migration  capacity  to  CCL21.    It  was  therefore 
concluded that treatment of pertussis toxin in vitro inhibits the migration of CD4 T 
cells to CCL21.  
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The migration capability of CD4 T cells to CCL21 was then assessed at time points 
following in vivo pertussis toxin or PBS administration.   Mice were injected with 
either pertussis toxin or PBS on days 0 and 2, These time points represented the time 
points in which pertussis would be given in the standard EAE protocol.  The MOG 
CFA injection was not necessary in this experiment as we specifically wanted to 
address the time frame in which pertussis toxin could be affecting CD4 T cells in 
vivo.  Lymph node cells from three or four mice from each group were assessed on 
days 3, 6, 10, and 19 after the initial injection.  
 
Cells from pertussis toxin-treated mice had a reduced migration capacity to CCL21 
on day 3, day 6 and day 10 after the first injection, which was statistically significant 
at day 3 according to the Mann Whitney U-test (Figure 3.18B), perhaps due to the 
fact that four mice rather than three mice were compared in this group.  By day 19, 
migration of the pertussis toxin-treated cells was comparable to the control cells 
from PBS-treated mice.  It was therefore concluded that pertussis toxin was affecting 
the migration capability of CD4 T cells up until at least the onset of disease at day 
10 and so could be exerting its effects in EAE at any point in this time frame. 
 
3.3.2 Pertussis toxin is required to be administered at the initiation stage of 
disease in order to initiate most severe EAE pathology 
 
Although the effects of pertussis toxin could be influencing EAE progression up to 
the  onset  of  disease,  we  wanted  to  investigate  more  specifically  when  it  was 
required.  Pertussis  toxin  is  routinely  given  at  days  0  and  2  to  initiate  EAE  in 
C57BL/6 mice and in some protocols it is given on days 1 and 3. If pertussis toxin 
was acting solely by increasing vascular permeability at the blood brain barrier in 
EAE then administration at later time points might be sufficient to allow activated 
CD4 T cells to enter the CNS and to initiate disease.  Studies using Evans blue dye 
reported an effect on vascular permeability four days after pertussis toxin injection 
(Clifford, Zarrabi et al. 2007).        Chapter 3 
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Mice were therefore immunised mice with MOG CFA on day 0, with pertussis toxin 
given on days 0 and 2, 1 and 3, 3 and 5, or 5 and 7.  Figure 3.19A shows the 
progression  of  the  disease  measured  by  mean  clinical  score  against  time  in  the 
different groups. Administration of pertussis toxin on days 0 and 2 induced the most 
severe disease, measured by the average maximum score and earliest onset (Figure 
3.19B).  Delaying the time of the pertussis toxin treatment still permited disease, 
however onset was later and the average maximum score was lower.  
 
In Figure 3.11, mice treated with pertussis toxin in combination with MOG CFA 
immunisation  had  a  marginally  higher  blood  granulocyte  count  than  mice 
immunised with MOG CFA alone.  We therefore hypothesised that administration of 
pertussis  toxin  may  contribute to  EAE  pathology  by  a  mechanism  involving  the 
increased mobilisation of granulocytes.  The experiment to investigate the timing of 
pertussis  toxin  injection  on  outcome  of  disease  provided  an  opportunity  to 
investigate  a  possible  relationship  between  pertussis  toxin  administration,  blood 
granulocyte counts and disease severity.  
 
Figure 3.20A shows the number of blood granulocytes measured 1, 3 and 7 days 
after the last pertussis toxin treatment.  Pertussis toxin treatment in combination with 
MOG CFA was associated with an increase in blood granulocytes when compared to 
mice  immunised  with  MOG  CFA  with  no  pertusssis  toxin  treatment.    However, 
granulocyte counts were lowest in the mice that were injected on days 0 and 2 with 
pertussis  toxin  and  these  mice  had  the  most  severe  disease.    Mice  with  higher 
granulocyte scores were from the groups injected at later time points, with lower 
disease  severity.    A  comparison  of  peak  blood  granulocytes  with  peak  disease 
severity  in  individual  mice  was  also  made  which  showed  no  direct  correlation 
(Figure  3.20B).    In  conclusion,  although  a  link  between  pertussis  toxin 
administration in combination with MOG CFA immunisation and increased blood 
neutrophilia was apparent, the levels of granulocytes measured in the blood did not 
directly correlate with severity.  However, an importance for pertussis toxin-induced     Chapter 3 
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neutropilia could not be excluded, as a mere increase in blood granulocytes over a 
threshold level may be important for disease development. 
 
3.3.3  Pertussis  toxin  amplifies  the  peripheral  MOG-specific  inflammatory 
cytokine response in EAE 
 
Since pertussis toxin was required at the initiation stage of EAE to give most severe 
disease, this suggested an effect on the T cell priming stage of disease induction.  In 
the first part of this chapter, the frequency of IL-17A and IFN-γ-expressing CD4 T 
cells in the lymph nodes and blood did not differ between the mice treated with and 
without pertussis toxin.  The method used for detection of these cytokine-expressing 
cells  was  intra-cellular  cytokine  staining  after  a  4  hour  stimulation  with  the 
mitogenic stimuli PdBu and ionomycin which would capture all cytokine-expressing 
cells  irrespective  of  antigen-specificity.    However,  it  was  still  a  possibility  that 
antigen-specific cytokine responses to MOG-peptide may differ between the two 
groups.  In order to assess this, lymph node cells were activated with MOG peptide, 
PdBu and ionomycin or medium alone for 24 hours in vitro and concentrations of 
IFN-γ and IL-17A protein were analysed in the supernatants.   In some cultures, 
brefeldin  A  was  added  in  the  last  6  hours  and  the  cells  were  analysed  by  flow 
cytometry in order to assess the number of cells that were responding to the stimuli. 
 
Inclusion of pertussis toxin with the MOG CFA immunisation increased the IL-17A 
and IFN-γ protein produced from lymph node cells in response to MOG peptide at 
day 7 and day 10 although this was only statistically significant using the Mann 
Whitney U Test at day 10 for IL-17A protein (Figure 3.21A). Stimulation with 
PdBu and ionomycin induced IL-17A and IFN-γ protein production from lymph 
nodes of both pertussis toxin-treated and untreated mice, with the pertussis toxin-
untreated  group  producing  similar,  or  slightly  more  protein  at  the  time  points 
measured.  (Figure 3.21B).  At day 10 some mice from the pertussis toxin-treated     Chapter 3 
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group produced IL-17A and IFN-γ protein even in the presence of medium alone  
(Figure 3.21C).  
 
The  results  indicated  that  the  MOG-specific  IL-17A  and  IFN-γ  response  was 
enhanced in the lymph nodes from mice treated with pertussis toxin, compared to 
those mice immunised with MOG CFA alone.  In order to confirm this result, IL-
17A and IFN-γ expression was investigated by intra-cellular staining in CD4 T cells 
stimulated with MOG peptide.  This would give information about the percentage 
and number of CD4 T cells responding to the peptide. 
 
The same experimental set-up was used, but this time brefeldin A was added into the 
cultures for the last 6 hours in order to retain protein inside the cell for detection by 
fluorescent  antibodies.  Representative  flow  cytometry  plots  are  shown  (Figure 
3.22A) and the data are summarised in the bar charts (Figure 3.22B).  Pertussis 
toxin administration in combination with MOG CFA immunisation increased the 
percentage of MOG-specific IL-17A-expressing, IFN-γ-expressing and IL-17A and 
IFN-γ  double-expressing  CD4  T  cells  in  the  lymph  nodes  at  day  7  after 
immunisation as well as the corresponding absolute numbers of these cells (Figure 
3.22B).  
 
The results showed that CD4 T cells from the mice immunised with pertussis toxin 
were secreting IL-17A and IFN-γ protein in response to MOG peptide, whereas the 
CD4 T cells from mice immunised with MOG CFA alone were not.  However in 
response to PdBu ionomycin stimulation the expression of IL-17A and IFN-γ protein 
from CD4 T cells was not different between the two groups.  This suggested that the 
effect  of  pertussis  toxin  on  the  CD4  T  cells  in  vivo  is  masked  by  the  PdBu 
ionomycin stimulation but revealed when cells are stimulated with MOG peptide. 
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3.3.4 Summary 
 
From  these  experiments,  it  was  determined  that  pertussis  toxin  effected  the 
migration  of  CD4  T  cells  to  CCL21  for  at  least  10  days  following  in  vivo 
administration and could therefore be exerting its effects in EAE up to the onset of 
disease, however the effects of pertussis toxin at the initiation stage of the immune 
response  are  important  for  most  severe  disease.    Furthermore,  pertussis  toxin 
enhances MOG-specific CD4 T cell production of IL-17A and IFN-γ, which could 
be directly attributed to pathogenesis in EAE, as the ability of CD4 T cells to be re-
activated  by  MOG  peptide  in  the  CNS  is  critical  in  the  induction  of  a  pro-
inflammatory  response  and  the  progression  of  clinical  disease  (Kawakami, 
Lassmann et al. 2004).  
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Figure 3.18 Injection of pertussis toxin impairs the migration capability of CD4 
T cells to CCL21 for at least 10 days following administration. 
 
Cells from the peripheral lymph nodes of two wild type, non-immunised C57BL/6 
mice  were  analysed  for  migration  to  different  concentrations  of  CCL21  in  a 
transwell assay after in vitro treatment with pertussis toxin.  The percentage of the 
cells that migrated across the transwell (% of input) is shown for pertussis toxin 
treated cells (red line) and control cells that were pertussis toxin un-treated (black 
line).  The mean and standard deviation of two assay replicates is shown for both 
groups at each concentration (A).  Mice were injected with pertussis toxin (red dots) 
or D-PBS (black dots) on day 0, with a second dose given two days later (day 2).  
Peripheral  lymph  nodes  were  harvested  on  day  three,  day  six,  day  ten  and  day 
nineteen and assessed for migration to CCL21 in a transwell assay. The peripheral 
lymph node cells from three or four mice were analysed individually at each time 
point  from  each  group  and  each  dot  on  the  graph  represents  the  mean  of  two 
replicates in the transwell assay for each mouse.  The mean for all the mice analysed 
for each group is shown as a horizontal line. Statistical analysis was carried out 
between the two groups of injected mice at each time point using the Mann-Whitney 
U-Test. (*) indicates P-value = 0.01-0.05 
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Figure 3.19 Delaying the treatment of pertussis toxin relative to MOG CFA 
immunisation,  reduces  the  severity  of  EAE  measured  by  onset,  peak  mean 
clinical score and incidence. 
 
C57BL/6 mice were immunised with MOG CFA and given either no pertussis toxin 
(no ptx), pertussis toxin by intraperitoneal injection on the same day as the MOG 
CFA immunisation and also two days later (0+2), or on days one and three (1+3), 
days  three  and  five  (3+5)  or  days  five  and  seven  (5+7)  following  MOG  CFA 
immunisation.    Mice  were  assessed  for  symptoms  of  clinical  paralysis  and  the 
progression of the disease is illustrated by mean clinical score for all of the groups of 
mice (A).  The incidence, mean day of onset and mean maximum score are shown 
for each group of mice.  The day of onset and maximum score results were analysed 
statistically using the Kruskal-Wallis test with a Dunn’s post test. (*) indicates P-
value = 0.01-0.05, (**) (B). 
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Figure  3.20  Following  immunisation  with  MOG  CFA,  injection  of  pertussis 
toxin leads to an increase in the number of blood granulocytes 
 
C57BL/6 mice were immunised with MOG CFA and given either no pertussis toxin 
(no ptx), pertussis toxin by intraperitoneal injection on the same day as the MOG 
CFA immunisation and also two days later (0+2), or on days one and three (1+3), 
days  three  and  five  (3+5)  or  days  five  and  seven  (5+7)  following  MOG  CFA 
immunisation. Blood samples were taken from the tail tip, one day, three days and 
seven days after the last pertussis toxin injection and were analysed using a Vetscan 
to determine the number of granulocytes in the blood. The same mice were also 
assessed  for  symptoms  of  clinical  paralysis.    The  mean  number  and  standard 
deviation of blood granulocytes from between four and eight individual mice in each 
group is shown in (A).  The peak number of granulocytes in mice injected with 
pertussis toxin is shown compared with the maximum clinical score of the mouse.  
The mean and standard deviation for between two and nine individual mice of each 
disease score is shown (B). 
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Figure  3.21  Following  immunisation  with  MOG  CFA,  injection  of  pertussis 
toxin enhances MOG-specific IL-17A and IFN-γ protein secretion from lymph 
node cells 
 
C57BL/6 mice were immunised into the base of the tail with MOG CFA emulsion in 
the presence or absence of pertussis toxin given by intra-peritoneal injection on the 
same day as the MOG CFA emulsion as well as two days later.  The draining lymph 
nodes were harvested seven and ten days following the MOG CFA immunisation 
and approximately 1 million cells from each mouse were cultured with either MOG 
peptide35-55, PdBu and ionomycin, or medium alone.  Supernatants were harvested 
24 hours later and were assessed for IL-17A and IFN-γ protein by Flowcytomix bead 
analysis.  Concentrations of IL-17A and IFN-γ are shown after MOG stimulation (A) 
after PdBu and ionomycin stimulation (B) or after medium stimulation alone (C).  
Red dots represent the results from individual mice immunised with MOG CFA and 
given pertussis toxin injections and black dots represent individual mice given MOG 
CFA immunisation alone.  The mean of each group is shown by a horizontal line.  
Statistical analysis was carried out between the groups of mice injected with and 
without  pertussis  toxin  at  each  time  point  using  the  Mann-Whitney  U-Test.  (*) 
indicates P-value = 0.01-0.05.  
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Figure  3.22  Following  immunisation  with  MOG  CFA,  injection  of  pertussis 
toxin enhances MOG-specific intra-cellular IL-17A and IFN-γ protein in CD4 T 
cells from the draining lymph nodes 
 
C57BL/6 mice were immunised at the base of the tail with MOG CFA emulsion in 
the presence or absence of pertussis toxin treatment.  Pertussis toxin, where given 
was  administered  by  intraperitoneal  injection  on  the  same  day  as  MOG  CFA 
immunisation, followed by a second dose two days later.  The draining lymph nodes 
were harvested seven days following MOG CFA emulsion and approximately equal 
numbers  of  cells  were  cultured  with  MOG  peptide35-55  for  twentyfour  hours.  
Brefeldin A was added to the cultures for the last six hours of culture and the cells 
were  harvested  for  analysis  of  intra-cellular  IL-17A  and  IFN-γ  protein  by  intra-
cellular staining.  An example of flow cytometry staining in CD4 T cells from mice 
injected with and without pertussis toxin is shown in (A). The number of these cells 
in the draining lymph nodes as well as the percentage of CD4 T cells expressing IL-
17A, IL-17A/ IFN-γ or IFN-γ is shown in (B).  The results are shown as the mean 
and standard deviation of two mice from the pertussis toxin injected group and three 
mice from the group immunised with MOG CFA alone. Red bars indicate mice 
injected  with  pertussis  toxin  in  combination  with  MOG  CFA  immunisation  and 
black bars indicate mice immunised with MOG CFA alone.  Where values for the 
group immunised without pertussis toxin cannot be seen on the graph, the mean is 
indicated. 
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3.4 Discussion 
 
The aim of the first part of this thesis was to define the sequence of immunological 
events  leading  to  the  development  of  a  pathological  immune  response  directed 
against a self-antigen.  EAE was chosen as an animal model of autoimmunity in 
which immunisation with CNS peptides and adjuvant culminates in a pathological 
immune response directed against self-antigens in the CNS. 
 
EAE has many similarities with the human disease multiple sclerosis including the 
presence of auto-reactive T cells in the CNS, the destruction of the myelin sheaths 
and the formation of perivascular inflammatory cell foci in the brain stem and spinal 
cord (Steinman and Zamvil 2006).  In addition, the majority of MS patients have a 
course  of  disease  that  is  relapsing  and  remitting,  however  some  patients  have  a 
primary progressive disease (Sospedra and Martin 2005) and this is also true for 
different models of EAE.  Factors that influence the course of disease progression in 
EAE include the genetic strain of animal used.  For example, SJL/J and Biozzi/ABH 
mice typically exhibit a relapsing and remitting disease (Brown and McFarlin 1981; 
Baker, O'Neill et al. 1990), whereas C57BL/6 mice typically develop chronic EAE 
(Mendel, Kerlero de Rosbo et al. 1995).  Factors such as the sex of the animal and 
the environment also determine disease outcome.  For example, it was shown that 
female  SJL/J  mice  immunised  with  PLP139-151  peptide  developed  relapsing  and 
remitting disease, however male SJL/J mice immunised with the same peptide did 
not relapse (Bebo, Vandenbark et al. 1996).  In one study a cohort of SJL/J mice 
derived from one breeder developed chronic disease, while from another breeder 
they  developed  relapsing  and  remitting  disease  (deLuca,  Pikor  et  al.  2010).    In 
addition,  the  method  of  disease  induction  can  influence  disease  outcome,  as 
C57BL/6  mice  immunised  with  sub-optimal  doses  of  peptide,  Mycobacterium 
tuberculosis and pertussis toxin developed relapsing and remitting disease (Berard, 
Wolak et al. 2010).  
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The potential of different CNS epitopes to induce disease is dependent upon the 
strain of mouse used.  For example, myelin oligodendrocyte glycoprotein (MOG) 
peptide35-55,  a  minor  component  of  CNS  myelin,  is  strongly  encephalitogenic  in 
C57BL/6 mice (Mendel, Kerlero de Rosbo et al. 1995), while in SJL/J mice MOG92-
106 (Amor, Groome et al. 1994), peptides of PLP (Tuohy, Lu et al. 1989; Greer, 
Kuchroo et al. 1992; Tuohy and Thomas 1995) and peptides of MBP (Amor, O'Neill 
et al. 1996) are more potent at inducing autoimmunity.  These differences are likely 
to be heavily dependent upon the different MHC backgrounds of the mice as MHC 
molecules are responsible for presenting peptides to T cells for their activation.   
 
Epitopes  of  MOG  are  strongly  encephalitogenic  in  mice,  rats,  monkeys  and 
marmosets  (Krishnamoorthy  and  Wekerle  2009),  and  T  cells  reactive  to  MOG 
epitopes have been detected in MS patients (Bernard, Johns et al. 1997; Iglesias, 
Bauer et al. 2001).  The capacity of MOG peptide to act as an auto-antigen in EAE 
and  MS  is  due  to  breakdown  in  self-tolerance  leading  to  development  of 
autoimmunity  directed  against  this  peptide.      During  T  cell  development,  auto-
reactive T cells are usually deleted by negative selection, which is heavily dependent 
upon  expression  of  the  peptide  in  the  thymus  (Derbinski,  Schulte  et  al.  2001). 
Indeed, it was  shown that T-cell epitopes that  were ectopically expressed in the 
thymus  were  not  targets  for  autoimmunity,  while  epitopes  not  expressed  in  the 
thymus were targets (Klein, Klugmann et al. 2000).  There is also an association 
between  expression  of  CNS  peptides  in  the  thymus  and  susceptibility  to  EAE 
induction.  For example, intra-thymic expression of the PLP peptide, DM20 is high, 
however  the  peptide  PLP139-151  is  not  expressed  in  the  thymus  and  it  has  been 
suggested that the high occurance of PLP139-151-reactive T cells in SJL/J mice is due 
to the lack of thymic expression of this peptide. (Anderson, Nicholson et al. 2000).  
Furthermore, BALB/C mice are usually resistant to EAE induced by MBP peptide, 
but if MBP-reactive cells are isolated from MBP-deficient mice and transferred into 
wild  type  recipients,  EAE  develops  (Targoni  and  Lehmann  1998).    These 
observations could be due to negative selection of these self-reactive clones in the 
periphery or positive selection of clones with regulatory function.   There have been     Chapter 3 
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some discrepancies with respect to detection of MOG expression in the thymus.  
Some  reports  have  suggested  MOG  expression  is  sequestered  in  the  CNS  (Mor, 
Boccaccio et al. 1998; Bruno, Sabater et al. 2002), however more recent work has 
suggested that MOG is expressed in the medullary epithelial cells in the thymus 
(Derbinski, Schulte et al. 2001).  Nevertheless, these discrepancies could indicate 
that  MOG  is  expressed  at  most  at  low  levels  in  the  thymus.      This  would  also 
correlate with the results from experiments using MOG knockout mice in which 
there have also been different findings.  One study showed that T cells from mice 
lacking MOG could transfer more severe disease than wild type T cells into wild 
type recipients, suggesting that expression of endogenous MOG exhibits some level 
of tolerance to this brain determinant (Linares, Mana et al. 2003).  However, another 
study using MOG-deficient mice showed that responses to MOG were the same in 
MOG-deficient mice as in wild type mice (Delarasse, Daubas et al. 2003).  That 
endogenous MOG peptide is not expressed highly enough in the periphery for the 
development of anergy or for the deletion of MOG-specific clones is supported by 
the fact that if MOG peptide is injected intravenously prior to EAE induction then 
the development of autoimmunity is prevented (Fazilleau, Delarasse et al. 2006).   
 
In summary, tolerance to MOG is incomplete, however under normal circumstances 
MOG-specific  T  cell  clones  do  not  become  activated  by  their  antigen  in  the 
periphery.    Specific  signals  induced  by  immunisation  with  MOG  in  CFA  and 
pertussis toxin can break tolerance to this peptide and induce encephalitogenic T 
cells, capable of initiating a pathological immune response in the CNS.  
 
To  investigate  the  implications  of  this  immunisation  we  first  investigated  the 
sequence of events following MOG CFA immunisation, an immunisation which in 
most cases does cause disease pathology. 
 
CFA containing heat-killed Mycobacterium tuberculosis is used to elicit a number of 
autoimmune models (Billiau and Matthys 2001) however the specific implications of 
injection with this adjuvant are not clearly defined.  In this study, immunisation with     Chapter 3 
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MOG peptide in CFA alone was sufficient to up-regulate peripheral IL-17A and 
IFN-γ  responses  detected  after  PdBu  and  ionomycin  ex  vivo  stimulation.    More 
specifically, an increase in the frequency of IL-17A-producers was detected within 
the CD4 and γδ T cell populations in the draining lymph nodes 7 days following 
immunisation (Figures 3.3B,3.4A), which was accompanied by an increase in the 
number of these cells in the blood (Figure 3.6A).  No change in the percentage of 
IFN-γ-producing cells within the CD4 T cell population was observed in the lymph 
nodes at this time point (Figure 3.3B), however an increase in the number of IL-
17A/IFN-γ- double producing CD4 T cells was observed in the blood (Figure 3.6A). 
Whether these observations are a result of the outgrowth or recruitment of already 
IL-17A or IFN-γ-expressing cells, or de novo generation cannot be determined from 
these experiments but could be investigated further using cytokine reporter mice.  In 
vitro, the generation of Th17 cells can be induced by activation of CD3 in the TCR 
complex  using  an  anti-CD3  antibody,  stimulation  of  CD28  using  an  anti-CD28 
antibody,  as  well  as  stimulation  with  the  cytokines  IL-6  and  TGF-β  (Veldhoen, 
Hocking  et  al.  2006),  and  in  vivo  these  signals  are  also  required  for  lineage 
commitment of Th17 cells given the absence Th17 cell generation in IL-6 knockout 
mice and in mice expressing a dominant negative form of TGF-β receptor II under 
the control of the CD4 promoter (Bettelli, Carrier et al. 2006; Veldhoen, Hocking et 
al. 2006)   In addition, generation of IFN-γ-expressing Th1 cells can be induced in 
vitro by anti-CD3, anti-CD28, plus addition of IL-12. Mycobacterium tuberculosis 
consists of a number of PAMPs including cell wall lipoproteins and polysaccharides 
that are capable of activating PRRs on DCs and macrophages (Akira, Uematsu et al. 
2006).  For example, Mycobacterium tuberculosis stimulated the production of IL-
12p40 from a human monocyte line (Brightbill, Libraty et al. 1999) and TNFα from 
a mouse macrophage cell line (Underhill, Ozinsky et al. 1999), which was dependent 
upon  TLR2  signalling,  and  has  also  been  shown  to  stimulate  TLR1  and  TLR4 
(Akira, Uematsu et al. 2006). Mycobacterium tuberculosis has been shown to drive 
the production of IL-17 and IFN-γ-producing cells in in vitro systems using bone 
marrow-derived dendritic cells rather than triggering with anti-CD3 and anti-CD28, 
suggesting that these signals are also delivered by the antigen presenting cells that     Chapter 3 
  150 
are  activated  by  Mycobacterium  tuberculosis  (Veldhoen,  Hocking  et  al.  2006; 
Zenaro, Donini et al. 2009).  The generation of IL-17-producing CD4 T cells in 
these cultures was inhibited by blocking the effects of TGFβ or IL-6 (Veldhoen, 
Hocking  et  al.  2006)  and  was  dependent  upon  Dectin-1  receptor  engagement 
(Zenaro,  Donini  et  al.  2009).  In  addition,  in  vivo  infection  with  Mycobacterium 
tuberculosis  has  been  shown  to  induce  IL-17-  and  IFNγ-producing  CD4  T  cells 
(Khader, Pearl et al. 2005; Cruz, Khader et al. 2006; Khader, Bell et al. 2007), which 
is in agreement with the in vivo, up-regulation of IL-17A and IFN-γ-expressing CD4 
T cells in this study. 
 
γδ T cells have also been described to have a number of surface PRRs including 
TLR2, TLR1 and Dectin-1 (Mokuno, Matsuguchi et al. 2000; Deetz, Hebbeler et al. 
2006; Schwacha and Daniel 2008; Martin, Hirota et al. 2009) and are activated to 
produce IL-17 in response to various microbial stimuli including Mycobacterium 
tuberculosis (Martin, Hirota et al. 2009), as well as cytokines such as IL-23 and IL-1 
(Sutton, Lalor et al. 2009) which supports the observation of IL-17A-expressing γδ 
T cells induced after immunisation with MOG CFA.  The MOG CFA immunisation 
alone  also  induced  marginal  accumulation  of  granulocytes  in  the  blood  (Figure 
3.6B),  which  are  predominately  neutrophils.  This  could  be  due  to  increased 
mobilisation of neutrophils from the bone marrow, increased survival of these cells 
or an accumulation of these cells in the blood due to an inhibition of the influx of 
these  cells  into  peripheral  tissue.  Neutrophils  were  also  observed  as  part  of  the 
cellular infiltrate in the spinal cord from day 7 after MOG CFA immunisation in the 
absence  of  pertussis  toxin  (Figure  3.13A),  suggesting  that  the  increase  in 
neutrophils in the blood was at least not solely due to an inhibition of cells to access 
peripheral tissue.   γδ T cells have been closely associated with neutrophil-dependent 
inflammatory responses (King, Hyde et al. 1999; Moore, Moore et al. 2000; Toth, 
Alexander et al. 2004) and IL-17-producing γδ T cells have been shown in other 
systems to induce recruitment of neutrophils after direct interaction with pathogens 
including Mycobacterium tuberculosis (Martin, Hirota et al. 2009).  In addition, IL-
17 has been associated with neutrophil accumulation in peripheral tissues (Forlow,     Chapter 3 
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Schurr et al. 2001; Ye, Rodriguez et al. 2001) and has been shown to be involved in 
the mobilisation of neutrophils from the bone marrow via upregulation of G-CSF 
(Fossiez, Djossou et al. 1996).  It is therefore conceivable that IL-17A production 
from  activated  CD4  T  cells  and  γδ  T  cells  in  response  to  Mycobacterium 
tuberculosis in CFA may contribute to up-regulation of neutrophil mobilisation after 
MOG CFA immunisation. 
 
The frequency of Foxp3-expressing cells within the CD4 T cell population was also 
increased in the lymph nodes by day 7 after immunisation with MOG CFA (Figure 
3.4B).  De novo generation of Foxp3 expression in naïve CD4 T cells has been 
shown  to  be  dependent  on  the  presence  of  TGF-β,  however  in  the  presence  of 
additional IL-6, naïve T cells can become Th17 cells.  Moreover, pro-inflammatory 
Th17 cells and  suppressive Foxp-3 expressing  T-regs can develop in a mutually 
exclusive fashion (Bettelli, Carrier et al. 2006).  Although this de novo generation 
has been shown to occur in vitro it is impossible to deduce from the experiments in 
this study whether the increase in this population is a result of de novo generation 
from naïve CD4 T cells or the outgrowth of an already differentiated population.  
However, studies using adoptive transfer experiments with Foxp3gfp mice, in which 
Foxp3 expression is reported by the presence of GFP, have suggested that in EAE 
the expansion of Foxp3-expressing regulatory T cells, is a result of the outgrowth of 
already Foxp3-expressing cells, rather than de novo generation (Korn, Reddy et al. 
2007).  
 
However, the MOG CFA-induced up-regulation of peripheral IL-17A and IFN-γ-
responses (detected after PdBu ionomycin re-stimulation) and granulocyte induction 
is insufficient alone to induce autoimmunity.  For EAE to develop, administration of 
pertussis toxin is also required.  
 
EAE is understood to be mediated by CD4 T cells because elimination of CD4 T 
cells prevented disease onset or reversed ongoing disease (Pettinelli and McFarlin 
1981; Brostoff and Mason 1984; Waldor, Sriram et al. 1985) and also auto-antigen     Chapter 3 
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specific  CD4  T  cell  lines  could  induce  disease  following  transfer  (Ben-Nun  and 
Cohen  1982;  Zamvil,  Nelson  et  al.  1985;  Satoh,  Sakai  et  al.  1987;  Bourdette, 
Vandenbark et al. 1989; van der Veen, Trotter et al. 1990; Kuchroo, Sobel et al. 
1991; Whitham, Bourdette et al. 1991; Kuchroo, Sobel et al. 1992). EAE was for a 
long  time  believed  to  be  mediated  by  Th1  effector  cells,  which  was  due  to  an 
association between IFN-γ expression in the target tissue and disease pathology, the 
transfer of disease by IFN-γ-expressing Th1 T cell lines  (Kuchroo, Martin et al. 
1993; Ramirez and Mason 2000), and disease resistance in mice lacking T-bet and 
STAT-4, which are transcription factors involved in Th1 cell development (Bettelli, 
Sullivan et al. 2004).  However, genetic deletion of IFN-γ (Ferber, Brocke et al. 
1996),  the  characteristic  cytokine  produced  by  Th1  cells,  as  well  as  the  IFN-γ 
receptor (IFN-γ R) (Willenborg, Fordham et al. 1996) resulted in enhanced disease 
severity.  In addition, deletion of genes involved in Th1 development such as IL-
12p35 (Gran, Zhang et al. 2002), IL-12Rβ2 (Zhang, Gran et al. 2003) and IL-18 
(Gutcher, Urich et al. 2006) had the same phenotype.  Molecules involved in the 
Th17  pathway,  on  the  other  hand,  have  been  found  important  for  disease 
development.  For example, genetic deletion of the IL-17A cytokine (Komiyama, 
Nakae  et  al.  2006)  and  neutralisation  of  IL-17A  with  a  monoclonal  antibody 
(Lubberts, Koenders et al. 2004) led to reduced disease severity in EAE. Removal of 
IL-23p19, which is required for the stability of Th17 cells in vivo, rendered mice 
resistant to EAE (Cua, Sherlock et al. 2003).  In addition, RORγt-deficient mice and 
mice that had defective signalling through TGFβ receptor II in CD4 T cells had 
undetectable Th17 cells also had attenuated disease development (Ivanov, McKenzie 
et al. 2006; Veldhoen, Hocking et al. 2006). Enhancing the production of Th17 cells 
in vivo by AHR ligation with FICZ enhanced EAE severity (Quintana, Basso et al. 
2008; Veldhoen, Hirota et al. 2008), which again supported a role for the Th17 
pathway in the development of EAE.  Nevertheless, adoptive transfer studies are 
inconclusive and auto-reactive clones polarised to both Th1 and Th17 phenotypes 
have been shown to be able to induce the development of EAE, and both IFN-γ-
producing Th1 cells and IL-17-producing Th17 cells have been detected in the CNS 
during EAE development in this study as well as others (Murphy, Lalor et al. 2010)     Chapter 3 
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(Ivanov, McKenzie et al. 2006; Suryani and Sutton 2007; O'Connor, Prendergast et 
al. 2008).  
 
For an auto-reactive T cell to be pathogenic it must have the ability to home to the 
target tissue, to be able to recognise its target antigen, and to secrete the appropriate 
pro-inflammatory molecules upon activation to initiate tissue injury.   Although IL-6 
and TGF-β are required in vitro and in vivo for lineage commitment of Th17 cells 
(Veldhoen, Hocking et al. 2006) (cytokines which can be induced from DCs by 
Mycobacterium  tuberculosis  in  vitro),  these  two  cytokines  are  not  sufficient  to 
promote  full  differentiation  of  inflammatory  pathogenic  Th17  cells  as  IL-23p19 
mice  (Cua,  Sherlock  et  al.  2003)  and IL-1R1-deficient  mice  have  reduced  Th17 
responses (Sutton, Brereton et al. 2006).   Furthermore, one report showed that IL-23 
was found necessary for full pathogenic function of myelin-specific T cells in EAE 
(McGeachy, Bak-Jensen et al. 2007) and another showed that the IL-17 production 
from γδ T cells produced in response to IL-23 and IL-1β could enhance CD4 T cell 
IL-17  responses,  providing  a  mechanism  by  which  IL-23  may  amplify  Th17 
responses  in  vivo  (Sutton,  Lalor  et  al.  2009).    This  therefore  suggests  that 
development of autoimmune pathology in EAE requires more than TGF-β and IL-6-
induced Th17 cells that can be induced by MOG CFA immunisation. 
 
One of the proposed functions of pertussis toxin in EAE is that it opens up the blood 
brain barrier, facilitating the movement of activated auto-antigen specific CD4 T 
cells into the CNS.  Indeed, administration of pertussis toxin is associated with an 
increase in vascular permeability (Kerfoot, Long et al. 2004).  However, it is known 
that activated CD4 T cells can access the CNS in the absence of pertusss toxin in 
non-immunised individuals, as exemplified in humans where T cells can be detected 
in the CSF of healthy individuals, albeit in low frequencies (Svenningsson, Hansson 
et al. 1993) and pertussis toxin is infrequently injected into the recipient mice when 
disease is induced by transfer of auto-reactive cells.  In this study, a basal level of 
IL-17A and IFN-γ-expressing CD4 T cells was observed in the spinal cords of mice 
immunised with MOG CFA alone (Figure 3.15A), suggesting that activated cells     Chapter 3 
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can  access  the  spinal  cord  to  some  extent  in  the  absence  of  pertussis  toxin.   In 
addition, an effect of pertussis toxin on the blood brain barrier can occur within 5 
hours  of  injection  (Kerfoot,  Long  et  al.  2004)  and  so  one  would  expect  that 
administration  of  pertussis  toxin  at  later  time  points  in  EAE  development  could 
induce EAE as efficiently.  However the most optimal time point at which pertussis 
toxin  should  be  administered  for  the  development  of  disease  was  day  0  and  2 
suggesting that pertussis toxin influences EAE development in other ways. 
   
Pertussis toxin is commonly used as an agent to inhibit signalling through G-protein 
receptors  such  as  chemokine  receptors.  In  these  experiments,  pertussis  toxin 
administration was associated with a non-selective reduction in the number of CD4, 
CD8 and γδ T cells, as well as B cells in the lymph nodes after immunisation with 
MOG CFA (Figure 3.8) which could be due to the effect of pertussis toxin on G-
protein associated-chemokine receptors such as CCR7 and sphingosine-1-phosphate 
which  are  responsible  for  cell  movement  into  and  out  of  the  lymph  nodes 
(Matloubian, Lo et al. 2004; Forster, Davalos-Misslitz et al. 2008).  In addition, 
pertussis toxin reduced signalling through CCR7, measured by migration of CD4 T 
cells to CCL21, for at least 10 days after administration (Figure 3.18B).   It seems 
paradoxical that inhibition of G-protein receptor signalling by pertussis toxin would 
allow  development  of  disease  given  that  chemokine  signalling  is  important  for 
leukocyte trafficking in both steady state and inflammatory environments (Rebenko-
Moll,  Liu  et  al.  2006)  and  is  also  important  in  the  movement  of  activated, 
encephalitogenic T cells into the central nervous system at the blood brain barrier 
(Ransohoff, Kivisakk et al. 2003).   One report showed that encephalitogenic T cells 
were treated with pertussis toxin in vitro before being injected into mice in order to 
inhibit  G-protein  receptor  signalling  and  these  mice  exhibited  delayed  onset  of 
disease  (Alt,  Laschinger  et  al.  2002).    In  addition,  various  chemokine  receptor 
deficient mice are resistant to EAE, such as the CCR7-deficient mice (Kuwabara, 
Ishikawa et al. 2009), CCR2 deficient mice (Fife, Huffnagle et al. 2000) and in some 
reports CCR6-deficient mice (Liston, Kohler et al. 2009; Villares, Cadenas et al. 
2009). This suggests that perhaps the dose and timing of pertussis injection given in     Chapter 3 
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EAE are not enough to completely inhibit the aspects of migration that are important 
in EAE.   Pertussis toxin is an AB exotoxin.  The A subunit possesses the ADP-
ribosylase activity capable of inactivating G-protein coupled receptors and the B 
subunit is responsible for binding to cell surface receptors and facilitating the entry 
of the A subunit into the cell.  In order to assess whether the G protein inhibitory 
activity  of  pertussis  toxin  is  required  for  EAE  induction,  the  encephalitogenic 
potential of a toxin that lacked the A subunit or that had been mutated to lack the 
ADP-ribosylase activity could be investigated.   
 
It  was  observed  that  pertussis  toxin  injected  in  combination  with  MOG  CFA 
immunisation  enhanced  peripheral  MOG-specific  CD4  T  cell  IL-17A  and  IFN-γ 
cytokine responses in vitro, when compared to the response of CD4 T cells from 
mice immunised with MOG CFA alone. More specifically, stimulation of lymph 
node cells from pertussis toxin-treated and untreated mice with PdBu and ionomycin 
for 24 hours did not reveal any substantial differences in the amount of IL-17A and 
IFN-γ protein detected in the supernatant (Figure 3.21B) and stimulation for 4 hours 
with these stimuli did not reveal any difference in the percentage of IL-17A and 
IFN-γ -expressing cells within the CD4 T cell population (Figure 3.9B). However, 
stimulation of lymph node cells from pertussis toxin-treated and untreated mice with 
MOG  peptide  for  24  hours  resulted  in  IL-17A  and  IFN-γ  detection  in  the 
supernatants of cell cultures from pertussis toxin-treated mice only (Figure 3.21A), 
and a substantial increase in the percentage of IL-17A and IFN-γ-expressing cells 
within the CD4 T cell population in the pertussis toxin-treated mice when detected 
by  flow  cytometry  (Figure  3.22).    This  observation  could  be  due  to  a  greater 
proportion of MOG-specific T cells producing IL-17A and IFN-γ in the lymph nodes 
of pertussis toxin-treated mice or it could be that the there are a similar proportion of 
MOG-specific cells in the two groups of mice but that MOG-specific T cells from 
pertussis toxin un-treated mice do not produce IL-17A and IFN-γ in response to 
MOG peptide.  Furthermore, PdBu and ionomycin are mitogenic stimuli and can 
activate  protein  kinase  C  and  up-regulate  intra-cellular  calcium  respectively, 
however MOG peptide is processed and presented on MHC class II molecules and     Chapter 3 
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can be presented to T cells for their activation in a conventional manner.  It could be 
envisaged  that  stimulation  by  PdBu  and  ionomycin  overrides  the  effects  of 
conventional T cell activation, triggering the production of cytokines that the cell is 
able  to  make,  however  MOG  peptide  stimulation  specifically  captures  cytokine 
triggered by re-stimulation with MOG peptide, a response which may be different. 
Detection of MOG-specific cells using a MOG tetramer would help to investigate 
this issue further. Nevertheless, this enhanced responsiveness to MOG is an effect 
which could be directly attributed to pathogenesis in EAE, as the ability of CD4 T 
cells to respond to MOG peptide in the CNS is a trigger for further inflammation to 
promote recruitment and activation of other effector cells such as macrophages and 
neutrophils to the target organ (Sobel and Kuchroo 1992). 
 
In  this  study  disease  development  was  associated  with  an  increase  in  the  total 
number of CD4 and γδ T cells recovered from the spinal cord starting at day 10, 
before the onset of disease (Figure 3.13B) which then increased further at the peak 
of disease (Figure 3.16B), and was not detected in groups of mice that did not 
develop  disease  at  the  same  time  points.  It  must  be  noted  that  the  anatomical 
organization  of  the  CNS  is  highly  complex  and  contains  numerous  fluid 
compartments,  membranes  and  vascular  beds  (Ransohoff,  Kivisakk  et  al.  2003).  
The  mechanisms  and  consequences  of  leukocyte  entry  into  these  different 
compartments will differ and have not been assessed in the context of this thesis.  
Furthermore, in EAE, although infiltration of mononuclear cells into the spinal cord 
parenchyma is a frequent observation, it has been suggested that T cells first enter 
the CNS via the choroid plexus in the brain (Reboldi, Coisne et al. 2009).  This 
provides the first wave of cells into the CNS, which can subsequently be activated 
by local antigen presenting cells present in the subarachnoid space (Kivisakk, Healy 
et al. 2009).   
 
Disease development was also associated with the persistence of neutrophils and 
monocytes in the spinal cord (Figure 3.16A).  These effector cells could be detected 
in  the  spinal  cord  following  immunisation  with  MOG  CFA  in  the  presence  and     Chapter 3 
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absence of pertussis toxin treatment before the onset of disease (Figure 3.13A) but 
only persisted in the mice that developed disease. Although a PBS perfusion was 
carried out prior to removal of the spinal cord in order to reduce the possibility of 
contaminating  blood  cells  in  the  spinal  cord  preparation,  this  possibility  can 
obviously not be completely excluded.  However, other studies have also reported 
the  presence  of  neutrophils  or  polymorphonuclear  cells  in  the  CNS  infiltrate  of 
animals with EAE using both flow cytometry and immunohistochemistry methods 
(Allen, Baker et al. 1993; Maatta, Sjoholm et al. 1998; Bettelli, Sullivan et al. 2004; 
Wu,  Cao  et  al.  2010)  which  supports  these  findings.  Monocytes  encompass  a 
heterogeneous  cell  population  based  upon  differential  expression  of  surface 
molecules.  However, they are typically blood-derived cells that migrate into tissue 
and differentiate into antigen presenting macrophages. Mice that lacked CCR2 were 
relatively resistant to the development of EAE, even in the presence of wild type T 
cells and this has been attributed to a lack of monocytes in the CNS of these mice 
suggesting a role for CCR2 in the transport of monocytes across the BBB and in the 
development of disease (Fife, Huffnagle et al. 2000).  In EAE, monocytic cells can 
migrate  into  the  CNS  and  differentiate  into  antigen  presenting  cells  for  the 
reactivation of myelin-reactive CD4 T cells (Deshpande, King et al. 2007; Miller, 
McMahon et al. 2007).   Activated macrophages can secrete numerous cytokines 
including  IL-1  and  TNF-α,  nitrous  oxide,  free  oxygen  radicals  and  protelolytic 
enzymes that can contribute to tissue damage (Scheurich, Thoma et al. 1987; Segal 
2005).  However, monocytic and macrophage populations have also been described 
to have suppressive implications in EAE (King, Dickendesher et al. 2009).  In the 
experiments in this thesis, monocytes were defined based on detection of a surface 
epitope by 7/4 antibody.   Reduction in the number of these cells could mean that the 
cells  had  down-regulated  this  epitope,  indeed  monocytes  have  been  reported  to 
reduce  expression  of  the  epitope  recognised  by  7/4  as  they  differentiate  into 
macrophages (Henderson, Hobbs et al. 2003).  
 
Pertussis  toxin  has  been  described  to  have  mitogenic  effects  on  T  cells  in  vitro 
(Kong and Morse 1977) so it could be conceived that treatment with pertussis toxin     Chapter 3 
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promotes  the  outgrowth  of  auto-reactive  T  cells.  However,  it  was  observed  that 
immunisation with MOG CFA in the absence of pertussis toxin led to the induction 
of  activated  IL-17A  and  IFN-γ-expressing  cells  that  were  induced  in  the  lymph 
nodes  and  were  detectable  in  the  blood  circulation  in  similar  numbers  as  in  the 
presence of pertussis toxin (Figure 3.11A) suggesting that pertussis toxin was not 
merely enhancing activated cell proliferation.  In addition, it has been shown in other 
studies  that  a  Vβ8-specific  superantigen  (SEB),  which  specifically  targets  the 
outgrowth of T cells expressing the TCR Vβ8 chain which is expressed in some 
encephalitogenic CNS T cell clones, and another mitogenic stimulus, Con A cannot 
substitute pertussis toxin in the induction of EAE (Kamradt, Soloway et al. 1991) 
 
As previously mentioned, pertussis is not usually required to be administered in 
adoptive  transfer  models  of  EAE  suggesting  that  the  effect  of  pertussis  toxin, 
whether indirect or direct is on the T cell itself. Furthermore, the effect of pertussis 
toxin is overridden by stimulation of cells in vitro with peptide and an antibody 
cocktail before adoptive transfer, suggesting that the effects of pertussis toxin in vivo 
could be due to induction of an environment which can alter the encephalitogenic 
potential of the T cell. One study showed that IL-1 -deficient mice are resistant to 
EAE and these mice also have reduced MOG-specific IL-17A and IFN-γ responses 
in the peripheral lymph nodes after immunisation with MOG CFA (Matsuki, Nakae 
et  al.  2006).  In  this  same  study, IL-1R  antagonist-deficient  mice,  which  lack  an 
endogenous  antagonist  for  IL-1  signalling,  develop  MOG-induced  EAE  in  the 
absence of pertussis toxin, unlike wild type mice.  This suggests that pertussis toxin 
may act through a mechanism dependent upon IL-1 signalling to induce enhanced 
MOG-specific IL-17A and IFN-γ responses in EAE.   IL-1 is produced by a number 
of cell types including APCs and can induce the expression of CD40 ligand and 
OX40 expression on T cells (Nakae, Asano et al. 2001), molecules which strengthen 
the interaction between T cells and APCs which can lead to more efficient T cell 
priming.   Pertussis toxin has been  shown to enhance antigen-specific responses 
previously (Sewell, Munoz et al. 1983; Sewell, de Moerloose et al. 1986; Mu and 
Sewell  1993;  Shive,  Hofstetter  et  al.  2000)  and  the  toxin  has  been  shown  to     Chapter 3 
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upregulate  cytokine  production  by  a  method  dependent  upon  its  effects  on  G-
proteins (He, Gurunathan et al. 2000).  Pertussis toxin has been reported to act on 
macrophages and B cells, by upregulating B7.1 and B7.2 molecules, and on T cells 
by  upregulating  CD28,  a  process  which  could  be  envisaged  to  enhance  T  cell 
activation (Ryan, McCarthy et al. 1998).  In addition, pertussis toxin has been shown 
to trigger the TCR directly, activating a number of signalling molecules downstream 
of  the  receptor  (Schneider,  Weiss  et  al.  2007;  Schneider,  Weiss  et  al.  2009),  a 
mechanism which again may lead to enhanced T cell activation.   
 
Pertussis toxin is a microbial agent capable of breaking immunological tolerance to 
MOG  peptide.  A  number  of  studies  have  clearly  shown  that  administration  of 
pertussis toxin can affect vascular permeability at the blood brain barrier, facilitating 
the  entry  of  radioactive  isotopes  and  serum  proteins  into  the  CNS  that  would 
normally be excluded by tight junctions, and this could also be attributed to EAE 
pathogenesis by facilitating entry of auto-reactive T cells into the CNS.  The results 
in this study, however show that the effects of pertussis toxin are most potent for 
EAE development if given at the same time as the MOG CFA immunisation, in the 
priming stage of disease, suggesting that its effects may extend beyond enhancing 
vascular  permeability,  which  can  occur  within  a  few  hours  of  pertussis  toxin 
injection  (Kerfoot,  Long  et  al.  2004).    Enhancing  antigen-specific  cytokine 
production may be one of the ways it does this. The priming of MOG peptide-
specific  CD4  T  cells  in  the  periphery  is  partially  dependent  upon  the  specific 
interaction between MOG peptide presented by MHC class II and the MOG-specific 
TCR, as well as other factors such as costimulatory molecules and cytokines.  This 
interaction may vary between strains of animal, dependent partly upon the repertoire 
of  MOG-specific  CD4  T  cells  selected  in  the  thymus,  which  might  explain 
differences in the requirement of pertussis toxin for disease development in different 
strains of animal. In one study it was suggested that that the effect of pertussis toxin 
on permeability at the blood brain barrier could be a consequence of the interaction 
between T cells and endothelial cells of the blood brain barrier, as blocking this 
interaction, blocked the increase in permeability of the blood brain barrier to FITC-    Chapter 3 
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dextran, observed with pertussis toxin administration (Kerfoot, Long et al. 2004).  
Thus, it could be that an effect of pertussis toxin on the encephalitogenic T cell in 
the priming stage of disease can enhance interactions between the T cell and the 
endothelial cells at the blood brain barrier, which consequently promotes vascular 
permeability.  That T cells can induce permeability at the blood brain barrier has 
also been suggested by a study showing that T cells enter the CNS in two waves in 
EAE:  the first wave through the choroid plexus in the brain which triggers the 
subsequent recruitment of another wave of effector T cells across the blood brain 
barrier (Reboldi, Coisne et al. 2009). 
 
Further investigations are required to understand the mechanisms by which pertussis 
toxin enhances responsiveness to antigen and can break immunological tolerance. In 
order to specifically address how pertussis toxin is influencing the expression of 
effector cytokines, mice which report cytokine expression could be utilised. Specific 
effects  of  pertussis  toxin  on  T  cells  and  APCs  in  the  context  of  EAE  could  be 
assessed and the receptors through which pertussis toxin is exerting its effects should 
be considered.      Chapter 4 
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Chapter 4: Generation and characterization of an IL-17A reporter 
mouse 
4.1 Introduction 
 
Effector T cell subsets are typically identified by the profile of cytokine genes they 
express.    Th1  cells  are  identified  by  the  expression  of  IFN-γ,  Th2  cells  by  the 
expression of IL-4 and Th17 cells by the expression of IL-17A and IL-17F.  The 
phenotype of individual cells can be determined by the expression of extra-cellular 
surface proteins and intra-cellular cytokine protein using flow cytometry methods.  
Indeed, this is currently the predominant method for identification of effector T cell 
subsets.  The  process  of  intra-cellular  cytokine  staining  uses  a  fixation  and 
permeablisation  step,  which  results  in  death  of  the  cells  and  therefore  does  not 
permit their use in further experiments.  In addition, an in vitro stimulation which is 
usually given by a mitogenic stimulus such as PdBu and ionomycin is usually also 
required in order to detect intra-cellular cytokine protein, a process which bypasses 
physiological signaling mechanisms through which the cell would be responding in 
its  natural  environment  and  is  therefore  not  necessarily  reflective  of  the  in  vivo 
situation.  Expression  of  cytokines  can  also  be  detected  in  cell  populations  by 
quantitative PCR, which measures mRNA levels, or by stimulating cell populations 
and  assessing  secreted  protein  in  the  supernatant.    This  however,  does  not  give 
information about gene expression in individual cells.  
 
Reporter mice have been used to circumvent these problems for IL-4, IFN-γ and IL-
10 genes (Mohrs, Shinkai et al. 2001; Stetson, Mohrs et al. 2003; Kamanaka, Kim et 
al. 2006), all of which inserted a fluorescent reporter gene immediately before the 
polyadenylation site of the target cytokine gene and made use of an IRES (internal 
ribosomal entry site) element to allow translation of the reporter gene.  The aim of 
this chapter was to generate an IL-17A reporter mouse to track the induction and the 
fate of cells that activate the IL-17A promoter in the periphery. As we wanted to     Chapter 4 
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determine the fate of these cells, we chose to employ the Cre recombinase/Loxp 
system,  rather  than  directly  inserting  the  reporter  gene  as  in  the  reporter  mice 
described above, in order to irreversibly report transcriptional activation of IL-17A.  
Expression of the reporter gene would allow a pure, live population of these cells to 
be sorted for use in other experiments.   
 
We aimed to generate this reporter mouse by directly targeting the IL-17A gene 
using  homologous  recombination  in  Embryonic  Stem  (ES)  cells  (Thomas  and 
Capecchi  1987).  Cre  recombinase  from  the  bacteriophage  P1  is  a  38kDa 
recombinase  (Sternberg  and  Hamilton  1981)  which  promotes  intra  and  inter-
molecular recombination at specific 34bp sites, called LoxP sites. Recombination of 
two LoxP sites in the same orientation leads to excision of the intervening DNA, 
leaving a single LoxP site behind (Sauer and Henderson 1988).  Insertion of the Cre 
recombinase gene immediately downstream of the IL-17A promoter would lead to 
expression  of  Cre  recombinase  in  cells  that  had  activated  IL-17A  transcription.  
Crossing the IL-17A_Cre heterozygous mice with a ROSA26_EYPF strain, in which 
expression of Enhanced Yellow Fluorescence Protein (EYFP) in the constitutively 
expressed ROSA26 locus is usually prevented by the presence of a LoxP-flanked-
transcriptional stop sequence, would lead to Cre recombinase-mediated excision of 
the transcriptional stop sequence and expression of EYFP.   
 
We chose to insert the Cre recombinase gene so that as little of the IL-17A gene was 
disrupted as possible. Although there would be no expression of IL-17A from the 
targeted allele, we did not want to remove any potential regulatory elements that 
may disrupt expression of IL-17A from the other allele or of any other nearby genes 
such as IL-17F which is 45kb downstream of IL-17A and has a similar expression 
pattern.  The generation of the IL-17A reporter would also allow us to generate an 
IL-17A knockout strain.  
     Chapter 4 
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4.2 Generation of an IL-17A_Cre construct 
 
In order to generate the IL-17A_Cre mice, where Cre Recombinase is expressed 
under the control of the IL-17A promoter, a targeting vector was first constructed.  
This  vector  would  briefly  consist  of  a  modified  Cre  Recombinase  (iCre)  gene 
inserted immediately downstream of the transcriptional start (the first ATG codon) 
of the IL-17A gene and would be followed by a LoxP-flanked neomycin resistance 
gene (neo) that would enable ES cells that had taken up the targeting construct to be 
positively selected.   
 
For the generation of this targeting vector, an iCrefloxneo knock-in cassette was first 
assembled by ligating a LoxP-flanked neomycin resistance (neo) gene downstream 
of a modified iCre exon with a Simian virus 40 (SV40) intron and SV40 polyA tail 
to enhance mRNA stability (Figure 4.1A). This generated the iCrefloxneo cassette, 
which was verified by sequencing and also in three analytical digests as shown in 
Figure 4.1B.  The neo gene would be constitutively expressed by the presence of the 
upstream  PKG  (phosphoglycerate  kinase)  promoter.  The  PKG  promoter  is  a 
promoter of the yeast gene encoding phosphoglycerate kinase and is widely used 
when  a  high  level  of  constituitive  gene  expression  is  required.  Neo  encodes  for 
neomycin  phosphotransferase,  which  inhibits  the  effects  of  the  aminoglycoside 
antibiotic,  G418  and  would  therefore  allow  positive  selection  of  ES  cell  clones 
containing  the  construct.  Cre  Recombinase  is  a  bacteriophage  protein,  normally 
expressed in bacteria.  The iCre gene used for this cloning had been previously 
modified for mammalian codon usage, so that it would be efficiently translated in 
mouse cells (Shimshek, Kim et al. 2002). 
 
The targeting vector was generated using Bacterial Artificial Chromosome (BAC) 
DNA from the 129SvEV/AB2.2 mouse strain made at the Wellcome Trust Sanger 
institute, as a source of genomic DNA.  The 5’ long arm of homology was generated 
by PCR amplification of a 4.5kb fragment from the IL-17A BAC clone.  Restriction 
sites were incorporated into the primers used for the PCR reaction, and these were     Chapter 4 
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subsequently used for cloning the PCR fragment into the iCrefloxNeo cassette. The 
ligation of the 5’ long arm of homology in this way resulted in generation of a five 
amino acid-linker peptide between the first ATG codon of IL-17A and the first ATG 
codon of iCre (Figure 4.2A).   An N-terminal peptide addition to iCre has been used 
successfully in other systems such as in a RAG1_Cre mouse (McCormack, Forster 
et al. 2003) and was not expected to have any effects on the functionality of the 
enzyme.  The 5’ amino acid linker sequence also encompassed a kozak consensus 
sequence (Kozak 1991) so that translation of Cre recombinase would be enhanced.   
  
For the generation of the 3’ short arm of homology, a 5.2kb BamHI fragment of 
DNA was first isolated from the BAC clone, which encompassed the 3 exons of the 
IL-17A gene and was cloned into a pBluescript vector (not shown in figure). From 
this sub-cloned fragment a 2.8kb 3’ short arm of homology, downstream of exon 1 
and encompassing exon 2 and part of exon 3 was ligated into a pBluescript vector. A 
double point mutation was introduced into exon 2 by PCR (AT→CA) to remove a 
potential start codon that may have lead to expression of a truncated form of IL-17A. 
The  3’  short  arm  of  homology  was  cloned  into  the  5’  long  arm  of 
homology_iCrefloxNeo  vector  in  order  to  complete  the  targeting  vector  (Figure 
4.2).  This  vector  was  confirmed  by  sequencing  and  by  six  analytical  digests  as 
shown in Figure 4.2B. 
 
It was observed that in some plasmid preparations of the iCrefloxNeo cassette or 
containing the iCrefloxNeo cassette described above (Figure 4.1), an unexpected 
digestion pattern appeared. An example of this was in a HindIII digest of the final 
construct.  This digest was predicted to give a 7.6kb band encompassing the plasmid 
backbone  and  5’  long  arm  of  homology,  a  3.9kb  band  encompassing  the 
iCrefloxNeo cassette and a 1.8kb band encompassing part of the 3’ short arm of 
homology. In some large scale plasmid DNA preps the 3.9kb band disappeared or 
became fainter and there was appearance of a 1.7kb band.  These digestion patterns 
suggested  removal  of  the  neo  gene  (Figure  4.3),  although  sequencing  both  the 
iCrefloxneo  (Figure  4.1)  and  the  final  construct  (Figure  4.2)  plasmid  preps     Chapter 4 
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indicated that the neo gene was still present. However, this could be due to the 
presence  of  plasmids  that  had  not  lost  the  neo  fragment  in  the  DNA  used  for 
sequencing. We hypothesised that the LoxP sites either side of the neo gene could be 
mediating recombination of the gene and therefore used competent cells lacking the 
recombination enzymes RecB and RecJ (SURE cells) and competent cells lacking 
RecA (INV alpha f’ cells) for transformation of the plasmid.  This reduced, but did 
not prevent the extent of the recombination seen in the analytical digests. Other 
possibilities for the loss of the neo gene included the expression of Cre recombinase 
from the plasmid or another endogenous prokaryote recombinase which may have 
been able to facilitate excision of the neo gene via the flanking LoxP sites.  Another 
possibility was the presence and close proximity of the Cre Recombinase and neo 
gene polyA tails, which may have lead to removal of the neo gene.  Nevertheless, 
enough targeting vector containing the neo gene was obtained by repeated, small 
scale cultures and this was used for targeting the IL-17A locus in ES cells.  
 
4.3 Targeting the IL-17A locus in ES cells and generation of IL-17A_Cre
EYFP 
reporter mice 
 
The final targeting vector was linearised and electroporated into 129Sv Embryonic 
Stem (ES) cells.  Neo-containing clones were positively selected by growth in G418 
and  correct  incorporation  of  the  targeting  construct  into  the  IL-17A  locus  by 
homologous recombination was verified by Southern blot.   
 
For southern blot analysis, 5’ and 3’ probes were generated by PCR amplification of 
the  IL-17A  BAC  DNA.    Primers  for  these  PCR  reactions  were  designed  with 
incorporated restriction sites to allow cloning of the probes into commercial vectors.  
A 537bp external 5’ probe hybridised to a 5.8kb band on an EcoRV digest of 129/Sv 
genomic DNA (Figure 4.4A). After incorporation of the targeting construct into the 
IL-17A locus by homologous recombination this probe was expected to hybridise to 
a 9kb band (Figure 4.4A).   This would give a clear distinction of the wild type and     Chapter 4 
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targeted bands on a Southern blot.  Three 3’ external probes were also tested for 
hybridisation to an XbaI digest of 129Sv and C57BL/6 genomic DNA, however 
none of these probes clearly hybridised to a band of the correct size.  A 3’ probe was 
predicted to bind to a 10.3kb band on an XbaI digest of wild type DNA and a 6.8kb 
band on targeted DNA (Figure 4.4B).  
 
The IL-17A_Cre construct as generated above did not result in the generation of any 
ES  cells  clones  which  had  incorporated  the  targeting  construct  by  homologous 
recombination.  This was verified by Southern blot analysis using the 5’ external 
probe to analyse a total of 1200 clones in two separate targeting experiments. In 
order not to compromise my chances to finish the PhD in a timely manner I stopped 
working on this project at this stage and the design of the targeting vector was re-
assessed  by  someone  else.  As  the  targeting  vector  was  highly  prone  to 
recombination as described in the previous section it was subsequently modified by 
insertion of a neo gene, flanked by frt sites rather that LoxP sites.   
 
Targeting of this modified construct into ES cells resulted in the generation of two 
positive clones which were subsequently injected into 3.5 day old blastocysts from 
C57BL/6 mice.  These blastocysts were injected into the uteri of foster mothers and 
were allowed to develop. This process gave rise to chimeric animals that would have 
been derived from both the donor stem cells and the host blastocyst. In mice where 
the targeted ES cells were in the germline, breeding with C57BL/6 wild type animals 
would give mice that were heterozygous for the IL-17A_Cre allele. These mice were 
bred with ROSA26 _EYFP mice to derive F1 generation reporter mice.  
 
4.4 Assessment of reporter functionality  
 
EYFP and IL-17A expression were analysed in the F1 generation IL-17A_Cre
EYFP 
reporter mice.  In an ideal situation all EYFP expressing cells would be positive for 
IL-17A expression detected by intra-cellular staining.      Chapter 4 
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EYFP expression and intra-cellular IL-17A expression were first analysed in a non-
immunised mouse.  The cells were stimulated with PdBu and ionomycin for 4 hours 
and analysed for IL-17A and EYFP expression.  EYFP expression was also analysed 
in non-stimulated cells to check that ex vivo stimulation of the cells had not altered 
EYFP expression (data not shown).  Cells were gated on counted cells, singlets and 
lymphocytes as shown previously in chapter 3. 
 
Figure 4.5A shows expression of IL-17A measured by intra-cellular staining versus 
EYFP  expression  in  CD4  T  cells  and  γδ  T  cells  in  the  lymph  nodes  of  a  non-
immunised  mouse.      Littermate  controls  have  the  ROSA26_EYFP  locus  but  no 
targeted IL-17A locus. The vast majority of EYFP expressing cells expressed IL-
17A detected by intra-cellular staining, indicating that EYFP faithfully reported IL-
17A expression in non-immunised mice. However, of the IL-17A-expressing CD4 T 
cells  within  the  lymph  nodes  measured  by  intra-cellular  cytokine  staining, 
approximately 80% of them were EYFP
- and of the γδ T cells, approximately 50% 
were EYFP
-.  
 
Given the fact that in chapter 3, using a 4 hour stimulation with PdBu and ionomycin 
and  intra-cellular  cytokine  staining,  there  was  no  difference  observed  in  IL-17A 
expression between mice immunised with MOG CFA alone and those immunised 
with MOG CFA and pertussis toxin and yet after 24 hour stimulation in the presence 
of MOG peptide, the pertussis toxin-treated mice had a higher percentage of IL-
17A-producers, we wanted to know how EYFP expression correlated with these 
results.  In order to assess this, F1 generation IL-17A_Cre
EYFP mice and littermate 
controls were immunised with MOG CFA into the base of the tail in the presence 
and absence of pertussis toxin.  Mice were sacrificed 7 days later and the lymph 
nodes were analysed for IL-17A expression by intra-cellular cytokine staining as 
well as EYFP expression. 
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The percentage and numbers of CD4 and γδ T cells expressing IL-17A and EYFP 
are shown in Figure 4.5B.  In the initial experiments we saw an increase in the 
percentage  of  CD4  and  γδ  T  cells  expressing  IL-17A  on  day  7  following 
immunisation in the draining lymph nodes.  Interestingly, although the number of 
CD4 T cells expressing IL-17A as well as the percentage of IL-17A-expressing cells 
within the CD4 T cell population expanded at day 7 as observed in the original 
kinetics experiments, this population was predominantly EYFP
-.  In contrast, like in 
the original kinetics experiments the number of γδ T cells expressing IL-17A as well 
as  the  percentage  of  IL-17A-expressing  cells  within  the  γδ  T  cell  population 
expanded  on  day  7  after  immunisation,  however  this  population  of  IL-17A-
expressing cells was predominantly EYFP
+.  There were no obvious differences in 
the EYFP expression in the lymph nodes of mice treated with and without pertussis 
toxin, indicating pertussis toxin does not modulate transcriptional activation of IL-
17A. 
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Figure 4.1 Cloning of an iCrefloxneo knock-in cassette. 
 
LoxP-flanked  neomycin  resistance  gene  (neo)  containing  a  PKG  promoter  and 
polyA  tail  (pA)  was  cloned  immediately  down-stream  of  a  modified  Cre 
Recombinase (iCre) exon with a Simian virus 40 (SV40) intron and SV40 polyA tail 
in a commercial pBluescript vector using XbaI and BamHI restriction sites.  LoxP 
sites are indicated by open triangles (A).  The product was verified by a three digests 
shown in (B).  Digest 1 was a HindIII and BamHI digest, predicted to give bands at 
4.9kb and 1.9kb. Digest 2 was a PstI digest, predicted to give bands at 6.8kb and 
0.2kb. Digest 3 was a PvuII digest, predicted to give bands at 2.5kb, 2kb, 1.4kb and 
0.8kb. M=marker. In ascending order the bands on the marker = 1kb, 1.5kb, 2kb, 
3kb, 4kb, 5kb, 6kb, 8kb, 10kb.  
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Figure 4.2 Generation of an IL-17A Cre targeting construct. 
 
The  5’  long  arm  of  homology  was  generated  by  PCR  amplification  of  a  4.5kb 
fragment  from  an  IL-17A  BAC  clone.    SalI  and  HindIII  restriction  sites  were 
incorporated  into  the  primers  used  for  the  PCR  reaction,  and  these  were 
subsequently used for cloning the PCR fragment into the iCrefloxNeo cassette. The 
ligation of the 5’ long arm of homology in this way resulted in the generation of a 
five amino acid-linker peptide between the first ATG codon of IL-17A and the first 
ATG codon of iCre.  A 2.8kb 3’ short arm of homology, downstream of exon 1 and 
encompassing exon 2 and part of exon 3 was ligated downstream of neo poly A into 
the 5’ long arm of homology_iCrefloxNeo vector using SacII and blunted ClaI and 
NotI  restriction  sites.  A  double  point  mutation  (AT  was  mutated  to  CA)  was 
introduced into exon 2 by PCR to remove a potential start codon that may have lead 
to  expression  of  a  truncated  form  of  IL-17A.  LoxP  sites  are  indicated  by  open 
triangles (A). The final targeting vector was confirmed by six analytical digests as 
shown in (B). Digest 1= SalI digest, predicted to give a 13.9kb band. Digest 2= 
SacII, predicted to give a 13.9kb band.  Digest 3= BamHI, predicted to give a 10kb 
band and 3.4kb band. Digest 4 = HindIII, predicted to give a 7.6kb band, 3.9kb band, 
1.8kb band, 0.3kb band and a 0.09kb band. Digest 5 = EcoRV, predicted to give a 
11kb band, a 2.2kb band and a 0.6kb band. Digest 6 = EcoRI, predicted to give a 
9.3kb  band  and  4.7kb  band.  UD=  undigested.  M=  molecular  weight  marker.  In 
ascending order the bands on the marker = 0.5kb, 1kb, 1.5kb, 2kb, 3kb, 4kb, 5kb, 
6kb, 8kb, 10kb.  
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Figure 4.3 The iCrefloxNeo targeting construct was prone to recombination 
 
A HindIII digest of the targeting construct was expected to yield a 7.6kb fragment, a 
3.9kb fragment and a 1.8kb fragment as illustrated in digest 1.  In some large-scale 
preparations the 3.9kb band was reduced and an additional 1.7kb band appeared 
which corresponded to the sizes of fragments expected after removal of the LoxP-
flanked neo gene as illustrated in digest 2. Red rectangle indicates iCre exon, blue 
rectangle indicates neo exon and open triangles indicate LoxP sites.  M = molecular 
weight marker.     Chapter 4 
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Figure 4.4 Southern Blot targeting strategy to detect integration of the targeting 
construct into the IL-17A locus in ES cells. 
 
A 5’ probe was generated by PCR amplification, which hybridised to a 5.8kb EcoRV 
fragment of wild type DNA in a Southern blot, outside the region of the targeting 
construct.    Upon  integration  of  the  targeting  construct  into  the  IL-17A  locus  an 
additional EcoRV site would be introduced into the IL-17A locus and the size of the 
fragment recognised by the 5’ probe would be increased to 9kb (A).  3’ probes were 
generated that were predicted to hybridise to a 10.3kb XbaI fragment outside the 
region of the targeting construct. Upon integration of the targeting construct into the 
IL-17A locus an additional XbaI site would be introduced into the locus and the size 
of the fragment recognised by the 3’ probe would be reduced to 6.8kb (B).  None of 
the 3’ probes tested, hybridised to genomic wild type DNA in a Southern blot. 
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Figure 4.5 Assessing the functionality of the reporter system 
 
Lymph nodes were harvested from non-immunised IL-17A_Cre
EFYP F1 generation 
reporter mice and littermate controls containing the ROSA26_EYFP locus but no 
targeted  IL-17A  locus  and  were  assessed  for  EYFP  and  IL-17A  expression 
following  a  4  hour  stimulation  with  PdBu,  ionomycin  and  brefeldin  A.   
Representative flow cytometry plots are shown for staining in CD4 and γδ T cells 
(A). A mixture of male and female IL-17A_Cre
EFYP F1 generation reporter mice and 
littermate controls mice were immunised with MOG CFA into the base of the tail 
and injected with and without pertussis toxin at the same time and also two days 
later.  Lymph nodes were harvested 7 days following MOG CFA immunisation and 
analysed  for  IL-17A  and  EYFP  expression  following  a  4  hour  stimulation  with 
PdBu, ionomycin and brefeldin A.  The number of CD4 and γδ T cells expressing 
IL-17A and EYFP as well as the percentage of IL-17A and EYFP-expressing cells 
within the CD4 and γδ T cell population are shown (B) The value shown on the bar 
chart is the mean and standard deviation of the results from two individual mice 
from each group 
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4.5 Discussion 
 
The Cre_LoxP system was employed in order to allow the identification of cells 
which  had  activated  the  IL-17A  promoter  without  the  need  for  intra-cellular 
cytokine staining.  Targeting of ES cells with an IL-17A_CrefloxNeo construct did 
not  result  in  the  generation  of  any  ES  clones  which  had  incorporated  the  gene 
mutation by homologous recombination.  In addition, this targeting vector displayed 
some  instability,  possibly  due  to  the  LoxP  sites  surrounding  the  neo  gene.  
Subsequent modification of this original vector by incorporation of frt sites flanking 
the neo gene lead to the successful generation of ES clones which had incorporated 
the  targeting  construct  into  the  correct  location  in  the  genome  and  this  was 
confirmed using 3’ and 5’ external probes in a Southern blot.  These clones were 
injected into developing blastocysts which were implanted into foster mothers to 
generate chimeric mice. Chimeras were then bred with C57BL/6 wild type mice to 
determine  germ  line  transmission  of  the  targeted  ES  cells.  Mice  that  were 
heterozygous for the targeted IL-17A gene were bred with ROSA26_EYFP mice to 
generate IL-17A_Cre
EYFP mice.  In these mice expression of IL-17A transcription 
should drive the expression of Cre recombinase which should excise a LoxP-flanked 
transcriptional  stop  sequence  upstream  of  EYFP  in  the  ubiquitously  expressed 
ROSA26  locus,  leading  to  irreversible  expression  of  EYFP  in  all  cells  that  had 
activated IL-17A. 
 
A  litter  of  IL-17A_Cre
EYFP  F1  generation
  mice  was  used  to  investigate  the 
functionality  of  the  reporter  system  in  steady  state  conditions  and  also  after 
immunisation.    These  mice  were  a  mixture  of  C57BL/6  and  129  strains  and 
contained  the  whole  targeting  construct  including  the  frt-flanked  neo  gene.    For 
future  experiments  these  mice  will  eventually  be  backcrossed  onto  the  C57BL/6 
background, which is the standard strain used for many experiments. It will also be 
important to remove the frt-flanked neo gene as there have been reports that the 
presence of positive selection markers can lead to a number of unanticipated effects.  
For example, the presence of the neo gene, often with its own promoter, can alter the     Chapter 4 
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expression of neighbouring loci (Olson, Arnold et al. 1996; Pham, MacIvor et al. 
1996).    This  could  be  achieved  by  breeding  the  mice  with  a  FLP  recombinase-
expressing mouse strain to initiate FLP recombinase-mediated recombination of the 
neo gene, with subsequent backcrossing onto a wild type background. 
 
Analysis of the F1 reporter mice showed that EYFP expression reliably reported IL-
17A expression detected by intra-cellular cytokine staining after a 4 hour stimulation 
with PdBu, ionomycin and brefeldin A, however not all IL-17A-expressing cells 
were EYFP positive.  Expression of EYFP and IL-17A, measured by intra-cellular 
cytokine staining were more comparable in γδ T cells where approximately 50% of 
the IL-17A-expressing cells were EYFP positive, versus only about 20% in CD4 T 
cells.    Following  immunisation  with  MOG  CFA  in  the  presence  or  absence  of 
pertussis toxin, the number of IL-17A-expressing CD4 and γδ T cells increased as 
well as the percentage of IL-17A-expressing cells within each of these populations, 
as  determined  in  chapter  3.    However  in  the  γδ  T  cell  population,  the  IL-17A-
expressing cells that increased following immunisation were predominantly EYFP
+ 
whereas  in  the  CD4  T  cell  population  the  IL-17A-expressing  cells  were  mostly 
EYFP
-. This confirmed the fact that EYFP more reliably reports expression of IL-
17A in γδ T cells. 
 
There are a number of reasons why EYFP expression and IL-17A expression may 
not  reflect  each  other.      It  is  possible  that  EYFP  may  leak  out  of  cells  upon 
permeabilisation, leading to absence of EYFP in IL-17A-expressing cells, however it 
is clear that this does not occur to the same extent in CD4 T cells and γδ T cells 
suggesting that either EYFP leaks more readily out of CD4 T cells or perhaps that 
there is another reason.  It is also possible that differential expression between EYFP 
and IL-17A may be due to the ability of the IL-17A promoter to drive the expression 
of  Cre  recombinase.    It  may  be  that  the  induction  of  IL-17A  and  therefore  Cre 
recombinase transcription by the IL-17A promoter in CD4 T cells and γδ T cells is 
different  and  that  in  γδ  T  cells  the  IL-17A  promoter  more  readily  drives  Cre 
expression.  Furthermore, it could be that there is a certain degree of monoallelic     Chapter 4 
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expression, and that in CD4 T cells in particular, the IL-17A promoter induces IL-
17A transcription from the intact allele but not expression of Cre recombinase on the 
targeted allele.  This however, might be expected to also work in the opposite way, 
so that in some cases the IL-17A promoter induces Cre recombinase transcription 
from the targeted allele without the expression  of IL-17A from the intact allele, 
however the expression of such EYFP
+IL-17A
- cells were not detected.  Differential 
expression of IL-17A and EYFP could also be due to a delay in expression of EYFP 
relative to expression of IL-17A, which is perhaps more delayed in CD4 T cells than 
γδ  T  cells.  One  group  generated  an  IL-17F  transgenic  reporter  using  a  similar 
Cre_LoxP system (Croxford, Kurschus et al. 2009) and also found a proportion of 
IL-17F-expressing cells that did not express EYFP, which they attributed to a delay 
in the expression of EYFP relative to IL-17F, although they did not confirm this.  
This could partly be assessed in the IL-17A_Cre
EYFP mice using in vitro analysis of 
EYFP expression after stimulation of CD4 T cells with Th17-polarising cytokines in 
order to investigate whether CD4 T cells do eventually express the reporter gene.    
 
The experiments in chapter 3 established that IL-17A-expressing CD4 and γδ T cells 
increased  in  number  and  the  percentage  of  IL-17A-expessing  cells  within  these 
populations  also  increased  upon  immunisation  with  MOG  CFA.    However  from 
those results it was not possible to say whether the increase in these populations was 
due to an increase in recruitment, proliferation, survival or de novo generation.  One 
way to address whether the increase in these populations was the result of de novo 
generation would be to transfer EYFP
- cells from the reporter mice into wild type 
hosts and investigate whether these cells up-regulate EYFP upon immunisation.  Up-
regulation of EYFP in this experiment could be attributed to de novo generation of 
IL-17A-expressing  cells  in  vivo  in  response  to  MOG  CFA  immunisation.    The 
experiments in chapter 3 also established that pertussis toxin was enhancing MOG-
specific IL-17A (and IFN-γ) responses in the periphery.  This could be the result of 
an enhanced number of MOG-specific CD4 T cells in the pertussis toxin-treated 
mice or an enhanced ability of MOG-specific cells to produce IL-17A.  In order to 
investigate  this,  MOG  tetramer  staining  could  be  used  in  combination  with     Chapter 4 
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intracellular cytokine staining after both MOG and PdBu and ionomycin stimulation 
and also using the reporter mice.  It would be interesting to investigate whether the 
MOG-specific CD4 cells respond differently to PdBu and ionomycin staining and 
MOG stimulation.  It could be that PdBu and ionomycin stimulation is reflective of 
transcriptional  expression  of  IL-17A  staining,  something  which  should  correlate 
with the expression of the EYFP in the reporter mice, but that MOG stimulation 
could highlight post-transcriptional expression of the cytokine, something that may 
be different in mice treated with and without pertussis toxin.  
 
The  experiments  in  chapter  3  also  showed  that  immunisation  with  MOG  CFA 
induced  double  producing  IL-17A  and  IFN-γ-expressing  CD4  T  cells  that  were 
detected in the blood and spinal cord. This indicates that there is a certain degree of 
plasticity between the Th1 and Th17 cell lineages. Experiments in vitro using an 
IFN-γ reporter mouse, have shown that Th17 cells can be induced without opening 
the IFN-γ locus (Veldhoen, Hocking et al. 2006), however it will be of interest to 
check  using  the  IL-17A_Cre
EYFP  mice,  whether  IFNγ-expressing  cells  in  both  in 
vitro and in vivo settings,  activate IL-17A expression.  
 
It should be considered when analysing the IL-17A_Cre
EYFP mice that these mice are 
heterozygous for the Cre insertion and only have IL-17A expression from one allele. 
Northern  blot  analysis  of  the  IL-17A  knockout  mice  generated  by  Nakae  et  al 
(Nakae,  Komiyama  et  al.  2002)  showed  reduced  IL-17A  mRNA  in  the  mice 
heterozygous for the knockout indicating that the deletion of one allele does result in 
reduced  transcription  of  IL-17A.  However,  these  mice  showed  a  phenotype 
comparable with wild type mice and so it is expected that the heterozygous IL-
17A_Cre
EYFP mice will be not phenotypically different from wild type mice.  It will 
also be of interest to investigate the IL-17F expression in these mice compared to the 
littermate controls with an intact IL-17 locus.  Nakae et al did not show any data on 
the expression of IL-17F from their knockout, however the close proximity of the 
IL-17A  and  IL-17F  genes  on  chromosome  1  and  the  presence  of  non-coding 
conserved sequences within their locus suggest that they share regulatory sequences     Chapter 4 
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and that interference with the IL-17A gene may affect the expression of the IL-17F 
gene in some way.  
 
The use of cytokine reporter mice is a recent approach whereby expression of a 
cytokine can be tracked in vivo by the expression of a fluorescent reporter gene.  
This method allows detection of cytokine expression on a single cell basis without 
the need for intracellular cytokine staining  which kills the cells via fixation and 
involves  in  vitro  stimulation  with  a  non-physiological  stimulus.    Cytokine-
expressing  cells  can  also  be  visualised  on  mouse  sections  using  fluorescent 
microscopy, giving information about the in vivo localisation and interactions of 
these cells (Stetson, Mohrs et al. 2003).  The design of cytokine reporter mice must 
be taken into consideration when interpreting observations. For example, many of 
the fluorescence genes used such as Enhanced Green Fluorescent Protein (EGFP) or 
Enhanced  Yellow  Fluorescent  Protein  (EYFP)  have  optimized  kozak  sequences 
(Kozak 1991) surrounding their start codons to ensure that after generation of their 
transcript, the translation of these mRNAs is efficient.  However, the process of 
translation  itself  is  one  that  may  be  critically  regulated  in  the  expression  of  the 
cytokine  gene  and  so  although  expression  of  the  fluorescent  gene  may  be 
representative of transcription it does not reflect secretion of the protein.  In the IL-
17A_Cre
EYFPmice,  Cre  recombinase  has  a  kozak  sequence  surrounding  the  start 
codon  which  will  enhance  translation  of  the  enzyme.    The  translation  of  Cre 
recombinase  and  IL-17A  should  therefore  be  disassociated  when  analysing  the 
mouse.  Another important factor to consider is incorporation of the knock-in gene 
in a way that is least likely to affect any potentially regulating elements within the 
target locus.  Incorporation of the reporter gene directly into the coding region of the 
target gene, under the control of its transcriptional promoter is one way of generating 
a reporter system which was used in the generation of the IL-17A_Cre
EYFP mice, 
however this effectively knocks out the target gene on one allele and the effects of 
any  deleted  cytokine  must  be  taken  into  consideration.    One  way  of  avoiding 
deletion  of  one  of  the  alleles  in  such  a  knock-in  system  is  by  generation  of  a 
bicistronic mRNA via use of an IRES (internal ribosomal entry site) element.  IRES-    Chapter 4 
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mediated translation involves initiation factors distinct from those required for cap-
mediated translation and allows initiation of translation in the middle of a mRNA 
sequence.  The IL-4, IFNγ and IL-10 reporter mice (Mohrs, Shinkai et al. 2001; 
Stetson, Mohrs et al. 2003; Kamanaka, Kim et al. 2006) all exploited this technology 
by  incorporation  of  an  IRES  element  within  the  bicistronic  mRNA  allowing 
translation of the reporter gene even after the translational stop codon of the target 
gene.  The desired result is that transcription of the target gene leads to transcription 
and translation of the reporter gene and there is no deletion of cytokine expression.  
However,  it  has  to  be  considered  that  this  method  involves  insertion  of  a  non-
mammalian  DNA  sequence  upstream  of  the  polyA  tail  of  a  gene  which  is  still 
expressed, therefore potentially disrupting the regulation of the gene. 
 
The IL-17A reporter mouse will be an invaluable tool, allowing the purification of a 
live population of cells which have activated IL-17A transcription, via FACS sorting 
the EYFP-expressing cells.  These cells can be stained for extracellular markers to 
determine the phenotypes of cells expressing IL-17A and used for quantitative PCR 
analysis to determine expression of other genes such as transcription factors. It will 
be of interest to investigate the location in which IL-17A expression is induced as 
well as the migration and lifespan of such cells in these immune responses.  Despite 
the concentrated study of IL-17A expression in CD4 and γδ T cells, the reporter can 
also be used to assess IL-17A expression in other cells such as CD8 and NK cells 
and the role of these cells in infection and autoimmune settings can be investigated. 
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Chapter 5: Final discussion 
 
Autoimmunity occurs as a result of a specific adaptive immune response against 
self-peptide.  In  order  to  further  understand  the  mechanisms  that  can  result  in 
autoimmunity,  the  aims  of  this  thesis  were  to  investigate  the  sequence  of 
immunological events that lead to the development of an autoimmune response and 
to generate and characterise a reporter mouse for IL-17A. 
 
In  order  to  generate  an  IL-17A  transcriptional  reporter  mouse,  an  IL-17A_Cre 
recombinase strain was first generated where Cre recombinase expression is driven 
by the IL-17A promoter.  This mouse was then crossed with a ROSA-26_EYFP 
strain,  in  which  expression  of  EYFP  is  usually  inhibited  by  the  presence  of  an 
upstream transcriptional stop sequence.  Expression of Cre recombinase in cells that 
have activated IL-17A leads to deletion of this transcriptional stop sequence, which 
is flanked by two LoxP sites, leading to irreversible expression of EYFP.  Analysis 
of the first generation of reporter mice indicated that expression of EYFP reliably 
reports IL-17A protein expression, measured after PdBu and ionomycin stimulation, 
however there are a proportion of cells that express intra-cellular IL-17A protein 
without expressing EYFP, and this proportion is higher in CD4 T cells than γδ T 
cells.  There could be numerous reasons for these observations which need to be 
investigated further, but one of the reasons could be that the IL-17A promoter is less 
able  to  drive  Cre  recombinase  expression  in  CD4  T  cells  than  in  γδ  T  cells, 
indicating differences in the way IL-17A may be expressed in different cell types.   
 
The sequence of immunological events leading to development of clinical EAE was 
assessed.  It was shown that following EAE induction, IL-17A-expressing cells were 
increased in frequency within the CD4 and γδ T cell populations in the draining 
lymph nodes, with a simultaneous increase in the number of these cell populations in 
the blood. Single IFN-γ-expressing cells within the CD4 T cell population did not 
increase in frequency within the time-frame assessed in the draining lymph nodes,     Chapter 5: Final discussion 
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however there was an increase in the number of CD4 T cells expressing both IL-17A 
and  IFN-γ  in  the  lymph  nodes  and  blood.  Disease  was  associated  with  the 
appearance of IL-17A and IFN-γ-expressing CD4 T cells, IL-17A-expressing γδ T 
cells, as well as monocytes and neutrophils in the spinal cord.  Although originally 
believed to be mediated by Th1 effector cells, IL-17-producing Th17 cells have been 
implicated as being important in the development of EAE after studies in which 
molecules involved in the generation of the two lineages are genetically knocked 
out, or depleted with depleting antibody.  However, there are contrasting reports 
about  the  capacity  of  both  Th1  and  Th17  polarised  cells  to  generate  disease  in 
adoptive transfer experiments. The IL-17A reporter mice could be used to further 
investigate the generation and plasticity of the IL-17A-expressing cells in EAE.  For 
example, to determine the origin of the double-producing IL-17A/IFN-γ-expressing 
CD4 T cells. 
 
In EAE, signals induced by MOG peptide, CFA and pertussis toxin facilitate the 
breakdown  of  peripheral  immune  tolerance  to  MOG  peptide  and  allow  the 
generation of encephalitogenic MOG-specific effector T cells capable of inducing a 
pathogenic immune response in the CNS.   Effector T cells exert their effects in part 
by the cytokines they express.  Furthermore, in this study it was shown that signals 
mediated by pertussis toxin in combination with MOG CFA immunisation could 
enhance expression of MOG-specific effector cytokines (IL-17A and IFN-γ), when 
compared to immunisation with MOG CFA alone. This complements other findings, 
which  have  also  observed  that  pertussis  toxin  can  enhance  auto-antigen  specific 
cytokine production (Caspi, Silver et al. 1996; Jee and Matsumoto 2001; Hofstetter, 
Shive et al. 2002; Hofstetter, Grau et al. 2007).  Interestingly, in this study, this 
effect was masked when cells were stimulated with PdBu and ionomycin instead of 
MOG peptide.   Enhancement of MOG-specific cytokine expression in CD4 T cells 
from  mice  treated  with  pertussis  toxin  could  be  due  to  an  enhancement  in  the 
number of MOG-specific CD4 T cells in the pertussis toxin-treated mice.  As MOG-
specific  cells  are  only  a  small  percentage  of  the  total  repertoire  of  T  cells,  any 
difference may not be detected by stimulation with PdBu and ionomycin, which     Chapter 5: Final discussion 
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stimulates every cell regardless of specificity.  Alternatively, it could be that MOG-
specific  CD4  T  cells  express  cytokine  in  response  to  MOG  stimulation  after 
immunisation with MOG CFA and pertussis toxin, but do not if immunised with 
MOG CFA only.  If the latter is the case, this could be due to an effect of pertussis 
toxin on post-transcriptional expression of the cytokines, for example in stabilising 
cytokine mRNA or  enhancing  storage or  secretion of the proteins.  The IL-17A 
reporter mouse was used to analyse the effect of pertussis toxin on EYFP expression.  
Expression of EYFP in CD4 T cells was low compared to the total IL-17A measured 
by  intra-cellular  cytokine  staining,  however  there  was  no  observed  difference  in 
EYFP  expression  in  CD4  T  cells  from  the  periphery  of  mice  immunised  in  the 
presence  and  absence  of  pertussis  toxin,  suggesting  that  pertusss  toxin  was  not 
having any effect on transcriptional activation of IL-17A in CD4 T cells.  
 
In summary, it was established that following EAE induction, IL-17A-expressing 
cells were increased in frequency within the CD4 and γδ T cell populations in the 
draining  lymph  nodes,  with  a  simultaneous  increase  in  the  number  of  these 
populations in the blood.  Disease development was associated with administration 
of pertussis toxin and the appearance of IL-17A and IFN-γ-expressing CD4 T cells, 
as  well  as  IL-17A-expressing  γδ  T  cells  in  the  spinal  cord.    It  was  found  that 
pertusssis  toxin  enhanced  antigen-specific  IL-17A  and  IFN-γ  production  in  the 
periphery.  The IL-17A reporter mouse will be a useful tool to investigate IL-17A 
expression in EAE further. 
 
Activated, effector CD4 T cells are central to the adaptive immune response and are 
important  players  in  many  models  of  autoimmune  disease.    The  specific 
requirements for what makes a CD4 T cell pathogenic or not, are still unknown.  
Expression of effector cytokines at a transcriptional level, which in EAE, may be 
induced through signals from Mycobacterium tuberculosis may not always reflect 
translation and secretion of these cytokines in vivo in response to specific antigen.  
Moreover, immunisation with CFA may be sufficient to upregulate transcriptional 
expression  of  Th1  and  Th17  cytokines  in  the  context  of  EAE,  but  may  not  be     Chapter 5: Final discussion 
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sufficient to allow cells to actually translate and secrete protein in response to MOG 
peptide, something which may be enhanced by the effects of pertussis toxin.  Further 
understanding of the characteristics of pathogenic CD4 T cells in EAE, as well as 
the  signals  required  to  generate  them  is  important  in  our  understanding  of  how 
autoimmune responses arise.     Bibliography 
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